

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
18 April 2002 (18.04.2002)

PCT

(10) International Publication Number
WO 02/31134 A2

(51) International Patent Classification⁷: C12N 9/64 (74) Agents: SAMPLES, Kenneth, H. et al.; Fitch, Even, Tabin & Flannery, 120 South LaSalle Street, Suite 1600, Chicago, IL 60603 (US).

(21) International Application Number: PCT/US01/31874 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 12 October 2001 (12.10.2001) (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English (30) Priority Data: 60/240,117 12 October 2000 (12.10.2000) US (71) Applicant (for all designated States except US): FERRING BV [US/US]; Polaris Avenue 144, NL-2132 JX Hoofdorp (NL).

(72) Inventors; and (75) Inventors/Applicants (for US only): QI, Steve [GB/US]; 11034 West Ocean Air Drive, Apt. 24B, San Diego, CA 92130 (US). AKINSANYA, Karen, O. [GB/US]; 7675 Palmilla Drive, Apt. 642B, San Diego, CA 92122-5094 (US). RIVIERE, Pierre, J.-M. [FR/US]; 3993 Via Cangrejo, San Diego, CA 92130 (US). JUNIEN, Jean-Louis [FR/FR]; Ferring SAS, F-75507 Paris (FR).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/31134 A2

(54) Title: NOVEL SERINE PROTEASE GENES RELATED TO DPPIV

(57) Abstract: Novel proteins or polypeptides having significant sequence homology to DPPIV, nucleic acids coding therefor, cells which have been modified with such nucleic acid so as to express these proteins, antibodies to these proteins, screening methods for the discovery of new therapeutic agents which are inhibitors of the activity of these proteins or of related proteins, and therapeutic agents discovered by such screening methods, as well as new therapeutic treatments, are all provided.

Best Available Copy

Novel Serine Protease Genes Related to DPPIV

Field of the Invention

The present invention relates to novel serine proteases related to dipeptidyl peptidase IV (DPPIV), and to isolated nucleic acids coding for these proteases, all of which are useful for the discovery of new therapeutic agents, for measuring protease 5 activity, and for determining the inhibitory activity of compounds against these proteases.

Background of the Invention

Proteases and peptidases are enzymes that catalyse the hydrolysis of peptidic amide bonds. Proteases play an important role in the regulation of biological processes 10 in almost every life-form from bacteria to virus to mammals. They perform critical functions in, for example, digestion, blood clotting, apoptosis, activation of immune responses, zymogen activation, viral maturation, protein secretion and protein trafficking. They can be classified according to a number of criteria, such as site of action, substrate preference, and mechanism. So, for example, aminopeptidases act 15 preferentially at the N-terminal residues of a peptide, while carboxypeptidases act preferentially at the C-terminus and endopeptidases act at sites removed from the two termini. Among the carboxy- and aminopeptidases, peptidyl peptidases cleave a single amino acid residue from the substrate, dipeptidyl peptidases cleave a dipeptide unit (two amino acids) from the substrate, and tripeptidases cleave three amino acids from the 20 substrate. Substrate preference is frequently expressed in terms of the amino acid residue immediately N-terminal to the cleavage site. For example, trypsin-like peptidases will preferentially cleave a peptide next to a basic amino acid (arginine or lysine), i.e. where the bond hydrolysed is the Arg/Lys-Xaa bond. As another example, the chymotrypsin-like family of peptidases preferentially hydrolyse peptides adjacent to 25 an aromatic residue. Mechanistically, peptidases are classified as being serine-dependent, cysteine-dependent, aspartic acid-dependent or zinc-dependent.

Because peptidases and proteases are involved in the regulation of many physiological processes, they are attractive targets for the development of therapeutic agents. Protease and peptidase inhibitors are, for example, used in the treatment of 30 hypertension, coagulation disorders, and viral infection.

Proteolytic enzymes that exploit serine in their catalytic activity are ubiquitous, being found in viruses, bacteria and eukaryotes. Over 20 families (denoted S1 - S27) of serine protease have been identified; these are grouped into 6 clans (SA, SB, SC, SE, SF

and SG) on the basis of structural similarity and other functional evidence. Structures are known for four of the clans (SA, SB, SC and SE); these appear to be totally unrelated, suggesting at least four evolutionary origins of serine peptidases and possibly many more, Rawlings and Barrett, Meth. Enzymol. 244: 19-61 (1994).

5 The prolyl oligopeptidase family consists of a number of evolutionarily related peptidases whose catalytic activity seems to be provided by a charge relay system similar to that of the trypsin family of serine proteases, but which evolved by independent convergent evolution. A conserved serine residue has been shown experimentally (in *E. coli* protease II as well as in pig and bacterial PE) to be necessary for the catalytic

10 mechanism. This serine, which is part of the catalytic triad (Ser, His, Asp), is generally located about 150 residues away from the C-terminal extremity of these enzymes (which are all proteins that contain about 700 to 800 amino acids).

One of the most intensively studied prolyl oligopeptidases is dipeptidyl peptidase IV (DPPIV, EC 3.414.5), a type II glycoprotein, which is the only well characterised

15 dipeptidyl aminopeptidase known to be located on the outer side of plasma membranes. As indicated above, dipeptidyl aminopeptidases are characterised by their ability to cleave N-terminal dipeptides from a variety of small peptides. Dipeptidyl aminopeptidases show different substrate specificities and cellular localisation, suggesting different functions of each activity in peptide processing. DPPIV is characterised by its capacity to cleave N-

20 terminal dipeptides containing proline or alanine as the penultimate residue. The DPPIV gene spans approximately 70 kb and contains 26 exons, ranging in size from 45 bp to 1.4 kb. The nucleotide sequence (3,465 bp) of the cDNA contains an open reading frame encoding a polypeptide comprising 766 amino acids. The nucleotides that encode the active site sequence (G-W-S-Y-G) are split between 2 exons. This clearly distinguishes

25 the genomic organisation of the prolyl oligopeptidase family from that of the classic serine protease family.

DPPIV is widely distributed in mammalian tissues and is found in great abundance in the kidney, intestinal epithelium and placenta (Yaron, A. and Naider, F., Critical Reviews in Biochem. Mol. Biol. 1993 [1], 31). In the human immune system,

30 the enzyme is expressed almost exclusively by activated T-lymphocytes of the CD4⁺ type where the enzyme has been shown to be synonymous with the cell-surface antigen CD26. Although the exact role of DP-IV in human physiology is still not completely understood, recent research has shown that the enzyme clearly has a major role in human physiology and pathophysiology.

On human T cells, DPPIV expression appears late in thymic differentiation and is preferentially restricted to the CD4⁺ helper/memory population, and CD26 can deliver a potent co-stimulatory T-cell activation signal. DPPIV, also known as T-cell activation antigen CD26, therefore plays an important role in the immune response via association with CD45 tyrosine phosphatase and, through its ability to bind adenosine deaminase (ADA) to the T-cell surface, protects the T-cell from adenosine-mediated inhibition of proliferation. Furthermore, the regulation of the function of chemokines by CD26/DPPIV appears to be essential for lymphocyte trafficking and infectivity of HIV strains. DPPIV has been associated with numerous functions including involvement in T-cell activation, cell adhesion, digestion of proline containing peptides in the kidney and intestines, HIV infection and apoptosis, and regulation of tumorigenicity in certain melanoma cells, Pethiyagoda et al., *Clin. Exp. Metastasis* 2000;18(5):391-400. DPPIV is also implicated in the endocrine regulation and metabolic physiology. More particularly, DPPIV cleaves the amino-terminal His-Ala dipeptide of GLP-1, generating a GLP-1 receptor antagonist, and thereby shortens the physiological response to GLP-1. Glucagon-like peptide-1 (GLP-1), an incretin that induces glucose-dependent insulin secretion, is rapidly degraded by DPPIV, and since the half-life for DPPIV cleavage is much shorter than the half-life for removal of GLP-1 from circulation, a significant increase in GLP-1 bioactivity (5- to 10- fold) is anticipated from DPP-IV inhibition.

Inhibitors of DPPIV are currently being studied in the clinic as potential therapeutic agents for type 2 diabetes and impaired glucose tolerance.

Various different inhibitors of DPPIV were known in 1993. One of these is a suicide inhibitor N-Ala-Pro-O-(nitrobenzoyl-) hydroxylamine. Another is a competitive inhibitor: e-(4-nitro) benzoxy carbonyl-Lys-Pro, and another is a polyclonal rabbit anti-porcine kidney DPPIV immunoglobulin. Others have since been developed and are described in detail in U.S. Patents Nos. 5,939,560, 6,110,949m 6,011,155 and 5,462,928.

In addition to, but independent of, its serine type catalytic activity, DPPIV binds closely to the soluble extracellular enzyme adenosine deaminase (ADA), acting as a receptor and is thought to mediate signal transduction. DPPIV structure is characterized by two extracellular domains, an α/β fold hydrolase domain and a 7-blade beta-propeller domain consisting of repeated beta sheets of about 50 amino acids. Recently it has been shown that, besides selecting substrates by size, the beta-propeller domain, containing 10 of the 12 highly conserved cysteine residues, contributes to catalysis of the peptidase domain. In addition, the cysteine-rich domain is responsible for DPPIV-binding to collagen I and to extracellular ADA. DPPIV is also reported to play a role in fibronectin-

mediated interactions of cells with extracellular matrix. Recent studies show that the protease activity of DPPIV is not required for its anti-invasive activity because mutants of DPPIV that lack the extracellular serine protease activity maintain such activity.

A number of proteins that share similarities with DPPIV have been reported in the literature. Several of these proteins have been cloned including DPP-I, DPP-II, DPP-III, DPP-X and fibroblast activation protein (FAP). These have been identified and characterised either by molecular cloning and functional studies of expressed proteins or as biochemical activities in tissue extracts. DPPIV-beta and other novel peptidases with functional similarities to DPPIV are not yet cloned. The identification, characterization and/or appropriate classification of further members of the family of prolyl oligopeptidases, the elucidation of their physiological (and particularly pathophysiological) role, and the application of that knowledge to the development of new therapeutic agents are significant challenges.

Summary of the Invention

The present invention provides proteins with prolyl oligopeptidase (post-proline cleaving) activities that constitute three novel members of a family of proteins related to DPPIV, including the full-length proteins, alternative splice forms, subunits, and mutants, as well as nucleotide sequences encoding the same. The present invention also provides methods of screening for substrates, interacting proteins, agonists, antagonists or inhibitors of the above proteins, and furthermore to pharmaceutical compositions comprising the proteins and/or mutants, derivatives and/or analogues thereof and/or ligands thereto.

These novel proteins having significant sequence homology to DPPIV are termed dipeptidyl peptidase IV-related protein-1, 2 & 3 (DPRP-1, DPRP-2 and DPRP-3). The amino acid sequences of DPRP-1, DPRP-2 and DPRP-3 are given in SEQ. ID NOS:1, 3 and 5 respectively. Further disclosed are nucleic acid sequences coding for these proteins (SEQ. ID NOS:2, 4 and 6). Table 1 illustrates the homology (i.e. similarity) between the novel proteins DPRP-1, DPRP-2 and DPRP-3 and other known serine proteases.

Table 1 – Comparison of the sequences of these three novel proteins with DPPIV and other Clan SC, Family S9 members and Subfamily B members

Protease Family	Protease name	No. of a.a.	Homology with DPPIV	TM region	Ser-Asp-His Triad	Gene location	Optimal pH
Clan CA, Family C1	DPPI	463	N	N	N	11q14.1-q14.3	-
Clan SC, Family S28	DPPII	500	N	Y	N	-	4.5-6.0
	QPP	492	N	N	N	-	4.5-7.5
	PCP	496	N	N	N	-	-
Unassigned	DPPIII	737	N	N	N	-	-
Clan SC, Family S9, Subfamily B	DPPIV	766	100	Y	Y	2q24.3	7.5-8.0
	DPPVI	865	52	Y	Mutation	7	-
	FAP	760	70	Y	Y	2q23	7.5-8.0
	DPRP-1	882	41	N	Y	15q22.1-15q22.2	7.5-8.0
	DPRP-2	864	39	N	Y	19p13.3	7.5-8.0
	DPRP-3	796	54	Y	Mutation	2q12.3-2q14.1	-

The greatest homology between DPRP-1, DPRP-2 and DPPIV is seen in the C-terminal sequences. On the basis of sequence homology with DPPIV (see Figure 1), one might predict that these DPRP proteins would have functions that include, but are not limited to, roles as enzymes. Cloning, expression, biochemical and molecular characterization have confirmed this hypothesis.

The expression pattern of DPRPs and the localization to specialized epithelial cells and plasma cells (Leydig cells, prostate epithelial cells, lymphocytes, B cells) is consistent with a role in differentiation, proliferation and inflammation. The localization of the DPRP-1 gene in hormone sensitive cancers (breast, prostate, testicular), tissues regulated by testosterone and the abundant expression in poorly differentiated cancers, demonstrate that DPRP-activating or inhibiting molecules will have numerous therapeutic applications in the treatment of disorders characterized by disregulated growth, differentiation and steroid or polypeptide hormone synthesis and degradation. Data disclosed herein supports the hypothesis that DPRP-1 and DPRP-2 are involved in the regulation of proliferation of *in vitro* models of prostate and testis cancer well known to those skilled in the art.

DPRP-1 and DPRP-2 activities described herein and their expression patterns are compatible with their having functional roles as physiological regulators of the immune and neuroendocrine systems through the enzymatic modification of biochemical mediators like peptides and chemokines. The numerous functions previously described

for DPPIV based upon the use of inhibitors may be due in part to its action and that of similar proteins, like the DPRPs. Therefore, the discovery of selective and potent inhibitors of DPPIV, of the DPRPs and of other related proteases like FAP is considered central to achieving effective and safe pharmaceutical use of these and any newly identified serine protease inhibitors, as well as other active compounds that modify the function(s) of such proteins.

The invention thus provides novel proteins or polypeptides, the nucleic acids coding therefor, cells which have been modified with the nucleic acid so as to express these proteins, antibodies to these proteins, a screening method for the discovery of new therapeutic agents which are inhibitors of the activity of these proteins (or which are inhibitors of DPPIV and not of the proteins), and therapeutic agents discovered by such screening methods. The novel proteins and the nucleic acids coding therefor can be used to discover new therapeutic agents for the treatment of certain diseases, such as for example, reproductive, inflammatory and metabolic disorders and also in the preparation of antibodies with therapeutic or diagnostic value.

In accordance with one aspect of the present invention, there are provided novel, mature, biologically active proteins, principally of human origin. Such proteins may be isolated in small quantities from suitable animal (including human) tissue or biological fluids by standard techniques; however, larger quantities are more conveniently prepared in cultures of cells genetically modified so as to express the protein.

In accordance with another aspect of the present invention, there are provided isolated nucleic acid molecules encoding polypeptides of the present invention including mRNAs, DNAs, cDNAs, genomic DNAs thereof.

In accordance with a further aspect of the present invention, nucleic acid probes are also provided comprising nucleic acid molecules of sufficient length to specifically hybridize to a nucleic acid sequence of the present invention.

In accordance with a still further aspect of the present invention, processes utilizing recombinant techniques are provided for producing such polypeptides useful for *in vitro* scientific research, for example, synthesis of DNA and manufacture of DNA vectors. Processes for producing such polypeptides include culturing recombinant prokaryotic and/or eukaryotic host cells that have been transfected with DNA vectors containing a nucleic acid sequence encoding such a polypeptide and/or the mature protein under conditions promoting expression of such protein and subsequent recovery of such protein or a fragment of the expressed product.

In accordance with still another aspect, the invention provides methods for using DPRP polypeptides and polynucleotides, including the treatment of infections, such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2, pain, diabetes, precocious puberty, infertility, obesity, anorexia, bulimia,

5 Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, angina pectoris, myocardial infarction, stroke, ulcers, asthma, allergies, benign prostatic hypertrophy, cancers including hormone-sensitive and androgen-independent cancers, migraines, vomiting, psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, dementia, and severe

10 mental retardation, and dyskinesias, hereinafter collectively referred to as "the Diseases".

In accordance with yet another aspect of the present invention, there is provided a process for utilizing such polypeptides, or polynucleotides encoding such polypeptides, for the discovery of compounds that inhibit the biological activity of the mature proteins thereof, e.g. by cleaving an N-terminal dipeptide, and such inhibitors are thus also

15 provided.

In accordance with a more specific aspect, the invention provides isolated nucleic acid which encodes (a) a polypeptide which includes the amino acid sequence of one of SEQ ID NOS:1, 3 and 5, or (b) a polypeptide having an amino acid sequence that is at least about 70% similar thereto and exhibits the same biological function, or which is an

20 alternative splice variant of one of SEQ ID NOS:2, 4 and 6, or which is a probe comprising at least 14 contiguous nucleotides from said nucleic acid encoding (a) or (b), or which is complementary to any one of the foregoing.

In accordance with another specific aspect, the invention provides a polypeptide which may be optionally glycosylated, and which (a) has the amino acid sequence of a

25 mature protein set forth in any one of SEQ ID NOS:1, 3 and 5; (b) has the amino acid sequence of a mature protein having at least about 70% similarity to one of the mature proteins of (a) and which exhibits the same biological function; (c) has the amino acid sequence of a mature protein having at least about 90% identity with a mature protein of any of SEQ ID NOS:1, 3 and 5; or (d) is an immunologically reactive fragment of (a).

30 In accordance with still another specific aspect, the invention provides a method for the screening for a compound capable of inhibiting the enzymatic activity of at least one mature protein of the invention, which method comprises incubating said mature protein and a suitable substrate for said mature protein in the presence of one or more test compounds or salts thereof, measuring the enzymatic activity of said mature protein,

35 comparing said activity with comparable activity determined in the absence of a test

compound, and selecting the test compound or compounds that reduce the enzymatic activity, and it also provides a method for screening for a compound capable of inhibiting the enzymatic activity of DPPIV that does not inhibit the enzymatic activity of at least one mature protein and a suitable substrate in the presence of one or more 5 inhibitors of DPPIV or salts thereof, measuring the enzymatic activity of said mature protein, comparing said activity with comparable activity determined in the absence of the DPPIV inhibitor, and selecting a compound that does not reduce the enzymatic activity of said mature protein.

These and other aspects of the present invention should be apparent to those 10 skilled in the art from the detailed description which follows.

Brief Description of the Drawings

FIGS. 1A and 1B show the co-linear alignment of DPRP-1, DPRP-2, DPRP-3 and DPPIV, with shading being supplied to indicate the same (black) or similar (gray) amino acid residues at a particular location.

15 FIG. 2 is similar to FIG. 1 and shows co-linear alignment of human and mouse DPRP-2.

FIG. 3 is a graph which shows the effects of various tetrapeptide amide inhibitors on dipeptidyl peptidase enzyme activity.

20 FIGS. 4A-4C show the effects of three inhibitor compounds on the proliferation of PC3 prostate cancer cell lines at various doses.

Detailed Description of the Preferred Embodiments

In accordance with an aspect of the present invention, there are provided isolated nucleic acid sequences (polynucleotides), which encode the mature polypeptides having the deduced amino acid sequences of the three DPRP's (SEQ ID NOS:1, 3 and 5).

25 The polynucleotides of this invention were discovered using a human testis cDNA library (DPRP-1), a human colon library (DPRP-2) and a human hypothalamus cDNA library (DPRP-3). Isolated nucleic acid for DPRP-1 contains an open reading frame encoding a protein of approximately 882 amino acids in length which is structurally related to human DPPIV, showing 26% identity, and 41% similarity over the 30 entire human DPPIV protein sequence. Isolated nucleic acid for DPRP-2 contains an open reading frame encoding for a protein of approximately 864 amino acids, which is 39% similar to the entire DPPIV amino acid sequence. Analysis of DPRP-1 and DPRP-2 primary amino acid sequence using hydrophobicity plots predicts that these two proteins do not have a transmembrane domain. Despite this fact, it is possible that these 35 intracellular serine proteases are secreted upon cellular activation. Quiescent cell proline

dipeptidase (QPP) is a serine protease that is targeted to intracellular vesicles that are distinct from lysosomes (Chiravuri M, et al., *J. Immunol.* 2000 Nov 15;165(10):5695-702). This hypothesis expands the potential site(s) and scope of DPRP-1 and DPRP-2 involvement in mechanisms for post-translational regulation of chemokines, cytokines, 5 peptides and polypeptides. The full length DPRP-3 sequence contains 796 amino acids, a signal peptide from 1 to 48, and a transmembrane domain between 34 and 56. The mature protein is predicted to be a type II membrane protein and may be cleaved to produce a soluble form. The amino acid sequence is set forth in SEQ ID NO:5, which was deduced from SEQ ID NO:6 and has 54% similarity with DPPIV.

10 Amino acid sequence alignments of these polypeptides with members of the prolyl oligopeptidase enzyme subfamily S9B show that all three DPRP proteins have overall sequence and structural homology to DPPIV and FAP. DPRPs are predicted to be members of the enzyme Clan SC (Serine nucleophile) with catalytic residues in the order Ser, Asp, His and the active site sequence (G-W-S-Y-G).

15 **Table 2.** Homology (i.e. similarity) between DPRP-1, DPRP-2, DPRP-3 and members of the prolyl oligopeptidase family S9B enzymes.

DPPIV

41	DPRP-1			DPRP-2		DPRP-3		FAP		DPPVI	
39	74										
54		39		40							
70		41		39		52					
52		40		42		68		54			

20 DPRP-1, DPRP-2 and DPRP-3 do not exhibit sequence similarity with any members of the classical serine protease families, chymotrypsin and subtilisin. The order of the catalytic triad residues is different in the three main related SC clan families: His-Asp-Ser in chymotrypsin, Asp-His-Ser in subtilisin and Ser-Asp-His in the prolyl oligopeptidases.

As shown in Table 2, DPRP-3 has the highest homology with DPPVI (68% homology and 51% identity). Wada et al isolated cDNA clones for DPPVI, a DPPIV-related protein, from bovine, rat (Wada et al., *Proc. Nat. Acad. Sci.* 89: 197-201. (1992)) and human (Yokotani et al., *Hum. Molec. Genet.* 2:1037-1039 (1993)) brain libraries. They demonstrated that, unlike DPPIV, the catalytic triad in DPPVI does not have the first serine residue. In DPRP-3 two of the amino acids in the catalytic triad

characteristic of the serine protease family are conserved. However, the serine residue itself is replaced by glycine. While the absence of the serine residue is likely to prevent protease activity at this site, it is possible that multiple other functions mediated by other functional domains of the protein remain intact.

5 As briefly described above, DPPIV is a multifunctional molecule that exerts important functions depending on the expressed cells and tissues, in addition to its catalytic activity as a peptidase. DPRP-3 and DPPVI are also likely to maintain multiple functions despite the absence of an intact catalytic triad. For example, DPPVI has been implicated in the regulation of neuronal plasticity. DPPVI is highly expressed in the
10 hippocampus, thalamus, hypothalamus and stiatum. In addition, developmental arrest and embryonic lethality of *rump white* *Rw/Rw* embryos is thought to be due to disruption of the DPPIV gene. *Rw* mutation is associated with a chromosomal inversion spanning 30 cM of the proximal portion of mouse chromosome 5. Genomic analysis of the DPPVI gene on the *Rw* chromosome places the inversion breakpoint in the coding region
15 resulting in loss of a significant fraction of the C-terminal region, Hough R.B. et al., *Proc. Nat. Acad. Sci.*, 95, 13800-13805 (1998).

The human DPRP-1 gene, predicted to be 32668bp in length, has at least 22 exons and eight transcripts. It maps to chromosome 15 (NT_010265) at position 15q21.1 – 15q22.1. The lengths of predicted alternative splice variant transcripts vary
20 between 602bp and 4523bp (see SEQ ID NOS: 7-22). This is in agreement with the multiple transcripts observed by Northern blot analysis (See Example 2). ESTs representing the transcripts were found in numerous tissues including senescent fibroblasts, T-lymphocytes, germinal center B-cells, germ cell seminoma, testis, melanocytes, uterus, ovary breast, multiple sclerosis lesions, pancreas and placenta.

25 Human DPRP-2 belongs to a gene with at least 27 exons and nine splice variants (see SEQ ID NOS:23-40). One SNP was observed in the 3' UTR. (88% (37) C vs. 12% (5) T). The DPRP-2 gene maps to region 19p13.3 of chromosome 19. This location is host to a number of disease markers and is associated with various disorders including hypocalciuric hypercalcemia, type II cerebellar ataxia, muscular dystrophy, convulsions,
30 susceptibility to atherosclerosis, psoriasis, ectodermal dysplasia, and acute myeloid leukemia. In agreement with the ubiquitous distribution of the mRNA observed by Northern blot analysis (see Example 2), DPRP-2 was expressed in a wide variety of tissues upon examination of EST's coverage (e.g. over 64 EST's expressed in liver, spleen, muscle, melanocytes, heart, lung, placenta, skin, pancreas, stomach, brain
35 parathyroid gland).

Human DPRP-3 belongs to a gene with at least 23 exons and two splice variants (see SEQ ID NOS:41-44). The gene maps to chromosome 2 (NT_005445) at position 2q12.3-2q14.1. Transcripts for DPRP-3 did not show as wide a distribution as DPRP-1 and DPRP-2. As shown by Northern blot in Example 2, DPRP-3 expression is restricted 5 to brain and pancreas. ESTs representing the DPRP-3 mRNA were abundant in tissue derived from multiple sclerosis lesions, hypothalamus, whole brain and nerves, with a few transcripts being found in uterus and colon.

The relationships among human and rodent proteases in clan SC, including DPRP-1 DPRP-2 and DPRP-3, were analyzed using Neighbor Joining method (NJ), see 10 Saitou and Nei, *Mol. Biol. Evol.*, 4, 406-525 (1987). Phylogenetic analysis shows that among the S9 proteases, DPRP-1 and DPRP-2, both lacking a transmembrane domain, are distinguished from DPPIV and its closely related proteins like FAP. Similarity is shown however between DPPIV and FAP and between DPRP-3 and DPPVI, which are all type II membrane proteins.

15 A database search for additional DPRP-related genes revealed the presence of a murine sequence related to DPRP-1. Alignment of this mouse sequence with the novel human proteases shows that the mDPRP-1 displays considerable homology with its human counterpart (FIG. 2). One skilled in the art will readily recognize that the novel mouse protease gene can be isolated using the sequence information disclosed herein and 20 can be readily incorporated into one of the routinely used expression constructs which are well known in the art. Use of this disclosed sequence by those skilled in the art to generate a transgenic mouse model will employ development of gene-targeting vectors, for example, that result in homologous recombination in mouse embryonic stem cells. The use of knockout mice in further analysis of the function of DPRP genes is a valuable 25 tool.

The polynucleotides of the present invention may be in the form of RNA or in the form of DNA; DNA should be understood to include cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded and, if single-stranded, may be the coding strand or non-coding (antisense) strand. The coding 30 sequence which encodes the mature polypeptide may be identical to the coding sequence shown in SEQ ID NOS:2, 4 and 6 respectively, or it may be a different coding sequence encoding the same mature polypeptide, as a result of the redundancy or degeneracy of the genetic code or a single nucleotide polymorphism. For example, it may also be an RNA transcript which includes the entire length of any one of SEQ ID NOS:2, 4 and 6.

The polynucleotides which encode the mature proteins of SEQ ID NOS:1, 3, 5, respectively, may include but are not limited to the coding sequence for the mature protein alone; the coding sequence for the mature polypeptide plus additional coding sequence, such as a leader or secretory sequence or a proprotein sequence; and the 5 coding sequence for the mature protein (and optionally additional coding sequence) plus non-coding sequence, such as introns or a non-coding sequence 5' and/or 3' of the coding sequence for the mature protein.

Thus, the term "polynucleotide encoding a polypeptide" or the term "nucleic acid encoding a polypeptide" should be understood to encompass a polynucleotide or nucleic 10 acid which includes only coding sequence for the mature protein as well as one which includes additional coding and/or non-coding sequence. The terms polynucleotides and nucleic acid are used interchangeably.

The present invention also includes polynucleotides where the coding sequence for the mature protein may be fused in the same reading frame to a polynucleotide 15 sequence which aids in expression and secretion of a polypeptide from a host cell; for example, a leader sequence which functions as a secretory sequence for controlling transport of a polypeptide from the cell may be so fused. The polypeptide having such a leader sequence is termed a proprotein or a preproprotein and may have the leader sequence cleaved, by the host cell to form the mature form of the protein. These 20 polynucleotides may have a 5' extended region so that it encodes a proprotein, which is the mature protein plus additional amino acid residues at the N-terminus. The expression product having such a prosequence is termed a proprotein, which is an inactive form of the mature protein; however, once the prosequence is cleaved an active mature protein remains. Thus, for example, the polynucleotides of the present invention 25 may encode mature proteins, or proteins having a prosequence, or proteins having both a prosequence and a presequence (leader sequence).

The polynucleotides of the present invention may also have the coding sequence fused in frame to a marker sequence which allows for purification of the polypeptides of the present invention. The marker sequence may be a polyhistidine tag, a hemagglutinin 30 (HA) tag, a c-myc tag or a V5 tag when a mammalian host, e.g. COS-1 cells, is used. The HA tag would correspond to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al., *Cell*, 37:767 (1984)), and the c-myc tag may be an epitope from human Myc protein (Evans, G.I. et al., *Mol. Cell. Biol.* 5: 3610-3616 (1985)).

The term "gene" means the segment of DNA involved in producing a polypeptide 35 chain; it includes regions preceding and following the coding region (leader and trailer)

as well as intervening sequences (introns) between individual coding segments (exons). The term "significant sequence homology" is intended to denote that at least 25%, preferably at least 40%, of the amino acid residues are conserved, and that, of the non-conserved residues, at least 40% are conservative substitutions.

5 Fragments of the full-length genes of the present invention may be used as a hybridization probe for a cDNA library to isolate full-length cDNA as well as to isolate other cDNAs which have significant sequence homology to the gene and will encode proteins or polypeptides having similar biological activity or function. By similar biological activity or function, for purposes of this application, is meant the ability to

10 cleave an N-terminal dipeptide having Ala or Pro as the penultimate residue or other amino acids. Such a probe of this type has at least 14 bases (at least 14 contiguous nucleotides from one of SEQ ID NOS:2, 4 or 6), preferably at least 30 bases, and such may contain, for example, 50 or more bases. Such probe may also be used to identify a cDNA clone corresponding to a full-length transcript and/or a genomic clone or clones

15 that contains the complete gene, including regulatory and promoter regions, exons, and introns. Labelled oligonucleotides having a sequence complementary to that of the gene of the present invention are useful to screen a library of human cDNA, genomic DNA or mRNA to locate members of the library to which the probe hybridizes. As an example, a known DNA sequence may be used to synthesize an oligonucleotide probe which is then

20 used in screening a library to isolate the coding region of a gene of interest.

The present invention is considered to further provide polynucleotides which hybridize to the hereinabove-described sequences wherein there is at least 70%, preferably at least 90%, and more preferably at least 95% identity or similarity between the sequences, and thus encode proteins having similar biological activity. Moreover, as

25 known in the art, there is "similarity" between two polypeptides when the amino acid sequences contain the same or conserved amino acid substitutes for each individual residue in the sequence. Identity and similarity may be measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). The present invention particularly provides such polynucleotides which hybridize under stringent conditions to the hereinabove-described polynucleotides. As herein used, the term "stringent conditions" means conditions which permit hybridization between polynucleotides sequences and the polynucleotide sequences of SEQ ID NOS:2, 4 and 6 where there is at least about 70% identity.

30 Suitably stringent conditions can be defined by, e.g., the concentrations of salt or

formamide in the prehybridization and hybridization solutions, or by the hybridization temperature, and are well known in the art. In particular, stringency can be increased by reducing the concentration of salt, by increasing the concentration of formamide, and/or by raising the hybridization temperature.

5 For example, hybridization under high stringency conditions may employ about 50% formamide at about 37°C to 42°C, whereas hybridization under reduced stringency conditions might employ about 35% to 25% formamide at about 30°C to 35°C. One particular set of conditions for hybridization under high stringency conditions employs 42°C, 50% formamide, 5x. SSPE, 0.3% SDS, and 200 µg/ml sheared and denatured

10 salmon sperm DNA. For hybridization under reduced stringency, similar conditions as described above may be used in 35% formamide at a reduced temperature of 35°C. The temperature range corresponding to a particular level of stringency can be further narrowed by calculating the purine to pyrimidine ratio of the nucleic acid of interest and adjusting the temperature accordingly. Variations on the above ranges and conditions

15 are well known in the art. Preferably, hybridization should occur only if there is at least 95%, and more preferably at least 97%, identity between the sequences. The polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode polypeptides which exhibit substantially the same biological function or activity as the mature protein encoded by one of the cDNAs of

20 SEQ ID NOS:2, 4 and 6.

As mentioned, a suitable polynucleotide probe may have at least 14 bases, preferably 30 bases, and more preferably at least 50 bases, and will hybridize to a polynucleotide of the present invention which has an identity thereto, as hereinabove described, and which may or may not retain activity. For example, such polynucleotides

25 may be employed as a probe for hybridizing to the polynucleotides of SEQ ID NOS:2, 4 and 6 respectively, for example, for recovery of such a polynucleotide, or as a diagnostic probe, or as a PCR primer. Thus, the present invention includes polynucleotides having at least a 70% identity, preferably at least a 90% identity, and more preferably at least a 95% identity to a polynucleotide which encodes the polypeptides of SEQ ID NOS:1, 3

30 and 5 respectively, as well as fragments thereof, which fragments preferably have at least 30 bases and more preferably at least 50 bases, and to polypeptides encoded by such polynucleotides.

As is well known in the art, the genetic code is redundant in that certain amino acids are coded for by more than one nucleotide triplet (codon), and the invention

35 includes those polynucleotide sequences which encode the same amino acids using a

different codon from that specifically exemplified in the sequences herein. Such a polynucleotide sequence is referred to herein as an "equivalent" polynucleotide sequence. The present invention further includes variants of the hereinabove described polynucleotides which encode for fragments, such as part or all of the mature protein,

5 analogs and derivatives of one of the polypeptides having the deduced amino acid sequence of SEQ ID NOS:1, 3 and 5 respectively. The variant forms of the polynucleotides may be a naturally occurring allelic variant of the polynucleotides or a non-naturally occurring variant of the polynucleotides. For example, the variant in the nucleic acid may simply be a difference in codon sequence for the amino acid resulting

10 from the degeneracy of the genetic code, or there may be deletion variants, substitution variants and addition or insertion variants. As known in the art, an allelic variant is an alternative form of a polynucleotide sequence which may have a substitution, deletion or addition of one or more nucleotides that does not substantially alter the biological function of the encoded polypeptide.

15 The present invention further includes polypeptides which have the deduced amino acid sequence of SEQ ID NOS:1, 3 and 5, as well as fragments, analogs and derivatives of such polypeptides. The terms "fragment," "derivative" and "analog", when referring to the polypeptides of SEQ ID NOS:1, 3 and 5, means polypeptides that retain essentially the same biological function or activity as such polypeptides. An

20 analog might, for example, include a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature protein. The polypeptides of the present invention may be recombinant polypeptides, natural polypeptides or synthetic polypeptide; however, they are preferably recombinant polypeptides, glycosylated or unglycosylated.

25 The fragment, derivative or analog of a polypeptide of SEQ ID NOS:1, 3 and 5 respectively, may be (i) one in which one or more of the amino acid residues is substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid

30 residues includes a substituent group, or (iii) one in which additional amino acids are fused to the mature protein, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art to provide upon the basis of the teachings herein.

The polypeptides and polynucleotides of the present invention should be in an isolated form, and preferably they are purified to substantial homogeneity or purity. By substantial homogeneity is meant a purity of at least about 85%.

The term "isolated" is used to mean that the material has been removed from its 5 original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally occurring polynucleotide or polypeptide present in a living animal is not considered to be isolated, but the same polynucleotide or polypeptide, when separated from substantially all of the coexisting materials in the natural system, is considered isolated. For DNA, the term includes, for example, a recombinant DNA 10 which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by polymerase chain reaction (PCR) or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional 15 polypeptide sequence, e.g., a fusion protein. Further included is recombinant DNA which includes a portion of the nucleotides shown in one of SEQ ID NO:2,4 or 6 which encodes an alternative splice variant of the DPRP. Various alternative splice variants are exemplified in SEQ ID NOS:8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44 and 46.

20 The polypeptides of the present invention include any one of the polypeptide of SEQ ID NOS:1, 3 and 5 (in particular the mature protein), as well as polypeptides which have at least 70% similarity (e.g. preferably at least 60% and more preferably at least 70% identity) to one of the polypeptides of SEQ ID NOS:1, 3 and 5, more preferably at least 90% similarity (e.g. preferably at least 90% identity) to one of the polypeptides of 25 SEQ ID NOS:1, 3 and 5, and most preferably at least 95% similarity (e.g. preferably at least 95% identity) to one of the polypeptides of SEQ ID NOS:1, 3 and 5. Moreover, they should preferably include exact portions of such polypeptides containing a sequence of at least 30 amino acids, and more preferably at least 50 amino acids.

30 Fragments or portions of the polypeptides of the present invention may be employed as intermediates for producing the corresponding full-length polypeptides by peptide synthesis. Fragments or portions of the polynucleotides of the present invention may also be used to synthesize full-length polynucleotides of the present invention.

35 The present invention also includes vectors which include such polynucleotides, host cells which are genetically engineered with such vectors and the production of polypeptides by recombinant techniques using the foregoing. Host cells are genetically

engineered (transduced or transformed or transfected) with such vectors which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, 5 selecting transformants or amplifying the genes of the present invention. The culture conditions, such as temperature, pH and the like, are those commonly used with the host cell selected for expression, as well known to the ordinarily skilled artisan.

The polynucleotides of the present invention may be employed for producing polypeptides by recombinant techniques. Thus, for example, the polynucleotides may be 10 included in any one of a variety of expression vectors for expressing polypeptides. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may 15 be used as long as it is replicable and viable in the host.

The appropriate DNA sequence may be inserted into the vector by any of a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures well known in the art, which procedures are deemed to be within the scope of those skilled in this art.

20 The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be mentioned: LTR or SV40 promoter, the *E. coli*. lac or trp, the phage lambda P.sub.L promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. 25 The expression vector should also contain a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells, such as dihydrofolate reductase or neomycin-resistance for 30 eukaryotic cell culture, or such as tetracycline- or ampicillin-resistance in *E. coli*.

The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein. As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as *E. coli*, 35 *Streptomyces*, *Salmonella typhimurium*; fungal cells, such as yeast; insect cells, such as

Drosophila S2 and Spodoptera Sf9; animal cells, such as CHO, COS or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

Synthetic production of nucleic acid sequences is well known in the art as is apparent from CLONTECH 95/96 Catalogue, pages 215-216, CLONTECH, 1020 East Meadow Circle, Palo Alto, Calif. 94303. Thus, the present invention also includes expression vectors useful for the production of the proteins of the present invention

The present invention further includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs may comprise a 10 vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The 15 following vectors are provided by way of example: Bacterial: pQE70, pQE60, pQE-9 (Qiagen), pBS, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene), ptrc99a, pKK223-3, pKK233-3, pDR540 and pRIT5 (Pharmacia); and Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, and pSVL (Pharmacia). However, any other suitable plasmid or 20 vector may be used as long as it is replicable and viable in the host.

Promoter regions can be selected from any desired gene using CAT (chloramphenicol acetyl transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial 25 promoters include lacI, lacZ, T3, T7, gpt, lambda P.sub.R, P.sub.L and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

Components of the expression vector may generally include: 1) a neomycin phosphotransferase (G418), or hygromycin B phosphotransferase (hyg) gene as a 30 selection marker, 2) an E. coli origin of replication, 3) a T7 and SP6 phage promoter sequence, 4) lac operator sequences, 5) the lactose operon repressor gene (lacIq) and 6) a multiple cloning site linker region. Such an origin of replication (oriC) may be derived from pUC19 (LTI, Gaithersburg, Md.).

A nucleotide sequence encoding one of the polypeptides SEQ ID NOS:2,4 and 6 35 having the appropriate restriction sites is generated, for example, according to the PCR

protocol described in Example 1 hereinafter, using PCR primers having restriction sites for KpnI (as the 5' primer) and NotI or SacI (as the 3' primer) for DPRP-1, or sites for HindIII (as the 5' primer) and NotI or BamHI (as the 3' primer) for DPRP-2. The PCR inserts are gel-purified and digested with compatible restriction enzymes. The insert and 5 vector are ligated according to standard protocols.

In a further embodiment, the present invention provides host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell 10 can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, lipofection or electroporation (Davis, L., Dibner, M., Battey, I., *Basic Methods in Molecular Biology*, (1986)).

Such constructs in host cells are preferably used in a conventional manner to produce the gene product encoded by the recombinant sequence. Alternatively, the 15 polypeptides of the invention can be synthetically produced by conventional peptide synthesizers or by chemical ligation of suitable fragments thus prepared.

Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of 20 the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor, N.Y., (1989).

Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector. 25 Enhancers include cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

30 Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin-resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes, such as 3-phosphoglycerate kinase (PGK), alpha-factor, acid phosphatase, or heat shock proteins, 35

among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion

5 protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter.

10 The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desired, provide amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may also be employed as a matter of

15 choice.

As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example,

20 pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM1 (Promega Biotec, Madison, Wis., U.S.A.). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g.,

25 temperature shift or chemical induction), and cells are cultured for an additional period. Cells are typically harvested by centrifugation and then disrupted by physical or chemical means, with the resulting crude extract being retained for further purification. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption and use of

30 cell-lysing agents; such methods are well known to those skilled in the art.

Various mammalian cell culture systems can also be employed to express a recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, *Cell*, 23:175 (1981). Other cell lines capable of expressing a compatible vector include, for example, the C127, 3T3,

35 CHO, HeLa and BHK cell lines. Mammalian expression vectors will generally comprise

an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to 5 provide required nontranscribed genetic elements.

The polypeptides can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography 10 and lectin chromatography. Recovery can be facilitated if the polypeptide is expressed at the surface of the cells, but such is not a prerequisite. Recovery may also be desirable of cleavage products that are cleaved following expression of a longer form of the polypeptide. Protein refolding steps as known in this art can be used, as necessary, to 15 complete configuration of the mature protein. High performance liquid chromatography (HPLC) can be employed for final purification steps.

The polypeptides of the present invention may be purified natural products, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect or mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the 20 present invention may be glycosylated or may be non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue.

In a preferred embodiment, the proteins of the invention are isolated and purified so as to be substantially free of contamination from other proteins. For example, the proteins of the invention should constitute at least 80% by weight of the total protein 25 present in a sample, more preferably at least 90%, even more preferably at least 95%, and most preferably at least 98% by weight of the total protein.

These proteins may be in the form of a solution in water, another suitable solvent, such as dimethyl sulphoxide (DMSO) or ethanol, or a mixture of suitable solvents. Examples of mixtures of solvents include 10% (by weight) ethanol in water and 2% (by 30 weight) DMSO in water. A solution may further comprise salts, buffering agents, chaotropic agents, detergents, preservatives and the like. Alternatively, the proteins may be in the form of a solid, such as a lyophilised powder or a crystalline solid, which may also comprise a residual solvent, a salt or the like.

As used herein, the term "antibodies" includes polyclonal antibodies, 35 affinity-purified polyclonal antibodies, monoclonal antibodies, and antigen-binding

fragments, such as F(ab'), and Fab' proteolytic fragments. Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen-binding peptides and polypeptides, are also included. Non-human antibodies may be humanized by grafting non-human

5 CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veeneered" antibody). In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through
10 humanizing antibodies, biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans should be reduced.

Alternative techniques for generating or selecting antibodies useful herein include in vitro exposure of lymphocytes to human prohormone DPRP protein or a peptide therefrom, and selection of antibody display libraries in phage or similar vectors
15 (for instance, through use of immobilized or labeled human DPRP protein or peptide). Genes encoding polypeptides having potential human DPRP polypeptide binding domains can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as *E. coli*. Nucleotide sequences encoding such polypeptides can be obtained in a number of ways well known in this art.

20 As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from inoculating a variety of warm-blooded animals, such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice and rats, with a human DPRP polypeptide or a fragment thereof. The immunogenicity of a human prohormone DPRP polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or
25 Freund's complete or incomplete adjuvant, or surface active substances, such as lyssolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH or dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and *Corynebacterium parvum* are especially preferable. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of DPRP or a portion
30 thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "hapten-like", such portion may be advantageously joined or linked to a macromolecular carrier, such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid, for immunization. Antibodies to DPRP may
35 also be generated using methods that are well known in the art. Such antibodies may

include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which block or modify interactions at the active sites) are especially preferred for therapeutic use.

5 For the production of antibodies, binding proteins, or peptides which bind specifically to DPRP, libraries of single chain antibodies, Fab fragments, other antibody fragments, non-antibody protein domains, or peptides may be screened. The libraries could be generated using phage display, other recombinant DNA methods, or peptide synthesis (Vaughan, T. J. et al. Nature Biotechnology 14: 309-314 (1996)). Such
10 libraries would commonly be screened using methods which are well known in the art to identify sequences which demonstrate specific binding to DPRP.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to DPRP have an amino acid sequence consisting of at least about 5 amino acids and, more preferably, of at least about 10 amino acids. It is also preferable that
15 these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of DPRP amino acids may also be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to DPRP may be prepared using any well known
20 technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique, although monoclonal antibodies produced by hybridoma cells may be preferred.

In addition, techniques developed for the production of "chimeric antibodies",
25 such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used, see Neuberger, M.S. et al. Nature 312: 604-608 (1984). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce DPRP-specific single chain antibodies. Antibodies with related
30 specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (Burton D. R. Proc. Natl. Acad. Sci. 88: 11120-11123 (1991)).

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly

specific binding reagents as disclosed in the literature. (Orlandi, R. et al. Proc. Natl. Acad. Sci. 86: 3833-3837 (1989)).

Antibody fragments which contain specific binding sites for DPRP may also be generated. For example, such fragments include, but are not limited to, F(ab')₂, 5 fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (Huse, W. D. et al. Science 254: 1275-1281 (1989)).

10 Various immunoassays may be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between DPRP and its specific antibody. A two-site, monoclonal-based 15 immunoassay utilizing monoclonal antibodies reactive to two non-interfering DPRP epitopes is preferred, but a competitive binding assay may also be employed.

As earlier mentioned, the DPRPs can be used in treatment of the Diseases. Pharmaceutical compositions suitable for use in this aspect of the invention include compositions wherein the active ingredients are contained in an effective amount to 20 achieve the intended purpose relating to one of the Diseases. The determination of a therapeutically effective dose is well within the capability of those skilled in the art and can be estimated initially either in cell culture assays, e.g. of neoplastic cells, or in animal models, usually mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration, which 25 information is then commonly used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, e.g. a DPRP or fragment thereof, antibodies of DPRP, or an agonist, antagonist or inhibitor of DPRP, which ameliorates particular symptoms or conditions of the Disease. For 30 example, the amount to be administered may be effective to cleave a desired target substrate upon contact therewith. Therapeutic efficacy and toxicity may likewise be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED₅₀ (the dose therapeutically effective in 50% of the population) or LD₅₀ (the dose lethal to 50% of the population) statistics. The dose 35 ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the

LD₅₀/ED₅₀ ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

5 An exact dosage will normally be determined by the medical practitioner in light of factors related to the subject requiring treatment, with dosage and administration being adjusted to provide a sufficient level of the active moiety or to maintain a desired 10 effect. Factors to be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and 15 tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or even once every two weeks, depending on the half-life and clearance rate of the particular formulation.

Yet another aspect of the invention provides polynucleotide molecules having 20 sequences that are antisense to mRNA transcripts of DPRP1, DPRP2 and DPRP-3 polynucleotides. Administration of an antisense polynucleotide molecule can block the production of the protein encoded by DPRP-1, DPRP2 or DPRP-3. The techniques for preparing antisense polynucleotide molecules and administering such molecules are known in the art. For example, antisense polynucleotide molecules can be encapsulated 25 into liposomes for fusion with cells.

In particular, the expression of DPRP-1, DPRP-2 and DPRP-3 in specialized 30 epithelial cells, immune cells (lymphocytes and B cells), astrocytic tumors, and in various hormone sensitive cancers provides evidence of a potential role in the pathophysiology of cancer, metaplasia and metastasis. Therefore in a further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate DPRP activity or expression levels. Antibodies that specifically bind DPRP may be used for the diagnosis of disorders characterized by expression of DPRP, or in assays to 35 monitor patients being treated with DPRP or with agonists or antagonists (inhibitors) of DPRP. Antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for DPRP include methods that utilize the antibody and a label to detect DPRP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and they may be labeled by covalent or non-covalent joining with a reporter molecule. A wide

variety of reporter molecules are known in the art. Recombinant DPRP proteins that have been modified so as to be catalytically inactive can also be used as dominant negative inhibitors. Such modifications include, for example, mutation of the active site.

A variety of protocols for measuring DPRP, including ELISAs, RIAs and FACS, 5 are known in the art and provide a basis for diagnosing altered or abnormal levels of DPRP expression. Normal or standard values for DPRP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to DPRP under conditions suitable for complex formation. The method for detecting DPRP in a biological sample would comprise the 10 steps of: a) providing a biological sample; b) combining the biological sample and an anti-DPRP antibody under conditions which are suitable for complex formation to occur between DPRP and the antibody; and c) detecting complex formation between DPRP and the antibody, thereby establishing the presence of DPRP in the biological sample. The amount of complex formation then may be quantified by various methods, 15 preferably by photometric means. Quantities of DPRP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding DPRP are used for diagnostic purposes, which polynucleotides may include oligonucleotide 20 sequences, complementary RNA and DNA molecules, and PNAs. These polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of DPRP may be correlated with one of the Diseases. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of DPRP and to monitor regulation of DPRP levels during therapeutic 25 intervention. Moreover, pharmacogenomic, single nucleotide polymorphisms (SNP) analysis of the DPRP genes can be used as a method to screen for mutations that indicate predisposition to disease or modified response to drugs.

DPRP polynucleotide and polypeptide sequences, fragments thereof, antibodies 30 of DPRPs, and agonists, antagonists or inhibitors of DPRPs can be used to as discovery tools to identify molecular recognition events and therefore proteins, polypeptides and peptides that interact with DPRP proteins. A specific example is phage display peptide libraries where greater than 108 peptide sequences can be screened in a single round of panning. Such methods as well as others are known within the art and can be utilized to identify compounds that inhibit or enhance DPRP-1, DPRP-2 or DPRP-3 activity. 35 Coupled links represent functional interactions such as complexes or pathways, and

proteins that interact with DPRPs can be identified by a yeast two-hybrid system, proteomics (differential 2D gel analysis and mass spectrometry) and genomics (differential gene expression by microarray or serial analysis of gene expression SAGE). Proteins identified as functionally linked to DPRPs and the process of interaction form

5 the basis of methods of screening for inhibitors, agonists and antagonists and modulators of these DPRP-protein interactions.

The term "antagonist," as it is used herein, refers to an inhibitor molecule which, when bound to DPRP, decreases the amount or the duration of the effect of the biological or immunological activity of DPRP, e.g. decreasing the enzymatic activity of

10 the peptidase to cleave the N-terminal dipeptide. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of DPRP; for example, they may include small molecules and organic compounds that bind to and inactivate DPRPs by a competitive or non-competitive type mechanism. Specific examples of DPRP tetrapeptide peptidic enzyme activity inhibitors are

15 described in Example 6 and 7. Inhibitors can be, for example, inhibitors of the DPRP protease activity, or alternatively inhibitors of the binding activity of the DPRP to proteins with which they interact. Specific examples of such inhibitors can include, for example, anti-DPRP antibodies, peptides, protein fragments, or small peptidyl protease inhibitors, or small non-peptide, organic molecule inhibitors which are formulated in a

20 medium that allows introduction into the desired cell type. Alternatively, such inhibitors can be attached to targeting ligands for introduction by cell-mediated endocytosis and other receptor mediated events. Such methods are described further below and can be practiced by those skilled in the art given the DPRP nucleotide and amino acid sequences described herein.

25 A further use for DPRPs is for the screening of potential antagonists for use as therapeutic agents, for example, for inhibiting binding to DPRP, as well as for screening for agonists. DPRP, its immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds which are prospective agonists or antagonists in any of a variety of drug screening techniques. The fragment employed in such screening

30 may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between DPRP and the agent being tested is then measured. Other assays to discover antagonists that will inhibit DPRP are apparent from the disclosures of U.S. Patents Nos. 6,011,155, 6,107,317, 6,110,949, 6,124,305 and 6,166,063, which describe inhibitors of DPPIV. Another worthwhile use

of these DPRPs is the screening of inhibitors of DPPIV to show that they will not have undesired side effects by also inhibiting one or more of the DPRPs.

A method provided for screening a library of small molecules to identify a molecule which binds DPRP generally comprises: a) providing a library of small molecules; b) combining the library of small molecules with the polypeptide of either SEQ ID NOS:1, 3 or 5, or with a fragment thereof, under conditions which are suitable for complex formation; and c) detecting complex formation, wherein the presence of such a complex identifies a small molecule which binds DPRP.

One method for identifying an antagonist comprises delivering a small molecule which binds DPRP into extracts from cells transformed with a vector expressing DPRP along with a chromogenic substrate (e.g. Ala-Pro-AFC or Ala-Pro-AMC) under conditions where cleavage would normally occur, and then assaying for inhibition of cleavage by the enzyme by monitoring changes in fluorescence, or UV light absorption, by spectrophotometry to identify molecules that inhibit cleavage. A reduced rate of reaction or total amount of fluorescence or UV light absorption, in the presence of the molecule, establishes that the small molecule is an antagonist which reduces DPRP catalytic/enzymatic activity. Once such molecules are identified, they may be administered to reduce or inhibit cleaving by a DPRP.

The term "agonist," as used herein, refers to a molecule which, when bound to DPRP, increases or prolongs the duration of the effect of DPRP. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules that bind to and modulate the effect of DPRP. Although it is less likely that small molecules will prove to be effective DPRP agonists, a method for identifying such a small molecule, which binds DPRP as an agonist, comprises delivering a chromogenic form of a small molecule that binds DPRP into cells transformed with a vector expressing DPRP and assaying for fluorescence or UV light absorption changes by spectrophotometry. An increased amount of UV absorption or fluorescence would establish that the small molecule is an agonist that increases DPRP activity.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with DPRP, or with fragments thereof, and then washed. Bound DPRP is then detected by methods well known in the art. Purified DPRP can also be coated directly onto plates for use in the

aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding DPRP specifically compete with a test 5 compound for binding DPRP. In this manner, antibodies can be used to detect the presence of any peptide that shares one or more antigenic determinants with DPRP.

As indicated above, by investigating the binding sites, ligands may be designed that, for example, have more interactions with DPRP than do its natural ligands. Such antagonist ligands will bind to DPRP with higher affinity and so function as competitive 10 ligands. Alternatively, synthetic or recombinant proteins homologous or analogous to the ligand binding site of native DPRP may be designed, as may other molecules having high affinity for DPRP. Such molecules should also be capable of displacing DPRP and provide a protective effect.

As indicated above, the knowledge of the structures of DPRP enables synthetic 15 binding site homologues and analogues to be designed. Such molecules will facilitate greatly the use of the binding properties to target potential therapeutic agents, and they may also be used to screen potential therapeutic agents. Furthermore, they may be used as immunogens in the production of monoclonal antibodies, which antibodies may themselves be used in diagnosis and/or therapy as described hereinbefore.

Given the ubiquitous expression of several members of the prolyl oligopeptidase 20 S9B family, cell lines in which targeted gene disruption of DPPIV, DPRP-1, DPRP-2, DPRP-3, FAP and DPPVI to establish the null phenotype will be of great value to assist screening for selective and potent compounds. Accordingly, the invention provides such cell lines engineered with Lox-Neo IRES tk cassette and GFP-IRES-Neo Knock-in/out 25 cassette DNA element for constructing somatic gene targeting vectors.

Example 1

Cloning and Expression of DPRP genes Using the Mammalian Expression System

DNA fragments encoding the full-length polypeptide DPRP-1 were amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene, 30 i.e. SEQ ID NO:45 and NO:46. In addition, DNA fragments encoding the full length polypeptide DPRP-2 were amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of that gene, i.e. SEQ ID NO:50 and NO:51. Furthermore, DNA fragments encoding the full length polypeptide DPRP-3 were amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of that gene, i.e. SEQ 35 ID NO:55 and NO:56.

The three amplified sequences were respectively isolated from a 0.7% agarose gel using commercially available kit (GFX PCR DNA and Gel Band Purification Kit, Amersham Pharmacia Biotech Inc., Piscataway NJ, USA). The fragments were then ligated into cloning vector, pGEM-7Zf(-) (Promega Corporation, Madison WI, USA) 5 and sequenced. The corresponding cloning constructs were respectively designated pGEM7-DPRP1, pGEM7-DPRP2 and pGEM7-DPRP3. The DNA sequences encoding the truncated DPRP-1 or DPRP-2 or DPRP-3 were amplified using pGEM7-DPRP1 or pGEM7-DPRP2 or pGEM7-DPRP3 as a template and PCR oligonucleotide primers. SEQ ID NO:45 and NO:47 were used for DPRP-1; SEQ ID NO:50 and NO:52 were used 10 for DPRP-2; and SEQ ID NO:57 and NO:58 for DPRP-3. The amplified sequences were again isolated from a 0.7% agarose gel using the same purification kits and sub-cloned into pGEM-7Zf(-). The resulting constructs were designated pGEM7-DPRP1f, pGEM7-DPRP2f and pGEM7-DPRP3f.

To make the DPRP-1 mammalian expression construct, pGEM7-DPRP1 was 15 digested with the restriction enzymes KpnI and NotI to release the full length DPRP-1 gene. The DNA fragment carrying the DPRP-1 gene was gel band purified using the above kit and then inserted into expression vector pcDNA3 (Invitrogen, Carlsbad CA, USA) to make the native DPRP-1 expression construct, which was designated pcDNA-DPRP1. pGEM7-DPRP1f was digested with the restriction enzymes XbaI and HindIII 20 to release the truncated DPRP-1f gene. The DNA fragment carrying the DPRP-1f gene was gel band purified using the above kit and then inserted into expression vector pcDNA3.1(-)/myc-His A (Invitrogen, Carlsbad CA, USA) to make the tagged DPRP-1 expression construct pcDNA-MycHis-DPRP1.

To make the DPRP-2 mammalian expression construct, pGEM7-DPRP2 was 25 digested with the restriction enzymes HindIII and BamHI to release the full length DPRP-2 gene. The DNA fragment carrying the DPRP-2 gene was gel band purified using the above kit and then inserted into expression vector pcDNA3 (Invitrogen, Carlsbad CA, USA) to make the native DPRP-2 expression construct, which was designated pcDNA-DPRP2. pGEM7-DPRP2f was digested with the restriction enzymes 30 EcoRI and BamHI to release the truncated DPRP-2f gene. The DNA fragment carrying the DPRP-2f gene was gel band purified using the above kit and then inserted into expression vector pcDNA3.1(-)/myc-His B (Invitrogen, Carlsbad CA, USA) to make the tagged DPRP-2 expression construct designated pcDNA-MycHis-DPRP2.

To make the DPRP-3 mammalian expression construct, pGEM7-DPRP3 was 35 digested with the restriction enzymes EcoRI and XhoI to release the full length DPRP-3

gene. The DNA fragment carrying the DPRP-3 gene was gel band purified using the above kit and then inserted into expression vector pcDNA3 (Invitrogen, Carlsbad CA, USA) to make the native DPRP-3 expression construct designated pcDNA-DPRP3. pGEM7-DPRP3f was digested with the restriction enzymes NheI and ApaI to release the 5 truncated DPRP-3f gene. The DNA fragment carrying the DPRP-3f gene was gel band purified using the above kit and then inserted into expression vector pcDNA3.1(-)/myc-His B (Invitrogen, Carlsbad CA, USA) to make the tagged DPRP-3 expression construct pcDNA-MycHis-DPRP3.

Example 2

10 Expression Pattern of DPRP genes in human tissues

Quantitative PCR analysis was carried out to examine the levels of expression of the mRNAs for the polypeptides of the present invention in human tissues. RT PCR was also carried out on a number of human cell lines including but not limited to prostate cancer cells (LNCaP, PC3, DU145), the MLTC-1 line (mouse testis), and MDA-MB231 15 cells (breast cancer). Bands of the expected sizes for DPRP-1, DPRP-2 and DPPIV were all expressed in the various cancer cells lines, with FAP also being expressed at very low levels.

Northern Blot Analysis

20 Northern blot analysis was performed with 2 μ g poly(A)⁺ RNA isolated from eight different tissues using DPRP probes. Specifically, a human Multiple Tissue Northern (MTN) blot (Clontech, Palo Alto, Calif.) was probed with a 1 kb N-terminal fragment that had been radioactively labeled by random priming in the presence of a ³²PdCTP (A. P. Feinberg et al., *Anal. Biochem.*, 132, 6 (1983)). Hybridization was performed at 68°C overnight in ExpressHybTM hybridization solution (Clontech, Palo 25 Alto, Calif.). The blots were first washed at room temperature in 2 times SSC and 0.05% SDS, and then washed at 60°C (DPRP-1 & DPRP-2) and 50°C (DPRP-3) in 0.1 times SSC and 0.1% SDS.

30 Northern analysis showed expression of DPRP-1 in several tissues with the most abundant signal being in testis, prostate, muscle and brain. Testis showed 3 transcripts approximately 7.5, 4.5 and 2.5 kb in length. The shorter mRNA species was very abundant in testis but negligible in the other tissues tested. DPRP-2 was ubiquitously expressed in every tissue with highest levels in liver and muscle and a predominant transcript at 5kb. DPRP-3 expression was limited to brain and pancreas. Further analysis was conducted for the three proteases in specific brain regions (cerebellum, 35 cortex, medulla, spinal cord, occipital lobe, frontal lobe temporal lobe and putamen).

DPRP-1 was expressed in all regions with low levels present in the spinal cord, while DPRP-2 was expressed in all brain regions tested.

Oligonucleotide primers SEQ ID NO:48 and NO:49 were used for DPRP-1 quantitative PCR, whereas oligonucleotide primers SEQ ID NO:53 and NO:54 were 5 used for DPRP-2 quantitative PCR. Human Multiple Tissue cDNA (MTCTM) Panel I and Panel II (Clontech, Palo Alto CA, USA) were used as normalized cDNA templates. 0.5 ng of each cDNA were used in a 25 μ l PCR reaction, with each primer at a final concentration of 300 nM. The PCR reaction was performed using a SYBR Green PCR Core Reagents Kit (Applied Biosystems, Foster City CA, USA) and detected with an 10 Applied Biosystems GeneAmp 5700 sequence detection system. Manufacturer's recommended thermal cycling parameter, e.g. 50°C for 2 min, 95°C for 10 min followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min was used. Data obtained shows relatively high rates of expression for both DPRP-1 and DPRP-2 in the pancreas, ovary and testis, and a particularly high rate for DPRP-2 in the liver.

15 **Example 3 – Production of DPRP Polyclonal Antibodies and Western Blotting**

The amino acid sequence deduced from the cDNA encoding DPRP-1 was analyzed using DNASTAR software (DNASTAR, Inc.) to determine regions of high immunogenicity, and a corresponding oligopeptide was synthesized and used to raise anti-DPRP-1 antibodies. The procedure was repeated for DPRP-2 and DPRP-3. The 20 selection of appropriate peptide sequences and the techniques for antibody production are methods well known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is well known in this art.

Typically, oligopeptides that are about 15 to 20 residues in length, e.g. SEQ ID NO:59 for DPRP-1, SEQ ID NO:60 for DPRP-2 and SEQ ID NO:61 for DPRP-3, were 25 synthesized using an Applied Biosystems Peptide Synthesizer Model 431 A. Fmoc-chemistry was used and the 19- or 15-residue peptides were respectively coupled to keyhole limpet hemocyanin (KLH, Sigma, St. Louis, Mo.) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS). Rabbits were immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting 30 antisera were tested for antipeptide activity, e.g., by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radioiodinated, goat anti-rabbit IgG.

Western blotting was performed using normal human protein samples (Protein Medley) obtained from Clontech (about 36 μ g of total proteins). Proteins were 35 fractionated through 10% SDS-polyacrylamide gels, and transferred to 0.45 mm

nitrocellulose membranes. Membranes were blocked in Tris-buffered saline (TBS) with 0.05% Tween 20 and 1% BSA. Anti DPRP-1 or DPRP-2 specific antibodies were used as primary antibodies and were diluted 1:5,000 in Tris-buffered saline with 0.05% Tween 20 (TBST) and the Alkaline Phosphatase (AP) conjugated goat anti-Rabbit IgG (Promega) was diluted 1: 5,000 in the same buffer before use. The positive reaction was visualized by incubating the membrane in Western Blue Stabilized Substrate (Promega) for AP until the bands of interest have reached the desired intensity. DPRP-1 and DPRP-2 proteins were detected in brain, muscles, kidney, prostate, testis and ovary tissues. DPRP-1 and DPRP-2 were synthesized as approximately 101kDa and 100kDa forms, respectively, which are in good agreement with the molecular masses estimated from their primary structure as shown in Table 3.

Table 3. Predicted Molecular Weight, Number of potential N-linked glycosylation sites (Asn residues) and predicted pI values of DPRP-1, DPRP-2 and DPRP-3, based on sequence analysis using the method developed by Hopp and Woods, Proc. Nat. Acad. Sci. 78:3824-3828 (1981).

	M.W. (Da.)	No. of Asn	pI
DPRP1	101422	26	5.39
DPRP2	98263	27	6.01
DPRP3	90914	33	6.11

Several additional bands of similar molecular weight were observed. These are thought to be due to the presence of post-translational glycosylation of the proteins. Table 3 also shows the number of potential N-glycosylation sites for the DPRP proteins. The presence of glycosylated and unglycosylated forms of the proteins was evaluated using tunicamycin, an inhibitor of the oligosaccharide synthesis. It is evident that the smaller forms were unglycosylated forms. The correlation between mRNA (Northern analysis) and protein quantity (Western analysis) for DPRP-1 is shown in Table 4.

Table 4. Correlation of mRNA and protein expression of DPRP-1 in human tissues

	Heart	Brain	Placenta	Muscles	Kidney	Prostate	Testis	Ovary
Northern	++	+++	+	+++	++	+++	++++	+
Western	-	++++	-	+	++	+	+++	+++

Example 4Immunohistochemical localization of DPRP proteins in human tissues

Four-micron sections were prepared from a number of different formalin-fixed, paraffin-embedded human tissues. Tissue sections were deparaffined through 4 immersions in xylenes for 5 minutes, followed by a graded alcohol series to distilled water. Steam heat induced epitope recovery (SHIER) was used with several different SHIER solutions with and without enzyme digestion tissue in two different concentrations (Ladner et al, Cancer Res.; 60, p 3493-3503, 2000). The treatments and antibody dilutions employed are outlined below.

10 1. Blocking Reagent for 15 minutes (Normal Goat Serum)
 2. Primary Antibody for 25, 60 min or overnight incubation
 3. Secondary Antibody for 25 minutes (Biotinylated Goat-anti-rabbit IgG)
 4. Endogenous Peroxidase Blocking for 3 x 1.5 minutes
 5. ABC (avidin-biotin complex) / Horse Radish Peroxidase for 25 minutes
15 6. DAB Chromogen for 3 x 5 minutes (Brown reaction product)
 7. Light Hematoxylin Counter Stain 1 minute

Positive controls were run to assure the detection chemistries and antigen pretreatments were working appropriately. Rabbit IgG was run as a negative control. An avidin-biotin based tissue staining system was used for the detection of the DPRP-1 antibody. Horseradish peroxide was used as a reporter enzyme with DAB as chromogen. After staining, slides were dehydrated through an alcohol series to absolute ethanol followed by xylene rinses. Slides were permanently coverslipped with glass coverslips and permount. Digital images of representative staining, where positive staining was indicated by a dark brown chromogen (DAB-HRP reaction product), were captured using a video camera from Olympus. Hematoxylin counterstain provides a blue nuclear stain to assess cell and tissue morphology.

DPRP-1 rabbit polyclonal antibody labels formalin-fixed, paraffin-embedded human tissues, including normal testis, prostate glands, endometrial glands, tonsils and pancreas. It was also present in endothelial cells of normal ovary, bladder and kidney. Staining was localized in the cytoplasm in epithelial and some stromal cells such as fibroblasts, endothelial cells and lymphocytes. Interestingly in normal testis tested with DPRP-1 antibodies, there was distinctive expression in Leydig cells and multinucleated macrophages found in interstitial tissue, which is the space surrounding the seminiferous tubules. Tonsil B cells were stained with DPRP-1 antibody.

Example 5**Mammalian and Insect Cell Expression of DPRP Proteins and Purification**

Plasmid DNA of pcDNA-DPRP1, pcDNA-MycHis-DPRP1, pcDNA-DPRP-2 or pcDNA-MycHis-DPRP2 was transfected into PEAK (EdgeBioSystems, Gaithersburg MD, USA) or COS-1 (ATCC CRL-1650) using LipofectAmine (Life Technologies, Gaithersburg MD, USA) method recommended by the manufacturer. Transfected cells were maintained in DMEM with 5% FBS at 37°C with 5% CO₂ for 48 hours. Cells were then collected and used for recombinant protein extraction. Cells were harvested 48 hours after transfection, homogenized and then spun at 18,000 x g for 40 min. The supernata were collected as cytosolic fractions. This fraction was loaded on TALON spin column (Clontech), and His-tagged proteins were eluted with 50mM PBS, 150mM imidazole, pH 7. Recombinant proteins were then detected by western blotting with anti-myc antibody and visualized using a ProtoBlot II AP system (Promega). Recombinant affinity purified fusions of the DPRP-1 and DPRP-2 were detected by western blot, and DPRP-1 and DPRP-2 were synthesized as 112kDa and 109kDa forms as predicted.

Naturally occurring or recombinant DPRP proteins were substantially purified by immunoaffinity chromatography using antibodies specific for DPRP-1, DPRP-2 or DPRP-3. An immunoaffinity column was constructed by covalently coupling DPRP antibodies to an activated chromatographic resin, such as CNBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin was blocked and washed according to the manufacturer's instructions.

Media or cell extracts containing DPRP proteins were passed over the immunoaffinity column, and the column was washed under conditions that allow the preferential absorbance of DPRPs (e.g., high ionic strength buffers in the presence of detergent). The column was eluted under conditions that disrupt antibody/DPRP binding (e.g., a buffer of pH 2-3 or a high concentration of a chaotrope, such as urea or thiocyanate ion), and purified DPRP was collected.

Example 6**Enzymatic Activity of DPRP proteins and Methods of Screening for Inhibitors**

The kinetic properties of recombinant DPRP-1 and DPRP-2 were determined in a continuous fluorimetric assay. Buffer, pH and temperature dependence optimization led to the following assay conditions: Enzyme assays were performed in 50mM PBS, pH7.4 50 µl (50 µg/ml) of purified enzymes were mixed with 1 µl of different concentration of Ala-Pro-AMC (Enzyme Systems). Plates were then incubated at 37°C for 30 min, and

fluorescence was detected using a Wallac 1420 Fluorimeter with λ ex40355 and λ em535. The K_m values of DPRP-1 and DPRP-2 were similar (208 and 161 μ M respectively).

Further biochemical characterization reveals that DPRP-1 and DPRP-2 have similar profiles to DPPIV. The two purified proteases and DPPIV were preincubated 5 with inhibitors at room temperature for 30 min. Substrate, Ala-Pro-AMC (100 μ M), was then added, and the fluorescence intensity was recorded as 60 readings during a 60 min period. The irreversible serine protease inhibitor AEBSF was the only inhibitor tested that showed strong inhibition of all three enzymes (Table 5). This confirms the structural and domain analysis prediction that these proteins belong to the serine protease 10 superfamily.

Table 5. Inhibition of DPRP-1 and DPRP-2 by Protease Inhibitors

Inhibitor	Inhibitor Property	Concentration	Residual activity (% of control)		
			DPRP-1	DPRP-2	DPPIV
AEBSF	serine, irreversible	5mM	29.6	23.9	21.1
Aprotinin	serine, reversible	5 μ g/ml	77.5	63.2	80.2
Pepstatin	aspartic, reversible	2 μ g/ml	97.3	95.0	93.5
DTT	cysteine	2mM	100.1	94.8	98.3
B-Mercaptoethonal	cysteine	100mM	93.2	84.0	98.0
EDTA	metallo, reversible	2mM	91.5	86.0	93.5
Leupeptin	serine, reversible	50 μ g/ml	91.1	90.4	90.7

20 In addition to Ala-Pro-AMC, additional substrates tested also confirmed that DPRP-1 and DPRP-2 are dipeptidyl peptidases. The data were derived by determining the fluorescence change following a 30-minute incubation of the substrates (125 μ M) with enzymes as a percentage of the fluorescence measured at Ala-Pro-AMC and Gly-Pro-AMC were the only good substrates among those tested.

25 **Table 6.** DPRP-1 and DPRP-2 are dipeptidyl peptidases.

Substrate	% Change in Fluorescence at 30 minutes		
	DPRP-1	DPRP-2	DPPIV
Ala-Pro-AMC	239.0	127.5	379.0
Gly-Pro-AMC	341.5	205.0	444.0
Ala-Pro-pNA	45.5	44.0	29.5
30 Pro-pNA	-1	-2.5	0.0
Gly-Arg-pNA	-4.5	-0.5	0.0
Lys-Ala-pNA	2.5	0.5	0.5
Ala-Phe-Pro-pNA	-4	-0.5	2.0

Additional natural and non-natural amino acid di-, tri- and tetra-peptides were tested in order to find an optimal substrate for testing each of the DPRP proteins that will also show reduced activity when incubated DPPIV.

The enzyme assay method described here is one of a number of methods that can 5 be utilized to screen for peptide and non-peptide inhibitors of the DPRP enzymes. Libraries of tetrapeptide inhibitors were tested to discover inhibitors of enzyme activity. Candidate inhibitors were prepared as 10-20 mM stock solutions in DMSO and stored at -20°C. Dilutions were made in assay buffer. Inhibition was determined by comparing the changes in fluorescence of the inhibited enzyme to the change in fluorescence of the 10 control (vehicle) enzyme. 100-(f1 units of sample/f1 units of control x 100) gives percent inhibition value. The percent inhibition and the inhibitor concentration at which the enzyme was 50% inhibited (IC_{50}) was ascertained by plotting percent inhibition vs. inhibitor concentration on the log scale. As shown in Figure 3, several tetrapeptides amides inhibited enzyme activity, wherein data are expressed as the % of activity in the 15 presence of vehicle (0.02% DMSO) alone. Compounds were added at 1 mM. Most interesting was the apparent differential activity of some tetrapeptides for DPRP-1 and DPRP-2, compared to DPPIV. While all three enzymes were inhibited by Peptide-1, only DPRP-1 and DPRP-2 were significantly inhibited by Peptide-4 and Peptide-5. This demonstrates that selective inhibition of the purified enzymes is achievable.

20 The assay described in this example can also be used to screen additional synthetic or naturally occurring compound libraries, including macromolecules, for agents that either inhibit or enhance DPRP activity. The DPRP-1 and DPRP-2 polypeptides to be used in the assay can be obtained by, for example, *in vitro* translation, recombinant expression (see Example 5) or biochemical procedures. Methods other than 25 those described here can also be used to screen and identify compounds that inhibit DPRP-1, DPRP-2 or DPRP-3, which methods can include, for example, binding assays such as ELISAs and RIAs.

Example 7

Effect of DPRP Inhibitors on the Proliferation of Human Cancer Cells In Vitro

30 In an attempt to assess the effect that several inhibitors of DPRP-1 and DPRP-2 activity may have on the proliferation of human cancer cells, LNCap, PC3 and Du145, mouse testis line MLTC-1 and MDA-MB231 breast cancer cells were plated (10^4 per well) in 96-well tissue culture plates and allowed to grow and attach for 24 hours at 37°C in a CO₂ incubator. Compounds at various dilutions (final dilutions: 0.1 nM – 10 μ M) 35 were then added to the wells for various incubation periods from 24 hours to 96 hours,

with fresh compound being replaced each day. Addition of the diluent DMSO alone served as the control. Following incubation with these compounds in triplicate, proliferation of the cells was determined using an XTT cell proliferation assay (Roche 1-465-015). The plates were read at 490 and 650nm 5 hours after the XTT mix was added.

5 An increase in cell proliferation was observed with three of the inhibitors at concentrations equal to 0.1, 1, 10 and 100 x IC₅₀, and the results are shown in FIGS. 4A, 4B and 4C for PC3 cells.

Overall, the DPRPs are expressed in a wide variety of tissues as has been demonstrated by mRNA amplification, western blotting and immunohistochemistry.

10 DPRP-1 was most abundant in the testis by Northern blot and western blot. The large number of expressed sequence tags (ESTs) from testis cDNA sources that are homologous to DPRP-1 also confirms abundant expression of DPRP-1 in testis. Example 4 describes the immunohistochemical localization of DPRP-1 protein in human testis using a specific DPRP-1 antibody. DPRP-1 is strongly expressed in epitheloid

15 Leydig cells, and Leydig cells are the primary source of testicular androgens (male steroid hormones) in the mammalian male. In the interstitium of the testis, Leydig cells and macrophages are in close association with "digitation" of Leydig cell process extending onto macrophage surface. Multinucleated cells in close proximity to the Leydig cells were also stained with DPRP-1 antibody suggesting that the protease was

20 also expressed in macrophages, and macrophages in the testis play an important role in the paracrine regulation of Leydig cells. Cytokines secreted by the testicular macrophages are mitogenic to Leydig cells and play an important role in the differentiation of mesenchymal progenitor cell into mature Leydig cells. A clearer understanding of the proteins and pathways involved in the maturation of the testis is

25 important for the discovery of new treatments for precocious puberty. In addition, Leydig cells cause tumors such as sex cord-stromal tumors via sexual steroid production (predominantly testosterone). Testosterone is associated with several neoplasia and diseases such as breast carcinoma and uterine cancers, ovarian carcinoma and androgenic alopecia (hair loss). Further examination of the localization of DPRP

30 proteins in other glands in the body (e.g. adrenal glands) that produce testosterone and other androgenic hormones are currently under investigation. The possible association of DPRP-1 with steroid and polypeptide hormone biosynthetic pathways functions is being investigated, and Example 7 is relevant to understanding the role of DPRP proteins in prostate, testis and breast in vitro cell models.

Immunochemical analysis also localized DPRP-1 to endometrial glands in the uterus (see Example 4), pancreatic acini, glomeruli of the kidney, plasma cells in the bladder, a subset of B-cells in the tonsils, columnar epithelial cells of the prostate and poorly differentiated prostate squamous metaplasia, Gleason grade 4 prostatic carcinoma, and hyperplastic glands in benign prostatic hyperplasia. Positive staining in breast carcinoma, as well as in seminoma and prostate squamous metaplasia, suggests a general association of DPRP-1 with hormone-sensitive tissues, particularly in cells that become poorly differentiated. The presence of the DPRP-1 in specialized epithelial cells and in inflammatory plasma cells (lymphocytes) is also of interest. Inflammatory breast carcinoma has an abundance of infiltrating lymphocytes and an overall bad prognosis. DPRP-1 and other DPRP proteins appear in medullary carcinomas that typically have a constant infiltrating lymphoplasmacytic component at the periphery of the tumor, which is thought to represent a reaction of the host tissues to the neoplasm. Most of the lymphocytes are T Cells, and most of the plasma cells are of the IgG-producing type.

Several antigens are abundant on B cells, a subgroup of breast-cancer cells, and other epithelial cancer cells, and these antigens are targets for a new class of therapeutic monoclonal antibodies with some notable success having been achieved with a humanized monoclonal antibody against the B-cell-specific antigen CD20. Accordingly, monoclonal antibodies to DPRP proteins are felt to be useful to diagnose and treat diseases in which they are involved, including cancer.

The expression of DPRP-1 in specialized epithelial cells of a number of tissues suggests that DPRP-1 and other DPRP proteins may be involved in growth and differentiation thereof. Testing using inhibitors described in Example 6 in *in vitro* models of prostate and testis cancer (Example 7) showed that DPRP-1/DPRP-2 inhibitors caused a 50-60% increase in proliferation of PC3 cells at nM concentrations as shown in FIGS. 4A-4C.

Although the invention has been described in accordance with its preferred embodiments, which constitute the best mode presently known to the inventors, it should be understood that changes and modifications as would be obvious to those skilled in this art may be made without departing from its scope which is set forth in the claims appended hereto. For example, although the disclosure focuses on DPRP-1 and DPRP-2 in certain instances, DPRP-3 and its fragments are considered to be similarly useful, as are nucleic acids encoding same. Particular features of the invention are emphasized in the claims that follow.

CLAIMS:

1. Isolated nucleic acid which encodes (a) a polypeptide, which includes the amino acid sequence of one of SEQ ID NOS:1, 3 and 5, or (b) a polypeptide having an amino acid sequence that is at least about 70% similar thereto and exhibits the same biological function; or which is an alternative splice variant of one of SEQ ID NOS:2, 4 and 6; or which is a probe comprising at least 14 contiguous nucleotides from said nucleic acid encoding (a) or (b) ; or which is complementary to any one of the foregoing.
2. The isolated nucleic acid of claim 1 which is DNA or RNA.
3. The isolated nucleic acid of claim 1 which is a DNA transcript that includes the entire length of any one of SEQ ID NOS:2, 4 and 6 or which is complementary to the entire coding region of one of SEQ ID NOS:2, 4 and 6.
4. An antisense oligonucleotide directed against the DNA of claim 3.
5. The isolated nucleic acid of claim 1 which is an RNA transcript which includes the entire length of any one of SEQ ID NOS:2, 4 and 6.
6. The isolated nucleic acid of claim 1 which is an alternative splice variant of one of SEQ ID NOS:2, 4 and 6.
7. A polypeptide encoded by the nucleic acid of claim 6.
8. The isolated nucleic acid of claim 1 which encodes a polypeptide having an amino acid that is at least about 90% similar to one of SEQ ID NOS:1, 3 and 5.
9. The isolated nucleic acid of claim 1 which encodes a polypeptide having an amino acid that is at least about 95% similar to one of SEQ ID NOS:1, 3 and 5.
10. The isolated nucleic acid of claim 1 which encodes a polypeptide that has at least about 90% identity with one of SEQ ID NOS:1, 3 and 5.
11. A nucleic acid probe according to claim 1 comprising at least 14 contiguous nucleotides from one of SEQ ID NOS:2, 4 and 6.
12. An isolated recombinant polynucleotide molecule comprising nucleic acid according to claim 1 plus expression-controlling elements linked operably with said nucleic acid to drive expression thereof.
13. An expression vector comprising the nucleic acid of claim 1 encoding a polypeptide having the entire amino acid sequence set forth in any one of SEQ ID NOS:1, 3 and 5 operably linked to a promoter, said expression vector being present in a compatible host cell.

14. A mammalian, insect or bacterial host cell that has been genetically engineered by the insertion of nucleic acid according to claim 1 which codes for at least the mature protein portion of the amino acid sequence of SEQ ID NO:1, 3 or 5.

15. A process for producing a polypeptide which includes the mature protein portion of one of SEQ ID NOS:1, 3 and 5, which process comprises culturing the host cell of claim 11 under conditions sufficient for the production of said polypeptide.

16. The process of claim 15 wherein said polypeptide is expressed at the surface of said cell and further includes the step of recovering the polypeptide or a fragment thereof from the culture.

17. A polypeptide

which may be optionally glycosylated, and

which (a) has the amino acid sequence of a mature protein set forth in any one of SEQ ID NOS:1, 3 and 5; (b) has the amino acid sequence of a mature protein having at least about 70% similarity to one of the mature proteins of (a) and which exhibits the same biological function; (c) has the amino acid sequence of a mature protein having at least about 90% identity with a mature protein of any of SEQ ID NOS:1, 3 and 5; or (d) is an immunologically reactive fragment of (a).

18. The polypeptide according to claim 14 which is a mature protein having at least about 95% similarity to a mature protein of (a).

19. The polypeptide according to claim 14 which is a mature protein having at least about 95% similarity to a mature protein of (a).

20. The polypeptide according to claim 14 having the amino acid sequence of the mature protein of one of SEQ ID NOS:1, 3 and 5, or is a fragment thereof which exhibits the same biological function as the respective mature protein.

21. A DPRP antagonist which inhibits the biological function of one of said mature proteins of claim 17, 18 and 19.

22. An antibody that recognizes a polypeptide or a fragment according to claim 17.

23. The antibody of claim 22 which recognizes a polypeptide having an amino acid sequence of SEQ ID NO:1 or 3 or 5.

24. A method for the screening for a compound capable of inhibiting the enzymatic activity of at least one mature protein of claim 17, which method comprises incubating said mature protein and a suitable substrate for said mature protein in the presence of one or more test compounds or salts thereof, measuring the enzymatic activity of said mature protein, comparing said activity with comparable activity determined in the

absence of a test compound, and selecting the test compound or compounds that reduce the enzymatic activity.

25. A method for the screening for a compound capable of inhibiting the enzymatic activity of DPPIV that does not inhibit the enzymatic activity of at least one of the mature proteins of claim 20, which method comprises incubating said mature protein and a suitable substrate for said mature protein in the presence of one or more inhibitors of DPPIV or salts thereof, measuring the enzymatic activity of said mature protein, comparing said activity with comparable activity determined in the absence of the DPPIV inhibitor, and selecting a compound that does not reduce the enzymatic activity of said mature protein.

DPP4	1MTPNIVLLCILC.....AAELWT
DPRP1	1	MAAAMETEQLGVEFETADCENIESQDRPKIPEFYVEYSWSLKKILEDTRKYHGYMM
DPRP2	1ATTGTPADRGDAAATDDPAARFQWAKHSWDGLESERHGRKYSGLV
DPRP3	1NOTAEVSHIHKCOPSKTEKELGSNSPPQESWKGLIAIALLVILVCS
DPP4	20	ITVPVVLLNKGTLCATADSRKTYLTD...MLKN..TYRLKLYSRWISDHEYLKQEN
DPRP1	61	AKAPHDFIFVKRNPDGPHSDRYYLAMSGENRENLFYSEIFKINRAAVIMLSUKPLL
DPRP2	50	NKAPHDEOFVORTDESGPHSHRYYLAMPYGSRENLLYSETPKKURKEALLLLSKOML
DPRP3	48	ITMSVILLSP..DELTNSSETRLSLED..LIRKE..EVLHD.PEARWINDTDVYKSEN
DPP4	75	LVFNAEYGNSS.....FLENSTFDEFCHSINDYSISPDGQENLLEYNYVKQMRHSYT
DPRP1	121	DEFQATIYGWYSREEELLRERKRIGTVGIASYDYHQG.SGTFLFOAGSGGTVVPGGP
DPRP2	110	DHFQATPHHGWWYSREEELLRERKRLGVFGTISYDLEHSE.SGLFLFOASMSLHCRDGGK
DPRP3	101	GHVIKLMETNAT.....LLLENTEFTF..KASRHSISPDLKMLLAYEVVKQIHDYSYT
DPP4	130	ASNDITYDLNK...RCLITEERIPNNTQWVTWSPVGHKLAQWNNNDIVVKIEPNLPSYR
DPRP1	179	QGETTQOPIEP...NIVETSCPNI. MDPKICPADPDWIAIHSNDIVISNIVTREERRLT
DPRP2	168	NGTMSPZEP...LEIKTQCSGPR. MDPKICPADPAEFLINNSDEVANIEETGEERRLT
DPRP3	155	ASIVIYNNTREVWELNPPEVEDSVIQAAGVQGQQLIIEENATIYQPDIKSSSLRLT
DPP4	187	SG.....KEPITYNCITDWVYEEEVFSAYSALWWSPNCTELAY.....A..QENLVEVP
DPRP1	235	VHNEILANMEEDARSAGVATEVLFQEEFDRYSYWWCPKAETTPS.GGKILRILYEEIDES
DPRP2	224	ECHOGLSNVLEDPKSAAGVATFVIQEEFDRYAYWWCPTAQEESEGLKTLRILYEEEVDES
DPRP3	215	SSG.....KEPIIFNQIADWLYEEELLHSHIAHWWSPDGERLAF.....QENLVEVP
DPP4	235	LEYSFYIDESLYPKTVRVYPKAGAVNP..TKEFVVNTDSLSSNTNATSIETAPAS
DPRP1	294	EVEIIHVTSPLETRRADSRYPKTGIANPKVTEKSEIMIDAEGRNIFDVIDKELIQPFE
DPRP2	284	EVEVIHVPSPALEERKTDSDYRYPKETGSKKNPKIAEKAEOFDTDSOGKIVSTQEKELEQPF
DPRP3	263	TEVVIPFTGAYP...KGKOYYPYKAGQVNP..TAKLEVNVLYG.....PTHTLELPEDS
DPP4	293	ELIG.DHYCDVTWAHQ.ERISQWLRRION.....
DPRP1	354	LFEGVEYIARAGWTPEGKYAWAFLLDRSOTRLQVLSPELFIPVEEDVMERQRLIESV
DPRP2	344	SLFPKVEYIARAGWTRDGKYAWAFLLDRPQSWLQVLLPPALFIPSTNEEQRLASARAV
DPRP3	314	FKSR.EYYITMVWKVN.TKTVWRWLNRPQN.....
DPP4	322	.YSVWDECDYIERSGRWNCLIVARQHEMSITGWVGRFRPSEEHFTLDGNSFYKIISNE..
DPRP1	414	PDSVTPIIYEEITDWINIHDIFHFFQDS. HEHEEEFIFASBECKTGFRHLYKITSELKE
DPRP2	404	PRNVQPYVVYEEVTNQWINIHDIFYPFPQSEGDEFCFIRANECKTGFOHLYKETAVLKS
DPRP3	343	.ISYETCETTTG.....ACSKYEMTSPTWLSQQNE.EPVFSRDGSFIMTVPVKQG

FIG. 1A

DPP4	379	E.....GRRHICYFQIDKR.....ECTEATKGTWEVEG....TEAETS EY LYYISNEYK
DPRP1	473	S EY KRSSGGLPAPS E FKCPIK.....EEIAITSGEWEVEGRHGSNIQVDEVR E LVYFEGTK
DPRP2	464	QGYDWSEPPFS E GED E FKCPIK.....EEIAITSGEWEVE E RHGSKIWVNE E LVYFEGTK
DPRP3	394	G.....GE E HIAFLIQSKSEQITVRH E TSGNWEV E K....I E AYDETTQK E YFLSTE
DPP4	424	GMPGGRNLYK E QLSDYTKVTCISCELNP E RCOYYSVSF E SK E KYY E YPLRGSGPG E PF E YTLH
DPRP1	529	DSPLER E HLVVVSYVNP E CEVTRL E DR E CYSHSCCISQHCD E LSKYS E QNP. HC E VSL E YKLS
DPRP2	520	D E PLE E HLVVVSY E AGE E VRL E TPG E SHSCMSQNFD E MF E SYSS E STP. PCVH E YKLS
DPRP3	445	SSPRGE E OLYSASTE E LLNRQC E CNFMKE E Q E YFDAS E SPMNQH E FLFOEG E PRVP E VSI E H
DPP4	484	SSVNDKGL E LEDNSA E LDKMLQ E ..VQ E PSKKL E DF E LEN E T E YQ E Q E ILPPHFD E SKK E YP
DPRP1	588	SP E DDPTC E KT E KEFWA E GGAGPL E PDY E TPPE E IF E FS E EST E FG E TYG E MLYK E PHD E LOPGKK E YP
DPRP2	579	GP E DDPLH E KOP E REW E WA E ME E ASC E PPD E Y E PPE E IF E FE E HER E SD E V E LYG E MEYK E PHAL E LOPGKK E HP
DPRP3	505	STDNP E AKYF E LESNSML E KE E AI E KKKIG E KP..ET E FE E HH E DD E Y E EL E PLQ E SL E PR E DFMDRNO E YA
DPP4	542	I E LDVY E AG E PC E SQKA E TV E FR..LN E WATYLA E EN E I E WAS E FDGRGSG E YQ E GD E KIMHAINR E RG
DPRP1	648	T E LF E YGGPQVQLVNN E FKG E KY E RLNT E IASL E GY E W E VV E VIDNRGS E CHRLK E FE E GA E FR E Y E NG
DPRP2	639	T E LFVY E GGPQVQLVNN E FKG E KY E RLNT E IASL E GY E W E VV E VIDGRGSC E Q E RG E LF E EG E AK E KN E PG
DPRP3	563	L E LI E DE E EP E GGQ E LV E TE E KF E ..IDWDSV E LDMDNV E VARF E DGRGSG E YQ E GLK E KI E Q E E E IR E RL E IG
DPP4	600	T E E E EDQ E FE E ARQ E E. KM E GF E DN E KR E IA E W E GSY E GGY E W E SMV E LG E SG E SG E V E KC E IA E W E AP E VER
DPRP1	708	Q E IE E EDQ E FE E LO E FLAS E RY E DF E IDL E DRV E I E H E GSY E GGY E LS E MA E LO E PSD E IF E EV E IA E GA E PT E
DPRP2	699	Q E IE E EDQ E FE E LO E FLAE E KY E GF E IDL E SRV E ATH E G E WSY E GG E LS E LM E GL E I E H E POV E FK E W E IA E GA E PT E
DPRP3	621	S E VE E KD E Q E TF E W E KF E IL. KLP E W E DS E KR E S E IE E FG E K E Y E GGY E W E SMIL E K E DE E K E FE E CS E V E V E AP E TD
DPP4	659	W E EYD E SV E YTERY E M E G E PT E PED E N E D E H E TRN E ST E V E MSRA E EN E FK E Q E VE E YL E SH E GTAD E UVH E FO E SA E Q
DPRP1	768	W E EYD E SV E YTERY E M E G E PT E PEN E NE E EGY E YL E GS E VA E Q E A E K E E E SE E PN E R E L E H E G E FL E D E EN E V E HE E HN E SI
DPRP2	759	W E EYD E SV E YTERY E M E D E P E EN E NG E GY E EA E GS E VA E H E VE E K E LP E NE E PN E R E L E H E G E FL E D E EN E V E HE E HN E NF
DPRP3	680	L E K E LY E AS E Y E TERY E G E PS E KE E ES..T E Y E Q E A E V E W E H E NV E H E GL E KE E EN E LL E SH E GTAD E TK E V E H E FO E SA E E
DPP4	719	LSKAL E D E V E G E V E D E Q E AM E W E Y E T E DE E H E GI E AS E ST E H E HI E Y E TH E SH E FE E K E CF E SL E P.....
DPRP1	828	LS E SFL E W E R E AG E K E P E D E L E Q E I E Y E P E Q E E E R E H E S E I E R E V E P E E E GE E H E Y E EL E H E L E LL E H E Q E E E N E L E G E S E R E I E A E ALK E VI.....
DPRP2	819	L E SQL E I E R E AG E K E P E Y E Q E I E Y E P E N E E E R E H E S E I E R E C E P E E E GE E H E Y E E E V E T E LL E H E F E Q E E E YL.....
DPRP3	738	L E E E KH E I E Y E AG E V E NY E T E Q E Y E P E D E E E G E H E N E SE E K. SK E Y E H E LY E ST E E E FF E S E C E L E KE E E E IS E V E L E P E E E DE

FIG. 1B

hDPRP1	1	MAAAMETEQLGVEIFETADCEEN. IESQDRPKLEPFYVERYSWSQLKKLLADTRKYHGYM
mDPRP1	1	MAAAMETEQLGVEIFETADCEEN. IESQDRPKLEPFYVERYSWSQLKKLLADTRKYHGYM
hDPRP1	60	MAKAPHDFMFVKRNDPDGPHSDRYYLAMSGENRENTLFYSEIPKTINRAAVLMLSWKPL
mDPRP1	61	MAKAPHDFMFVKRNDPDGPHSDRYYLAMSGENRENTLFYSEIPKTINRAAVLMLSWKPL
hDPRP1	120	LDLFQATLDYGMYSREEELLRERKRIGTVGIA SYDYHOGSGTFLFQAGSGIYH KDGGPQ
mDPRP1	121	LDLFQATLDYGMYSREEELLRERKRIGTVGIA AYDYHOGSGTFLFQAGSGIYH KDGGPQ
hDPRP1	180	GFTQQPLRPNLVETSCPNTIRMDPKLCPADPDWIAFIHSNDIWINSTVTRERRTYVHNE
mDPRP1	181	GFTQQPLRPNLVETSCPNTIRMDPKLCPADPDWIAFIHSNDIWINSTVTRERRTYVHNE
hDPRP1	240	LANMEEDARSAGVATFVLQEEFDRYSGYWWCPKAERTPSGGKILRILYEENDESEVEIIH
mDPRP1	241	LANMEEDPRSAGVATFVLQEEFDRYSGYWWCPQAERTPSGGKILRILYEENDESEVEIIH
hDPRP1	300	VTSPMLETRRADSFYRYPKTGTANPKVTFKMSEI DAEGRILDVIDKEL QPFEILFEGV
mDPRP1	301	VTSPMLETRRADSFYRYPKTGTANPKVTFKMSEI DAAGGIIDVIDKEL QPFEILFEGV
hDPRP1	360	EYIARAGWTPEGKIAWSILLDRSQTRLQIVLISPELFIPVVEDDVM RQLIESVPDSVTP
mDPRP1	361	EYIARAGWTPEGKIAWSILLDRSQTRLQIVLISPELFIPVVEDDAM RQLIESVPDSVTP
hDPRP1	420	LIIYEETTDIWINIHDIFHVFPQHE EIEFIFASECKTGFRLHYKITSILKESKYKRSS
mDPRP1	421	LIIYEETTDIWINIHDIFHVFPQHE EIEFIFASECKTGFRLHYKITSILKESKYKRSS
hDPRP1	480	GGLPAPSDFKCPIKEEIAITSGEWEVLGRHGSNIQVDEVR LVYFEGTKDSPLEHHLYVV
mDPRP1	481	GGLPAPSDFKCPIKEEITITSGEWEVLGRHGSNIWVDEAR LVYFEGTKDSPLEHHLYVT
hDPRP1	540	SYVNPGEVTRLTDRGYSHSCC SOHCDFFISKYSNQKNPHCVSLYKLSSPEDDP TCKTKE
mDPRP1	541	SYANPGEVVRLTDRGYSHSCC SRHCDFFISKYSNQKNPHCVSLYKLSSPEDDPVHKTKE
hDPRP1	600	FWATILDSAGPLPDYTPPEIFSFESTTGFTLYGMLYKPHDLQPGKKPTVLFYGGPQVQ
mDPRP1	601	FWATILDSAGPLPDYTPPEIFSFESTTGFTLYGMLYKPHDLQPGKKPTVLFYGGPQVQ
hDPRP1	660	LVNNRFKGVKYFRLNTLASLGYVVVVIDNRGSCHRGLKFEGAFKYKMGQIEIDDQVEGLQ
mDPRP1	661	LVNNRFKGVKYFRLNTLASLGYVVVVIDNRGSCHRGLKFEGAFKYKMGQIEIDDQVEGLQ
hDPRP1	720	YLASRYDFTDLDRVGIGHGWSYGGYLSIMALMQRSDIFRVAIAGAPVTLWIFYDTGYTERY
mDPRP1	721	YLASQYDFTDLDRVGIGHGWSYGGYLSIMALMQRSDIFRVAIAGAPVTLWIFYDTGYTERY
hDPRP1	780	MGHPDQNEQGYYLGSVAMQAEKFPSEPNRLLLLHGFLENDVHFAHTSILLSFLVRAGKPY
mDPRP1	781	MGHPDQNEQGYYLGSVAMQAEKFPSEPNRLLLLHGFLENDVHFAHTSILLSFLVRAGKPY
hDPRP1	840	DLQIYPQERHSIRVPESGEHYELHILHYLQENLGSRIAALKVI
mDPRP1	841	DLQIYPQERHSIRVPESGEHYELHLLHYLQENLGSRIAALKVI




FIG. 3




FIG. 4A




FIG. 4B




FIG. 4C

Sequence Listing Summary

SEQ ID.

1. DPRP1 a.a. sequence
2. DPRP1 DNA sequence
- 5 3. DPRP2 a.a. sequence
4. DPRP2 DNA sequence
5. DPRP-3 a.a. sequence
6. DPRP-3 DNA sequence
7. DPRP-1 transcript 0 a.a. sequence
- 10 8. DPRP-1 transcript 0 DNA sequence
9. DPRP-1 transcript 1 a.a. sequence
10. DPRP-1 transcript 1 DNA sequence
11. DPRP-1 transcript 2 a.a. sequence
12. DPRP-1 transcript 2 DNA sequence
- 15 13. DPRP-1 transcript 3 a.a. sequence
14. DPRP-1 transcript 3 DNA sequence
15. DPRP-1 transcript 4 a.a. sequence
16. DPRP-1 transcript 4 DNA sequence
17. DPRP-1 transcript 5 a.a. sequence
- 20 18. DPRP-1 transcript 5 DNA sequence
19. DPRP-1 transcript 6 a.a. sequence
20. DPRP-1 transcript 6 DNA sequence
21. DPRP-1 transcript 7 a.a. sequence
22. DPRP-1 transcript 7 DNA sequence
- 25 23. DPRP-2 transcript 0 a.a. sequence
24. DPRP-2 transcript 0 DNA sequence
25. DPRP-2 transcript 1 a.a. sequence
26. DPRP-2 transcript 1 DNA sequence
27. DPRP-2 transcript 2 a.a. sequence
- 30 28. DPRP-2 transcript 2 DNA sequence
29. DPRP-2 transcript 3 a.a. sequence
30. DPRP-2 transcript 3 DNA sequence
31. DPRP-2 transcript 4 a.a. sequence
32. DPRP-2 transcript 4 DNA sequence
- 35 33. DPRP-2 transcript 5 a.a. sequence

34. DPRP-2 transcript 5 DNA sequence
35. DPRP-2 transcript 6 a.a. sequence
36. DPRP-2 transcript 6 DNA sequence
37. DPRP-2 transcript 7 a.a. sequence
- 5 38. DPRP-2 transcript 7 DNA sequence
39. DPRP-2 transcript 8 a.a. sequence
40. DPRP-2 transcript 8 DNA sequence
41. DPRP-3 transcript 0 a.a. sequence
42. DPRP-3 transcript 0 DNA. Sequence
- 10 43. DPRP-3 transcript 1 a.a. sequence
44. DPRP-3 transcript 1 DNA sequence
45. DPRP1 forward primer used for cloning
46. DPRP1 reverse primer used for cloning full length gene
47. DPRP1 reverse primer used for cloning fusion gene
- 15 48. DPRP1 forward primer used for expression profiling
49. DPRP1 reverse primer used for expression profiling
50. DPRP2 forward primer used for cloning
51. DPRP2 reverse primer used for cloning full length gene
52. DPRP2 reverse primer used for cloning fusion gene
- 20 53. DPRP2 forward primer used for expression profiling
54. DPRP2 reverse primer used for expression profiling
55. DPRP3 forward primer used for cloning
56. DPRP3 reverse primer used for cloning full length gene
57. DPRP3 forward primer used for cloning fusion gene
- 25 58. DPRP3 reverse primer used for cloning fusion gene
59. DPRP1 peptide antigen sequences
60. DPRP2 peptide antigen sequences
61. DPRP3 peptide antigen sequences

SEQUENCE LISTING

<110> Qi, Steve
Akinsanya, Karen
Riviere, Pierre
Junien, Jean-Louis

<120> NOVEL SERINE PROTEASE GENES RELATED TO DPPIV

<130> 70669

<150> US 60/240,117

<151> 2000-10-12

<160> 61

<170> Patent In version 3.1

<210> 1
<211> 882
<212> PRT
<213> Homo sapiens
<400> 1

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
1 5 10 15
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
20 25 30
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
35 40 45
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
50 55 60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
65 70 75 80
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
85 90 95
Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu
100 105 110
Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp
115 120 125
Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg
130 135 140
Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly
145 150 155 160
Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly
165 170 175
Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu
180 185 190
Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp
195 200 205
Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn
210 215 220
Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu
225 230 235 240
Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val
245 250 255

Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys
 260 265 270
 Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu
 275 280 285
 Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met
 290 295 300
 Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr
 305 310 315 320
 Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala
 325 330 335
 Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe
 340 345 350
 Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr
 355 360 365
 Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr
 370 375 380
 Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu
 385 390 395 400
 Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser
 405 410 415
 Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn
 420 425 430
 Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Glu Ile
 435 440 445
 Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr
 450 455 460
 Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly
 465 470 475 480
 Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile
 485 490 495
 Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn
 500 505 510
 Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys
 515 520 525
 Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro
 530 535 540
 Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys
 545 550 555 560
 Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys
 565 570 575
 Asn Pro His Cys Val Ser Leu Tyr Lys Leu Ser Ser Pro Glu Asp Asp
 580 585 590
 Pro Thr Cys Lys Thr Lys Glu Phe Trp Ala Thr Ile Leu Asp Ser Ala
 595 600 605
 Gly Pro Leu Pro Asp Tyr Thr Pro Pro Glu Ile Phe Ser Phe Glu Ser
 610 615 620
 Thr Thr Gly Phe Thr Leu Tyr Gly Met Leu Tyr Lys Pro His Asp Leu
 625 630 635 640
 Gln Pro Gly Lys Lys Tyr Pro Thr Val Leu Phe Ile Tyr Gly Gly Pro
 645 650 655
 Gln Val Gln Leu Val Asn Asn Arg Phe Lys Gly Val Lys Tyr Phe Arg
 660 665 670
 Leu Asn Thr Leu Ala Ser Leu Gly Tyr Val Val Val Val Ile Asp Asn
 675 680 685
 Arg Gly Ser Cys His Arg Gly Leu Lys Phe Glu Gly Ala Phe Lys Tyr
 690 695 700
 Lys Met Gly Gln Ile Glu Ile Asp Asp Gln Val Glu Gly Leu Gln Tyr
 705 710 715 720

Leu Ala Ser Arg Tyr Asp Phe Ile Asp Leu Asp Arg Val Gly Ile His
 725 730 735
 Gly Trp Ser Tyr Gly Gly Tyr Leu Ser Leu Met Ala Leu Met Gln Arg
 740 745 750
 Ser Asp Ile Phe Arg Val Ala Ile Ala Gly Ala Pro Val Thr Leu Trp
 755 760 765
 Ile Phe Tyr Asp Thr Gly Tyr Thr Glu Arg Tyr Met Gly His Pro Asp
 770 775 780
 Gln Asn Glu Gln Gly Tyr Tyr Leu Gly Ser Val Ala Met Gln Ala Glu
 785 790 795 800
 Lys Phe Pro Ser Glu Pro Asn Arg Leu Leu Leu His Gly Phe Leu
 805 810 815
 Asp Glu Asn Val His Phe Ala His Thr Ser Ile Leu Leu Ser Phe Leu
 820 825 830
 Val Arg Ala Gly Lys Pro Tyr Asp Leu Gln Ile Tyr Pro Gln Glu Arg
 835 840 845
 His Ser Ile Arg Val Pro Glu Ser Gly Glu His Tyr Glu Leu His Leu
 850 855 860
 Leu His Tyr Leu Gln Glu Asn Leu Gly Ser Arg Ile Ala Ala Leu Lys
 865 870 875 880
 Val Ile

<210> 2
 <211> 2671
 <212> DNA
 <213> Homo sapiens
 <400> 2

cggattccatg gcagcagcaa tggaaacaga acagctgggt gttgagatat ttgaaactgc 60
 ggactgtgag gagaatattt aatcacagga tcggcctaaa ttggagcctt tttatgttga 120
 gcggtattcc tggagtgcgc ttaaaaagct gcttgcgcat accagaaaat atcatggcta 180
 catatggct aaggcaccac atgatttcat gtttgtgaag aggaatgatc cagatggacc 240
 tcattcagac agaatetattt accttgccat gtctggtag aacagagaaa atacactgtt 300
 ttattctgaa attcccaaaa ctatcaatag agcagcagtc ttaatgctct cttggaaagcc 360
 tctttggat cttttcagg caacactgga ctatggatg tattctcgag aagaagaact 420
 attaagagaa agaaaacgca ttggaacagt cggatttgct tcttacgatt atcaccaagg 480
 aagtggaca tttctgtttc aagccggtag tggaaatttat cacgtaaaag atggaggggcc 540
 acaaggattt acgcaacaac ctttaaggcc caatctatgt gaaacttagtt gtcccaacat 600
 acggatggat cccaaattat gcctgctga tccagactgg attgctttt tacatagcaa 660
 ccatatggat atatctaaca tcgttaaccag agaagaaaagg agactcaatt atgtgcacaa 720
 ttagctagcc aacatggaaag aagatgccag atcagctgga gtcgctaccc ttgttctcca 780
 agaagaattt gatagatatt ctggctattt gtgggtgtcca aaagctgaaa caactccag 840
 tgggtgtaaa attcttagaa ttctatatga agaaaatgtt gaatctgagg tggaaatttat 900
 tcatgttaca tcccctatgt tggaaacaag gagggcagat tcattccgtt atcctaaaac 960
 aggtacagca aatcctaaaag tcactttaa gatgtcagaa ataatgattt atgctgaagg 1020
 aaggatcata gatgtcatag ataaggaact aattcaaccc tttgagattt tatttgaagg 1080
 agttgaatat attgccagag ctggatggac tcctgaggaa aatatgtttt ggtccatcc 1140
 actagatcgc tcccagactc gcctgcagat agtgttgatc tcacctgaat tatttacccc 1200
 agttagaagat gatgttatgg aaaggcagag actcatttgatc tcagtcctt attctgtgac 1260
 gccactaatt atctatgttcaaaacacaga catctggata aatatccatg acatcttca 1320
 tgttttccctt caaagtccacg aagagggaaat tgagtttattt tttgcctctg aatgaaaac 1380
 aggtttccgtt catttataca aaattacatc tattttaaag gaaagcaaat ataaacgatc 1440
 cagtgggtggg ctgcctgctc caagtgttca gatgtgcctt atcaaagagg agatagcaat 1500
 taccagtgggtt gaatggaaag ttcttggcccg gcatggatct aatatccaaat ttgtatgttca 1560
 cagaaggctgtt gtatattttt aaggcaccaaa agactcccctt ttagagcatc acctgtacgt 1620
 agtcagttac gtaaaatccatc gagaggtgac aaggctgact gaccgtggctt actcacattc 1680
 ttgctgcattc agtcagact gtgacttctt tataagtaag tataagtaacc agaagaatcc 1740
 acactgtgttgc tcccttataca agtatacaag tcctgaagat gacccaaactt gcaaaaacaaa 1800
 ggaattttggg gccaccattt tgattcagc aggtccctt cctgactata ctcctccaga 1860
 aattttctctt tttgaaagta ctactggatt tacattgtat gggatgttctt acaagcctca 1920

tgatctacag	cctggaaaaga	aatatcctac	tgtgctgttc	atatatggtg	gtcctcaggt	1980
gcagttggtg	aataatcgat	ttaaaggagt	caagtatttc	cgcttgaata	ccctagcctc	2040
tctaggttat	gtgggtttag	tgatagacaa	cagggatcc	tgtcaccgag	ggcttaaatt	2100
tgaaggcgcc	tttaaatata	aatatgggtca	aatagaatt	gacgatcagg	tggaaggact	2160
ccaatatcta	gcttctcgat	atgatttcat	tgacttagat	cgtgtggca	tccacggctg	2220
gtcctatgga	ggataacctct	ccctgatggc	attaatgcag	aggtcagata	tcttcagggt	2280
tgctattgct	ggggccccag	tcactctgtg	gatcttctat	gatacaggat	acacaggaacg	2340
ttatatgggt	caccctgacc	agaatgaaca	gggctattac	ttaggatctg	tggccatgca	2400
agcagaaaag	ttcccccctctg	aaccaaattcg	tttactgctc	ttacatgggt	tcctggatga	2460
gaatgtccat	tttgcacata	ccagtatatt	actgagttt	ttagtgaggg	ctggaaaagcc	2520
atatgattta	cagatctatc	ctcaggagag	acacagcata	agagttcctg	aatcgggaga	2580
acattatgaa	ctgcacatctt	tgcaactacct	tcaagaaaac	cttggatcac	gtattgctgc	2640
tctaaaagtg	atatgagcgg	ccgcgagctc	c			2671

<210> 3
 <211> 863
 <212> PRT
 <213> Homo sapiens
 <400> 3

Met	Ala	Thr	Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala
1				5				10					15		
Thr	Asp	Asp	Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp
							20			25				30	
Gly	Leu	Arg	Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile
							35		40				45		
Val	Asn	Lys	Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu
							50		55			60			
Ser	Gly	Pro	His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly
							65		70		75		80		
Ser	Arg	Glu	Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg
							85		90		95				
Lys	Glu	Ala	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	
							100		105		110				
Gln	Ala	Thr	Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu
							115		120		125				
Arg	Glu	Arg	Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe
							130		135		140				
His	Ser	Glu	Ser	Gly	Leu	Phe	Leu	Phe	Gln	Ala	Ser	Asn	Ser	Leu	Phe
							145		150		155		160		
His	Cys	Arg	Asp	Gly	Gly	Lys	Asn	Gly	Phe	Met	Val	Ser	Pro	Met	Lys
							165		170		175				
Pro	Leu	Glu	Ile	Lys	Thr	Gln	Cys	Ser	Gly	Pro	Arg	Met	Asp	Pro	Lys
							180		185		190				
Ile	Cys	Pro	Ala	Asp	Pro	Ala	Phe	Phe	Ser	Ile	Asn	Asn	Ser	Asp	
							195		200		205				
Leu	Trp	Val	Ala	Asn	Ile	Glu	Thr	Gly	Glu	Glu	Arg	Arg	Leu	Thr	Phe
							210		215		220				
Cys	His	Gln	Gly	Leu	Ser	Asn	Val	Leu	Asp	Asp	Pro	Lys	Ser	Ala	Gly
							225		230		235		240		
Val	Ala	Thr	Phe	Val	Ile	Gln	Glu	Glu	Phe	Asp	Arg	Phe	Thr	Gly	Tyr
							245		250		255				
Trp	Trp	Cys	Pro	Thr	Ala	Ser	Trp	Glu	Gly	Ser	Glu	Gly	Leu	Lys	Thr
							260		265		270				
Leu	Arg	Ile	Leu	Tyr	Glu	Glu	Val	Asp	Glu	Ser	Glu	Val	Glu	Val	Ile
							275		280		285				
His	Val	Pro	Ser	Pro	Ala	Leu	Glu	Glu	Arg	Lys	Thr	Asp	Ser	Tyr	Arg
							290		295		300				
Tyr	Pro	Arg	Thr	Gly	Ser	Lys	Asn	Pro	Lys	Ile	Ala	Leu	Lys	Leu	Ala
							305		310		315		320		

Glu Phe Gln Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys
 325 330 335
 Glu Leu Val Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile
 340 345 350
 Ala Arg Ala Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe
 355 360 365
 Leu Asp Arg Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala
 370 375 380
 Leu Phe Ile Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala
 385 390 395 400
 Arg Ala Val Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val
 405 410 415
 Thr Asn Val Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln
 420 425 430
 Ser Glu Gly Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys
 435 440 445
 Thr Gly Phe Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln
 450 455 460
 Gly Tyr Asp Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys
 465 470 475 480
 Cys Pro Ile Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val
 485 490 495
 Leu Ala Arg His Gly Ser Lys Ile Trp Val Asn Glu Glu Thr Lys Leu
 500 505 510
 Val Tyr Phe Gln Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr
 515 520 525
 Val Val Ser Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro
 530 535 540
 Gly Phe Ser His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val
 545 550 555 560
 Ser His Tyr Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys
 565 570 575
 Leu Ser Gly Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp
 580 585 590
 Ala Ser Met Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro
 595 600 605
 Glu Ile Phe His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met
 610 615 620
 Ile Tyr Lys Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val
 625 630 635 640
 Leu Phe Val Tyr Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe
 645 650 655
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr
 660 665 670
 Ala Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg
 675 680 685
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp
 690 695 700
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp
 705 710 715 720
 Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser
 725 730 735
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Val Ala Ile Ala
 740 745 750
 Gly Ala Pro Val Thr Val Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu
 755 760 765

Arg	Tyr	Met	Asp	Val	Pro	Glu	Asn	Asn	Gln	His	Gly	Tyr	Glu	Ala	Gly
770					775					780					
Ser	Val	Ala	Leu	His	Val	Glu	Lys	Leu	Pro	Asn	Glu	Pro	Asn	Arg	Leu
785					790					795					800
Leu	Ile	Leu	His	Gly	Phe	Leu	Asp	Glu	Asn	Val	His	Phe	His	Thr	
					805					810					815
Asn	Phe	Leu	Val	Ser	Gln	Leu	Ile	Arg	Ala	Gly	Lys	Pro	Tyr	Gln	Leu
					820					825					830
Gln	Ile	Tyr	Pro	Asn	Glu	Arg	His	Ser	Ile	Arg	Cys	Pro	Glu	Ser	Gly
					835					840					845
Glu	His	Tyr	Glu	Val	Thr	Leu	Leu	His	Phe	Leu	Gln	Glu	Tyr	Leu	
					850					855					860

<210> 4

<211> 2617

<212> DNA

<213> Homo sapiens

<400> 4

caagcttacc	atggccacca	ccgggacccc	aacggccgac	cgaggcgacg	cagccgccac	60
agatgacccg	gcccggcgt	tccagggtca	gaagcactcg	tgggacgggc	tccggagcat	120
catccacggc	agccgcaga	actcgggcct	cattgtcaac	aaggcgcccc	acgacttcca	180
gttggcag	aagacggatg	agtctggcc	ccactccac	cgcctctact	acctggaaat	240
gccatatggc	agccgagaga	actccctcct	ctactctgag	attcccaaga	aggtccggaa	300
agaggctctg	ctgctcctgt	ccttggaaagca	gatgctggat	catttccagg	ccacgccccca	360
ccatggggtc	tactctcggg	aggaggagct	gctgagggag	cggaaacgccc	tgggggtctt	420
cggcatcacc	tcctacgact	tccacagcga	gagtggcetc	ttccttctcc	aggccagcaa	480
cagcctcttc	cactgtcgcg	acggcggcaa	gaacggcttc	atgggtgtccc	ctatgaaacc	540
gctggaaatc	aagaccagg	gctcaggggcc	ccggatggac	cccaaaatct	gccctgcccga	600
ccctgccttc	ttctccttca	tcaataacag	cgacctgtgg	gtggccaaca	tgcagacagg	660
cgaggagcgg	cggctgaccc	tcttggccacca	aggtttatcc	aatgtcttgg	atgaccccaa	720
gtctgcgggt	gtggccaccc	tctgtatata	ggaagagttc	gaccgcttca	ctgggtactg	780
gtggtgcggcc	acagcctcct	gggaagggttc	agagggcctc	aagacgctgc	gaatcctgta	840
tgaggaagtc	gatgatccg	agggtggaggt	cattcacgtc	ccctcttctg	cgctagaaga	900
aaggaagacg	gactcgatc	ggtaccccg	gacaggcagc	aagaatccca	agattgcctt	960
gaaactggct	gagttccaga	ctgacagccca	gggcaagatc	gtctcgaccc	aggagaagga	1020
gctggtgcag	cccttcagct	cgtgttccc	gaaggtggag	tacatgccc	gggcccgggtg	1080
gaccggggat	ggcaaatacg	cctggccat	gttcctggac	cggcccccagc	agtggctcca	1140
gctcgtcctc	ctcccccccg	ccctgttcat	cccgagcaca	gagaatgagg	agcagcggct	1200
agcctctgcc	agagctgtcc	ccaggaatgt	ccagccgtat	gtgggttacg	aggaggtcac	1260
caacgtctgg	atcaatgttc	atgacatctt	ctatcccttc	ccccaaatcg	agggagagaga	1320
cgagctctgc	tttctcccg	ccaatgaatg	caagacggc	ttctgccatt	tgtacaaatg	1380
caccgcgtt	ttaaaatccc	agggtacga	ttggagttag	cccttcagcc	ccggggaaaga	1440
tgaatttaag	tgccccatt	aggaagagat	tgctctgacc	agcgggtaat	gggaggtttt	1500
ggcgaggcac	ggctccaaga	tctgggtcaa	tgaggagacc	aagctgtgt	acttccagg	1560
caccaaggac	acgcccgtgg	agcaccaccc	ctacgtggc	agctatgagg	cgcccccggc	1620
gatcgta	ctcaccacgc	ccggcttctc	ccatagctgc	tccatgagcc	agaacttcga	1680
catgttcgtc	agccactaca	gcagcgttag	cacgcccccc	tgcgtgcacg	tctacaagct	1740
gagggcccc	gacgacgacc	ccctgcacaa	gcagcccccc	ttctgggct	gcatgatgga	1800
ggcagccagc	tgcccccccg	attatgtcc	tccagagatc	ttccatttcc	acacgcgc	1860
ggatgtgcgg	ctctacggca	tgtatctacaa	gccccacgccc	ttgcagccag	ggaagaagca	1920
cccaccgtc	ctctttgtat	atggaggccc	ccaggtgcag	ctgggtgaata	actcctcaa	1980
aggcatcaag	tacttgcggc	tcaacacact	ggcctccctg	ggctacgcgg	tgggtgtat	2040
tgacggcagg	ggctcctgtc	agcgagggt	tcgggtcgaa	ggggccctga	aaaaccaat	2100
ggggccagggt	gagatcgagg	accaggtgga	gggcctgcag	ttcgtggcc	agaagtatgg	2160
cttcatcgac	ctgagccgag	ttgcccattca	tggctggcc	tacgggggt	tcctctcgct	2220
catggggcta	atccacaaggc	cccagggttt	caagggtggcc	atcgccgggt	ccccgggtac	2280
cgtctggatg	gcctacgaca	cagggtacac	tgagcgtac	atggacgtcc	ctgagaacaa	2340
ccagcacggc	tatgaggcgg	gttccgtggc	cctgcacgtg	gagaagctgc	ccaatgagcc	2400
caaccgcgtt	cttacatcctc	acggcttct	ggacgaaaac	gtgcacttt	tccacacaaa	2460

cttcctcgctc tcccaactga tccgaggcagg gaaacccctac cagctccaga tctaccccaa 2520
 cgagagacac agtattcgct gccccgagtc gggcgagcac tatgaagtca cgttgctgca 2580
 ctttctacag gaataccctct gagcggccgc ggatccg 2617

<210> 5
 <211> 796
 <212> PRT
 <213> Homo sapiens
 <400> 5

Met Asn Gln Thr Ala Ser Val Ser His His Ile Lys Cys Gln Pro Ser
 1 5 10 15
 Lys Thr Ile Lys Glu Leu Gly Ser Asn Ser Pro Pro Gln Arg Asn Trp
 20 25 30
 Lys Gly Ile Ala Ile Ala Leu Leu Val Ile Leu Val Val Cys Ser Leu
 35 40 45
 Ile Thr Met Ser Val Ile Leu Leu Ser Pro Asp Glu Leu Thr Asn Ser
 50 55 60
 Ser Glu Thr Arg Leu Ser Leu Glu Asp Leu Phe Arg Lys Asp Phe Val
 65 70 75 80
 Leu His Asp Pro Glu Ala Arg Trp Ile Asn Asp Thr Asp Val Val Tyr
 85 90 95
 Lys Ser Glu Asn Gly His Val Ile Lys Leu Asn Ile Glu Thr Asn Ala
 100 105 110
 Thr Thr Leu Leu Leu Glu Asn Thr Thr Phe Val Thr Phe Lys Ala Ser
 115 120 125
 Arg His Ser Val Ser Pro Asp Leu Lys Tyr Val Leu Leu Ala Tyr Asp
 130 135 140
 Val Lys Gln Ile Phe His Tyr Ser Tyr Thr Ala Ser Tyr Val Ile Tyr
 145 150 155 160
 Asn Ile His Thr Arg Glu Val Trp Glu Leu Asn Pro Pro Glu Val Glu
 165 170 175
 Asp Ser Val Leu Gln Tyr Ala Ala Trp Gly Val Gln Gly Gln Gln Leu
 180 185 190
 Ile Tyr Ile Phe Glu Asn Asn Ile Tyr Tyr Gln Pro Asp Ile Lys Ser
 195 200 205
 Ser Ser Leu Arg Leu Thr Ser Ser Gly Lys Glu Glu Ile Ile Phe Asn
 210 215 220
 Gly Ile Ala Asp Trp Leu Tyr Glu Glu Glu Leu Leu His Ser His Ile
 225 230 235 240
 Ala His Trp Trp Ser Pro Asp Gly Glu Arg Leu Ala Phe Leu Met Ile
 245 250 255
 Asn Asp Ser Leu Val Pro Thr Met Val Ile Pro Arg Phe Thr Gly Ala
 260 265 270
 Leu Tyr Pro Lys Gly Lys Gln Tyr Pro Tyr Pro Lys Ala Gly Gln Val
 275 280 285
 Asn Pro Thr Ile Lys Leu Tyr Val Val Asn Leu Tyr Gly Pro Thr His
 290 295 300
 Thr Leu Glu Leu Met Pro Pro Asp Ser Phe Lys Ser Arg Glu Tyr Tyr
 305 310 315 320
 Ile Thr Met Val Lys Trp Val Ser Asn Thr Lys Thr Val Val Arg Trp
 325 330 335
 Leu Asn Arg Pro Gln Asn Ile Ser Ile Leu Thr Val Cys Glu Thr Thr
 340 345 350
 Thr Gly Ala Cys Ser Lys Lys Tyr Glu Met Thr Ser Asp Thr Trp Leu
 355 360 365
 Ser Gln Gln Asn Glu Glu Pro Val Phe Ser Arg Asp Gly Ser Lys Phe
 370 375 380
 Phe Met Thr Val Pro Val Lys Gln Gly Gly Arg Gly Glu Phe His His
 385 390 395 400

Ile Ala Met Phe Leu Ile Gln Ser Lys Ser Glu Gln Ile Thr Val Arg
 405 410 415
 His Leu Thr Ser Gly Asn Trp Glu Val Ile Lys Ile Leu Ala Tyr Asp
 420 425 430
 Glu Thr Thr Gln Lys Ile Tyr Phe Leu Ser Thr Glu Ser Ser Pro Arg
 435 440 445
 Gly Arg Gln Leu Tyr Ser Ala Ser Thr Glu Gly Leu Leu Asn Arg Gln
 450 455 460
 Cys Ile Ser Cys Asn Phe Met Lys Glu Gln Cys Thr Tyr Phe Asp Ala
 465 470 475 480
 Ser Phe Ser Pro Met Asn Gln His Phe Leu Leu Phe Cys Glu Gly Pro
 485 490 495
 Arg Val Pro Val Val Ser Leu His Ser Thr Asp Asn Pro Ala Lys Tyr
 500 505 510
 Phe Ile Leu Glu Ser Asn Ser Met Leu Lys Glu Ala Ile Leu Lys Lys
 515 520 525
 Lys Ile Gly Lys Pro Glu Ile Lys Ile Leu His Ile Asp Asp Tyr Glu
 530 535 540
 Leu Pro Leu Gln Leu Ser Leu Pro Lys Asp Phe Met Asp Arg Asn Gln
 545 550 555 560
 Tyr Ala Leu Leu Leu Ile Met Asp Glu Glu Pro Gly Gly Gln Leu Val
 565 570 575
 Thr Asp Lys Phe His Ile Asp Trp Asp Ser Val Leu Ile Asp Met Asp
 580 585 590
 Asn Val Ile Val Ala Arg Phe Asp Gly Arg Gly Ser Gly Phe Gln Gly
 595 600 605
 Leu Lys Ile Leu Gln Glu Ile His Arg Arg Leu Gly Ser Val Glu Val
 610 615 620
 Lys Asp Gln Ile Thr Ala Val Lys Phe Leu Leu Lys Leu Pro Tyr Ile
 625 630 635 640
 Asp Ser Lys Arg Leu Ser Ile Phe Gly Lys Gly Tyr Gly Tyr Ile
 645 650 655
 Ala Ser Met Ile Leu Lys Ser Asp Glu Lys Leu Phe Lys Cys Gly Ser
 660 665 670
 Val Val Ala Pro Ile Thr Asp Leu Lys Leu Tyr Ala Ser Ala Phe Ser
 675 680 685
 Glu Arg Tyr Leu Gly Met Pro Ser Lys Glu Glu Ser Thr Tyr Gln Ala
 690 695 700
 Ala Ser Val Leu His Asn Val His Gly Leu Lys Glu Glu Asn Ile Leu
 705 710 715 720
 Ile Ile His Gly Thr Ala Asp Thr Lys Val His Phe Gln His Ser Ala
 725 730 735
 Glu Leu Ile Lys His Leu Ile Lys Ala Gly Val Asn Tyr Thr Met Gln
 740 745 750
 Val Tyr Pro Asp Glu Gly His Asn Val Ser Glu Lys Ser Lys Tyr His
 755 760 765
 Leu Tyr Ser Thr Ile Leu Lys Phe Phe Ser Asp Cys Leu Lys Glu Glu
 770 775 780
 Ile Ser Val Leu Pro Gln Glu Pro Glu Glu Asp Glu
 785 790 795

<210> 6
 <211> 2583
 <212> DNA
 <213> Homo sapiens
 <400> 6

gcctgggatt gtgcactgtc cagggtcctg aaacatgaac caaaactgcca gcgtgtccca 60
 tcacatcaag tgtcaaccct caaaaacaat caaggaactg ggaagttaaca gccctccaca 120
 gagaaaactgg aagggaaattg ctattgctct gctggtgatt ttagttgtat gtcactcat 180

cactatgtca	gtcatccctct	taagcccaga	tgaactcaca	aattcgtcag	aaaccagatt	240
gtctttggaa	gacctctta	ggaaagactt	tgtgcttcac	gatccagagg	ctcggtggat	300
caatgataca	gatgtggtgt	ataaaagcga	gaatggacat	gtcattaaac	tgaatataga	360
aacaatgtc	accacattat	tattggaaaa	cacaactttt	gtaaccttca	aagcatcaag	420
acattcagtt	tcaccagatt	taaaatatgt	ccttctggca	tatgatgtca	aacagatttt	480
tcattattcg	tatactgctt	catactgtat	ttacaacata	cacactaggg	aagtttggga	540
gttaaatcct	ccagaagtag	aggactccgt	cttcgactac	gcggcctggg	gtgtccaagg	600
gcagcagctg	atttatattt	ttgaaaataa	tatctactat	caacctgata	taaagagcag	660
ttcattgcga	ctgacatctt	ctggaaaaga	agaaataatt	ttaatggga	ttgctgactg	720
gttatatgaa	gaggaactcc	tgattctca	catgc(cc)ac	tgggtggcac	cagatggaga	780
aagacttgcc	ttcctgtatga	taaatgactc	tttggtaccc	accatggta	tccctcggtt	840
tactggagcg	ttgtatccca	aaggaaagca	gtatccgtat	cctaaggcag	gtcaagtcaa	900
cccaacaata	aaattatatg	ttgtaaacct	gtatggacca	actcacactt	tggagctcat	960
gccacctgac	agctttaaat	caagagaata	ctatatcact	atggtaaat	gggtaagcaa	1020
taccaagact	gtggtaagat	ggttaaaccg	acctcagaac	atctccatcc	tcacagtctg	1080
tgagaccact	acaggtgctt	gtatgaaaaa	atatgagatg	acatcagata	cgtggctctc	1140
tcagcagaat	gaggagcccg	tgtttctag	agacggcagc	aaattctta	tgacagtgcc	1200
tgttaagcaa	gggggacgtg	gagaatttca	ccacatagct	atgttcctca	tccagagtaa	1260
aagttagcaa	attaccgtgc	ggcatctgac	atcagggaaac	tgggaagtga	taaagatctt	1320
ggcatacgat	gaaactactc	aaaaaaattt	cttctgagc	actgaatctt	ctcccagagg	1380
aaggcagctg	tacagtgctt	ctactgaagg	attattgaat	cgccaatgca	tttcatgtaa	1440
tttcatgaaa	gaacaatgta	catatttga	tgccagttt	agtcccattg	atcaacattt	1500
cttattattc	tgtgaaggc	caagggtccc	agtggtcagc	ctacatagta	cggacaaccc	1560
agcaaaaat	tttatattgg	aaagcaattc	tatgctgaag	gaagctatcc	tgaagaagaa	1620
gataggaaag	ccagaaatta	aaatccttca	tattgacgac	tatgaacttc	ctttacagtt	1680
gtcccttccc	aaagatttt	tggaccggaa	ccagtagct	cttctgttaa	taatggatga	1740
agaaccagga	ggccagctgg	ttacagataa	gttccatatt	gactgggatt	ccgtactcat	1800
tgacatggat	aatgtcattt	tagcaagatt	tgatggcaga	ggaagtggat	tccagggtct	1860
gaaaattttg	caggagattc	atcgaagatt	agtttcagta	gaagtaaagg	accaaataac	1920
agctgtgaaa	tttttgctga	aactgcctt	cattgactcc	aaaagattaa	gcatttttg	1980
aaagggttat	ggtggtata	ttgcatcaat	gatctaaaa	ttagatgaaa	agctttttaa	2040
atgtggatcc	gtgggtgcac	ctatcacaga	cttggaaattt	tatgcctcag	ctttctctga	2100
aaagataaccc	gggatgcccatt	ctaaggaaga	aagcacttac	caggcagcca	gtgtgttaca	2160
taatgttcat	ggcttggaaag	aagaaaat	attaataatt	catggactg	ctgacacaaa	2220
agttcatttc	caacactcag	cagaattaa	caagcaccta	ataaaagctg	gagtgaatta	2280
tactatgcag	gtctaccat	atgaaggtca	taacgtatct	gagaagagca	agtatcatct	2340
ctacagcaca	atcctcaaatt	tcttcagtga	tttggtaag	gaagaaat	ctgtgttacc	2400
acaggaacca	gaagaagatg	aataatggac	cgtattata	cagaactgaa	gggaatattt	2460
aggctcaatg	aaacctgaca	aagagactgt	aatattgtt	ttgctccaga	atgtcaaggg	2520
cagcttacgg	agatgtcact	ggagcagcac	gctcagagac	agtgaactg	catttgaata	2580
cac						2583

<210> 7
 <211> 690
 <212> PRT
 <213> Homo sapiens
 <400> 7

Met	Ala	Ala	Ala	Met	Glu	Thr	Glu	Gln	Leu	Gly	Val	Glu	Ile	Phe	Glu
1				5				10				15			
Thr	Ala	Asp	Cys	Glu	Glu	Asn	Ile	Glu	Ser	Gln	Asp	Arg	Pro	Lys	Leu
					20				25			30			
Glu	Pro	Phe	Tyr	Val	Glu	Arg	Tyr	Ser	Trp	Ser	Gln	Leu	Lys	Lys	Leu
					35			40			45				
Leu	Ala	Asp	Thr	Arg	Lys	Tyr	His	Gly	Tyr	Met	Met	Ala	Lys	Ala	Pro
					50			55			60				
His	Asp	Phe	Met	Phe	Val	Lys	Arg	Asn	Asp	Pro	Asp	Gly	Pro	His	Ser
					65			70			75			80	
Asp	Arg	Ile	Tyr	Tyr	Leu	Ala	Met	Ser	Gly	Glu	Asn	Arg	Glu	Asn	Thr
					85			90			95				

Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu
 100 105 110
 Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp
 115 120 125
 Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg
 130 135 140
 Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly
 145 150 155 160
 Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly
 165 170 175
 Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu
 180 185 190
 Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp
 195 200 205
 Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn
 210 215 220
 Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu
 225 230 235 240
 Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val
 245 250 255
 Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys
 260 265 270
 Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu
 275 280 285
 Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met
 290 295 300
 Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr
 305 310 315 320
 Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala
 325 330 335
 Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe
 340 345 350
 Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr
 355 360 365
 Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr
 370 375 380
 Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu
 385 390 395 400
 Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser
 405 410 415
 Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn
 420 425 430
 Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Glu Ile
 435 440 445
 Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr
 450 455 460
 Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly
 465 470 475 480
 Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile
 485 490 495
 Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn
 500 505 510
 Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys
 515 520 525
 Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro
 530 535 540
 Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys
 545 550 555 560
 Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys
 565 570 575

Asn	Pro	His	Cys	Val	Ser	Leu	Tyr	Lys	Leu	Ser	Ser	Pro	Glu	Asp	Asp
580								585					590		
Pro	Thr	Cys	Lys	Thr	Lys	Glu	Phe	Trp	Ala	Thr	Ile	Leu	Asp	Ser	Ala
595								600					605		
Gly	Pro	Leu	Pro	Asp	Tyr	Thr	Pro	Pro	Glu	Ile	Phe	Ser	Phe	Glu	Ser
610								615					620		
Thr	Thr	Gly	Phe	Thr	Leu	Tyr	Gly	Met	Leu	Tyr	Lys	Pro	His	Asp	Leu
625								630					635		
Gln	Pro	Gly	Lys	Lys	Tyr	Pro	Thr	Val	Leu	Phe	Ile	Tyr	Gly	Gly	Arg
645								650					655		
Leu	Leu	Leu	Gly	Pro	Gln	Ser	Leu	Cys	Gly	Ser	Ser	Met	Ile	Gln	
660								665					670		
Asp	Thr	Arg	Asn	Val	Ile	Trp	Val	Thr	Leu	Thr	Arg	Met	Asn	Arg	Ala
675								680					685		
Ile	Thr														
690															

<210> 8
 <211> 4523
 <212> DNA
 <213> Homo sapiens
 <400> 8

aagtgctaaa	gcctccgagg	ccaaggccgc	tgctactgcc	gccgctgctt	cttagtgccg	60
cgttcgcgc	ctgggttgtc	accggcgcgc	ccgcccggagga	agccactgca	accaggacgg	120
gagtggaggc	ggcgcaagcat	gaagcggcgc	aggcccgcgc	catagcgcac	gtcgggacgg	180
tccggggcggg	gcccgggggga	aggaaaatgc	aacatggcag	cagcaatgga	aacagaacag	240
ctgggtgttg	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaatttgg	agccttttta	tgttgagcgg	tattcctgga	gtcagcttaa	aaagctgctt	360
gccgataccca	aaaaatatca	tggctacatg	atggcttaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tctattacat	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgttttat	tctgaaattc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctcttctt	gaaggcctt	ttggatctt	ttcaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtcgga	660
attgcttctt	acgattatca	ccaaggaagt	ggaacatttc	tgttcaagc	cggtagtgga	720
atttacacg	taaaagatgg	aggccacaa	ggatttacgc	aacaacctt	aaggccaaat	780
ctagtgaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgccc	tgctgatcca	840
gactggattt	cttttataca	tagcaacgt	atttggatat	ctaacatcg	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggaagaaga	tgccagatca	960
gctggagtgc	ctaccttgc	tctccaagaa	gaatttgata	gatattctgg	ctattggtgg	1020
tgtccaaaag	ctgaaacaac	tcccagtgg	ggtaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgaggtgga	aatttattcat	gttacatccc	ctatgttgg	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacagg	acagcaaattc	ctaaagtca	ttttaagatg	1200
tcagaaataa	tgattgatgc	tgaaggaagg	atcatagatg	tcatagataa	ggaactaatt	1260
caaccttttgc	agattctatt	tgaaggagtt	gaatatattg	ccagagctgg	atggactcct	1320
gagggaaaat	atgcttggtc	catcctacta	gatcgctccc	agactcgct	acagatagt	1380
ttgatctcac	ctgaattatt	tatcccagta	gaagatgatg	ttatggaaag	gcagagactc	1440
attgagtcag	tgcctgattc	tgtgacgcca	ctaattatct	atgaagaaac	aacagacatc	1500
tggataaata	tccatgacat	ctttcatgtt	tttcccaaa	gtcacgaa	ggaatttgag	1560
tttatttttg	cctctgaatg	caaaacagg	ttccgtcatt	tataaaaaat	tacatctatt	1620
ttaaaggaaa	gcaaataaa	acatccag	ggtggctgc	ctgctccaag	tgatttcaag	1680
tgtcctatca	aagaggagat	agcaattacc	agtggtaat	ggaagttt	tggccggcat	1740
ggatctaata	tccaagg	tgaagtcaga	aggctggat	attttgaagg	caccaaagac	1800
tcccctttag	agcatcac	gtacgtagtc	agttacgtaa	atcctggaga	ggtgacaagg	1860
ctgactgacc	gtggctactc	acattttgc	tgcacatgtc	agcaactgt	cttcttata	1920
agtaagtata	gtaaccagaa	gaatccacac	tgtgttccc	tttacaagct	atcaagtct	1980
gaagatgacc	caacttgca	aacaaaggaa	ttttggcca	ccattttgga	ttcagcaggt	2040
cctttccctg	actatactcc	tccagaaatt	ttctcttttg	aaagtactac	tggatttaca	2100
ttgtatggga	tgctctacaa	gcctcatgtat	ctacagcctg	gaaagaaaata	tcctactgt	2160

ctgttcata	atgggtggtcg	gttgctattg	ctggggcccc	agtcactctg	tggatcttct	2220
atgatacagg	atacacggaa	cgttatatgg	gtcacccctga	ccagaatgaa	cagggctatt	2280
acttaggatc	tgtggccatg	caagcagaaa	agttccctc	tgaaccaa	at cgtttactgc	2340
tcttacatgg	tttcctggat	gagaatgtcc	atttgcaca	taccagtata	ttactgagtt	2400
ttttagttag	ggctggaaag	ccatatgatt	tacagatcta	tcctcaggag	agacacagca	2460
taagagttcc	tgaatcggga	gaacattatg	aactgcac	tttgcactac	cttcaagaaa	2520
accttggatc	acgtattgtc	gctctaaaag	tgatataatt	ttgacctgtg	tagaactctc	2580
tggtatacac	tggctattt	acccaaatgag	gagggttaat	caacagaaaa	cacagaattt	2640
atcatcacat	tttgatacct	gccatgtaac	atctactcct	gaaaataaaat	gtgggccat	2700
gcaggggtct	acggttgtg	gtagtaatct	aataccttaa	ccccacatgc	tcaaaatcaa	2760
atgatacata	ttcctgagag	acccagcaat	accataagaa	ttactaaaaa	aaaaaaaaaa	2820
aaaaagacat	tagcaccatg	tattcatact	accctattt	cacttttaat	agtattataa	2880
acttcatgaa	cttaattatg	gtattttac	agtatactt	tgagttgtt	aaaatatgat	2940
gatattatgt	attgggttgg	ttcagttcca	gaatcttga	ctagttacag	atttgatagc	3000
acttaaatgt	aattgaatag	ttatgcctt	attgcttggg	catatccagc	atgttatgaa	3060
ctaataacta	ttaaacttga	cttaaccagt	cattcattaa	taattttca	aggataactt	3120
agtggcctcc	taaagacact	tgtttggca	ctgaccagtt	tttagccaat	ttaatctgta	3180
tctagtataa	ataattctca	tttttcttt	atgatattaa	cagagtggc	ttttcctttt	3240
gcataaaaggc	tagtaactgt	atatgttagca	tggatttaat	tagtcatgat	attgataatt	3300
acaggcagaa	aatttttaat	caaatgatta	gagcttaaaat	atttgcagc	aagtttttt	3360
ttttccttta	agaaaaggaa	aaagtacaca	ttcactagaa	ttcttcagaa	aatttagtgg	3420
tgccagttt	catttggat	ttccttatta	aaatattcta	gaattttaag	gagattgaag	3480
ggaatcacag	tgggggtggg	agacctgggt	ttggggatg	acagagagaa	gaggtggta	3540
ggccctgatt	aaaaactaag	cagaagtgt	tttaacaaaaa	atactcatga	aaatgtttgg	3600
aaactgaaat	ttaaacaact	gtaatattaa	ggaaaccaga	atcaataaaat	cactgtctt	3660
ccagcacagc	tacagagtaa	catgattcag	gggagggaaa	ttcccttaga	gttactttt	3720
taattcttt	ttttttcct	cttaggttta	gaaatcttac	aaatttaaac	tttattcctt	3780
taaaattatt	tgaacataat	ttagatattt	taagcttaaa	atacaaatgt	tttagataaa	3840
cctctttacc	ataaaacta	ccctggcaag	ccatgctct	ctttttttt	ttgggttta	3900
aagcctgtaa	acagttttc	tgaatgatca	tgaactttt	ttgggttagc	actaggattt	3960
agctatgaag	agagctata	ggctttcagg	tgctaattga	gatctgccct	gttagagtct	4020
tggggtgcta	gattggtcac	attgacacca	gtggcaggg	aggcatctat	gagtttgatg	4080
ctttttatca	cacacttcag	tgtttagaaa	gttattacca	atactttaa	acaacactcc	4140
aagaaaattt	gctatattt	tttctcatca	ctacagagag	agtagattt	cccatagaga	4200
gcacagcctc	cattagtaag	gtgggtgact	attggtaaga	ggtggacttc	attgacacca	4260
agtgggaggt	agggaaagcc	cagaaatggc	aggatgatat	ggtggttctg	tcgttggaa	4320
aggtatttgg	tttgctgtt	tgtatttata	ctgtataata	gataccacgc	tttttcttat	4380
tatctgtata	tgtatttgc	ttcatgtttt	atattttccc	atgccaagat	ttgttttat	4440
atattttcaa	tgttaaatta	aattgatttt	ggtaactttc	ttccccaaaga	aagtattttc	4500
cccccttaagt	ataaaatctga	ctg				4523

<210> 9
 <211> 241
 <212> PRT
 <213> Homo sapiens
 <400> 9

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
 1 5 10 15
 Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
 20 25 30
 Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
 35 40 45
 Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
 50 55 60
 His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
 65 70 75 80
 Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
 85 90 95
 Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu

	100		105		110										
Met	Leu	Ser	Trp	Lys	Pro	Leu	Leu	Asp	Leu	Phe	Gln	Ala	Thr	Leu	Asp
	115						120					125			
Tyr	Gly	Met	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg	Lys	Arg
	130						135					140			
Ile	Gly	Thr	Val	Gly	Ile	Ala	Ser	Tyr	Asp	Tyr	His	Gln	Gly	Ser	Gly
	145						150				155			160	
Thr	Phe	Leu	Phe	Gln	Ala	Gly	Ser	Gly	Ile	Tyr	His	Val	Lys	Asp	Gly
	165						170					175			
Gly	Pro	Gln	Gly	Phe	Thr	Gln	Gln	Pro	Leu	Arg	Pro	Asn	Leu	Val	Glu
	180						185					190			
Thr	Ser	Cys	Pro	Asn	Ile	Arg	Met	Asp	Pro	Lys	Leu	Cys	Pro	Ala	Asp
	195						200					205			
Pro	Asp	Trp	Ile	Ala	Phe	Ile	His	Ser	Asn	Asp	Ile	Trp	Ile	Ser	Asn
	210						215					220			
Ile	Val	Thr	Arg	Glu	Glu	Arg	Arg	Leu	Thr	Tyr	Val	His	Asn	Gly	Lys
	225						230				235			240	
Ala															

<210> 10

<211> 1356

<212> DNA

<213> Homo sapiens

<400> 10

aagtgcataaa	gcctccgagg	ccaaggccgc	tgctactgcc	gccgctgctt	cttagtgccg	60
cgttcgccgc	ctgggttgtc	accggcgccg	ccgcccggagga	agccactgca	accaggacgg	120
gagtggaggc	ggcgcagcat	gaagcgccgc	aggccccctc	catagcgcac	gtcgggacgg	180
tccgggcccc	gcccggggga	aggaaaatgc	aacatggcag	cagcaatgg	aacagaacag	240
ctgggtgtgtg	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaatttgg	agccttttta	tgtttagcgg	tattcttgg	gtcagcttaa	aaagctgctt	360
gccgatacca	aaaaatataca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagaggaa	atgtatccaga	tggacctcat	tcagacagaa	tctattacct	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgtttat	tctgaaattc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctcttttgc	gaagccttctt	ttggatcttt	tccaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtccga	660
attgcttctt	acgattatca	ccaaggaatg	ggaacatttc	tgttcaagc	cggtatgtgg	720
atttatcact	taaaagatgg	agggccacaa	ggatttacgc	aacaacctt	aaggcccaat	780
ctagtggaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgcc	tgctgatcca	840
gactggattt	cttttataca	tagcaacgt	atttggatat	ctaacatctt	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgg	aaggcgtatg	tcttcagatt	tactttctt	960
aacagtattt	tttgaagtat	aatttgcgtc	ttgcatttttgc	aaatttagatt	accacgttgg	1020
gtgatcttta	tatttgaat	tcaagtcttt	aaaattttta	aaaaatggag	aaaagtacag	1080
aggataactt	gtatgtacca	catgtataat	attcattttta	atgttttaat	gttcatttttgc	1140
aaacagtggaa	acaaaagaac	ctctgacatg	attgttcttt	tagtttgctt	agactgccag	1200
aatttccca	aaactgttct	tattaaaata	aaatttttagg	ctaggcatgg	tggctcatgc	1260
ctgttaatctt	agcactctgg	gaggctgagg	caggcagatt	gtttgagccc	agaagttcaa	1320
gatcaggatg	ggcaacatgg	tgacacctcg	tttgac			1356

<210> 11

<211> 661

<212> PRT

<213> Homo sapiens

<400> 11

Met	Ala	Ala	Ala	Met	Glu	Thr	Glu	Gln	Leu	Gly	Val	Glu	Ile	Phe	Glu
1				5				10					15		
Thr	Ala	Asp	Cys	Glu	Glu	Asn	Ile	Glu	Ser	Gln	Asp	Arg	Pro	Lys	Leu
				20				25				30			
Glu	Pro	Phe	Tyr	Val	Glu	Arg	Tyr	Ser	Trp	Ser	Gln	Leu	Lys	Lys	Leu

35	40	45
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro		
50	55	60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser		
65	70	75
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr		80
85	90	95
Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu		
100	105	110
Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp		
115	120	125
Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg		
130	135	140
Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly		
145	150	155
Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly		160
165	170	175
Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu		
180	185	190
Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp		
195	200	205
Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn		
210	215	220
Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu		
225	230	235
Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val		240
245	250	255
Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys		
260	265	270
Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu		
275	280	285
Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met		
290	295	300
Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr		
305	310	315
Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala		320
325	330	335
Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe		
340	345	350
Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr		
355	360	365
Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr		
370	375	380
Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu		
385	390	395
Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser		400
405	410	415
Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn		
420	425	430
Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Glu Ile		
435	440	445
Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr		
450	455	460
Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly		
465	470	475
Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile		480
485	490	495
Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn		
500	505	510
Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys		

515	520	525
Asp Ser Pro Leu Glu His His	Leu Tyr Val Val	Ser Tyr Val Asn Pro
530	535	540
Gly Glu Val Thr Arg Leu Thr Asp Arg	Gly Tyr Ser His Ser Cys Cys	
545	550	555
Ile Ser Gln His Cys Asp Phe Phe	Ile Ser Lys Tyr Ser Asn Gln Lys	560
565	570	575
Asn Pro His Cys Val Ser Leu Tyr Lys	Leu Ser Ser Pro Glu Asp Asp	
580	585	590
Pro Thr Cys Lys Thr Lys Glu Phe Trp	Ala Thr Ile Leu Asp Ser Ala	
595	600	605
Gly Pro Leu Pro Asp Tyr Thr Pro Pro Glu	Ile Phe Ser Phe Glu Ser	
610	615	620
Thr Thr Gly Phe Thr Leu Tyr Gly Met	Leu Tyr Lys Pro His Asp Leu	
625	630	635
Gln Pro Gly Lys Lys Tyr Pro Thr Val	Leu Phe Ile Tyr Gly Gly Leu	640
645	650	655
Leu Arg Cys Ser Trp		
660		

<210> 12
 <211> 4829
 <212> DNA
 <213> Homo sapiens
 <400> 12

aagtgc	aaa	gcctccgagg	ccaaggccgc	tgctactgcc	ggcgctgctt	cttagtgccg	60
cgttcgccgc	ctgggttgtc	accggcgccg	ccgcccgg	agccactgca	accaggaccg	120	
gagtggaggc	ggcgcagcat	gaagcggcg	aggcccgtc	catagcgcac	gtcgggacgg	180	
tcggggcg	ggcgggggg	aggaaaatgc	aacatggcag	cagcaatgg	aacagaacag	240	
ctgggtgtt	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcg	300	
cctaaattgg	agccttttta	tgtgagcgg	tattcttgg	gtcagcttaa	aaagctgctt	360	
gcgcatacc	gaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420	
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tctattac	tgccatgtct	480	
ggtgagaaca	gagaaaatac	actgtttat	tctgaaattc	ccaaaactat	caatagagca	540	
gcagtctta	tgctcttgc	gaagcctctt	ttggatctt	ttcaggcaac	actggactat	600	
ggaaatgtatt	ctcgagaaga	agaactatta	agagaaaagaa	aacgcattgg	aacagtccg	660	
attgcttctt	acgattatca	ccaaggaagt	ggaacatttc	tgtttcaagc	cggtatgtt	720	
atttatcacg	taaaagatgg	aggccacaa	ggatttacgc	aacaacctt	aaggccaaat	780	
ctagtggaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgccc	tgctgtatcca	840	
gactggattt	ctttatatac	tagcaacgt	atttggatat	ctaacatcgt	aaccagagaa	900	
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggagaaga	tgccagatca	960	
gctggagtcg	ctaccttgc	tctccaagaa	gaatttgata	gatattctgg	ctattggatgg	1020	
tgtccaaaag	ctgaaacaac	tcccagtgg	ggtaaaaattc	ttagaatttct	atatgaagaa	1080	
aatgatgaat	ctgagggtt	aattattcat	gttacatccc	ctatgttgg	aacaaggagg	1140	
gcagattcat	tccgttatcc	taaaacagg	acagcaaattc	ctaaagtcc	ttttaagatg	1200	
tcagaaataa	tgattgtatc	tgaaggaagg	atcatagatg	tcatagataa	ggaactaatt	1260	
caaccttttgc	agattctatt	tgaaggagtt	gaatatattg	ccagagctgg	atggactcct	1320	
gaggaaaat	atgcttggtc	catcctacta	gatcgctccc	agactcgct	acagatagt	1380	
ttgatctcac	ctgaatttatt	tatcccagg	gaagatgatg	ttatggaaag	gcagagactc	1440	
attgagtcag	tgcctgattc	tgtgacgcca	ctaattatct	atgaagaaac	aacagacatc	1500	
tggataaata	tccatgacat	cttcatgtt	tttccccaaa	gtcacgaaga	ggaatttgag	1560	
tttatttttgc	cctctgaatg	caaaacagg	ttccgtcatt	tataaaaaat	tacatctatt	1620	
ttaaaggaaa	gcaaataataa	acgatccagt	ggtgggctgc	ctgctccaag	tgatttcaag	1680	
tgtcctatca	aagaggagat	agcaattacc	agtggtgaat	ggaaagtctt	tggccggcat	1740	
gcatctaata	tccaagg	tgaagtcaga	aggctgtt	attttgaagg	caccaaagac	1800	
tccccttttag	agcatcacct	gtacgtatgc	agttacgtaa	atcctggaga	ggtgacaagg	1860	
ctgactgacc	gtggctactc	acattcttgc	tgcacatgtc	agcactgtga	cttcttata	1920	
agtaagtata	gtaaccagaa	gaatccacac	tgtgtgtccc	tttacaagct	atcaagtcc	1980	
gaagatgacc	caacttgcaa	aacaaaggaa	ttttggcca	ccattttgg	ttcagcaggt	2040	

cctcttcctg	actatactcc	tccagaaaatt	ttctcttttgc	aaagtactac	tggatttaca	2100
ttgtatggga	tgctctacaa	gcctcatgt	ctacagcctg	gaaagaaaata	tcctactgtg	2160
ctgttcataat	atgggtgtt	cctcagggtgc	agttggtgaa	taatcggttt	aaaggagtca	2220
agtatttccg	cttgaatacc	ctagcctctc	taggttatgt	ggtttagtgc	atagacaaca	2280
ggggatcctg	tcaccgaggg	cttaaattttg	aaggccctt	taaatataaa	atgggtcaaa	2340
tagaaaattga	cgatcagggtg	gaaggactcc	aatatctagc	ttctcgatata	gatttcatttgc	2400
acttagatcg	tgtggcattc	cacggctgtt	cctatggagg	atacctctcc	ctgatggcat	2460
taatgcagag	gtcagatata	ttcagggttg	ctattgtgg	ggccccagtc	actctgtgga	2520
tcttctatga	tacaggatac	acggaacgtt	atatggtca	ccctgaccag	aatgaacagg	2580
gctattactt	aggatctgtg	gccatgcag	cagaaaagtt	ccctctgaa	ccaaatcggtt	2640
tactgctctt	acatggtttgc	ctggatgaga	atgtccattt	tgcacataacc	agtatattac	2700
tgagtttttgc	ggaaagccat	atgatttaca	gatctatcct	caggagagac	2760	
acacgataaag	agttctgaa	tcgggagaac	attatgaact	gcatcttttgc	caactaccc	2820
aagaaaacct	tggatcacgt	attgctgctc	taaaagtgtat	ataattttgaa	cctgtgtaga	2880
actctctgg	atacactggc	tatthaacca	aatgaggagg	ttaatcaac	agaaaacaca	2940
gaattgtca	tcacattttgc	atacctgcca	tgtaacatct	actcctgaaa	ataaatgtgg	3000
tgcctatgcag	gggtctacgg	tttgggttag	taatctaata	ccttaacc	acatgctcaa	3060
aatcaaatttgc	tacatattcc	tgagagaccc	agcaatacc	taagaattac	taaaaaaaaaa	3120
aaaaaaaaaaaa	agacatttgc	acatgtatttgc	catactaccc	tattttcaact	ttaatagta	3180
ttataaactt	catgaactt	attagtgtat	ttttacagta	tactttttag	tttggtaaaa	3240
tatgtatgtat	tttagtatttgc	gttccagaat	ctttgacttag	ttacagattt	gatagcattt	3300
gatagcactt	aaatgtat	gaatagctt	tgcttcatttgc	cttgggcata	tccagcatgt	3360
tatgaactaa	taactattaa	acttgcatttgc	accagtcatttgc	cattaataat	ttttcaagga	3420
taacttagtgc	gcctccat	gacacttgc	ttggcacttgc	ccagtttttgc	ccaaatttgc	3480
tctgtatctt	gtataaataa	tttcatttttgc	tcttttgcatttgc	tatthaacaga	gtgggcttttgc	3540
ccttttgcatttgc	aaaggctgtt	aactgtatata	gtagcatggc	ttaattttgc	catgatatttgc	3600
ataattacag	gcagaaaatttgc	ttaatcaaa	tgattagagc	ttaatattttgc	gcaggcaagt	3660
tttttttttttgc	cctttaagaa	aaggaaaaatgc	tacacatttgc	ctagaatttgc	tcagaaaatttgc	3720
tagtggtgcc	agtttccatttgc	ttgtatttttgc	ttatthaat	attctagaat	ttaaggaga	3780
ttgaaggggaa	tcacagtggg	gtggggagac	ctggggttgc	ggaatgacag	agagaagagg	3840
ttgtgaggggc	ctgattaaaa	actaaggcaga	agtagtttgc	acaaaaatata	tcatgaaaat	3900
gtttggaaac	tgaatttttgc	acaactgtaa	tatthaaggaa	accagaatata	ataaatcact	3960
gtcttgcac	cacagctaca	gagtaacatgc	attcaggggc	ggaaaagtttgc	cttagagtttgc	4020
cttttataat	tcttttttttgc	tttcatttttgc	gttttagaaa	tcttacaaat	ttaatcttgc	4080
tccttttataat	attatttgc	cataattttgc	atattgttgc	cttaaaatata	aaatgttttgc	4140
agataaaccttgc	tttaccat	actaattcccttgc	ggcaagccat	ggctctcttgc	tttttttttgc	4200
tgtttaaagc	ctgttaacag	tttttcttgc	tgatcatgc	cttttcttgc	tttagcacttgc	4260
ggattttagtgc	atgaagagag	ctcataggcttgc	ttcagggtgc	atttgagatc	tgccctgttgc	4320
gagtcttggg	gtgcttagatttgc	ggtcacatttgc	acaccagg	cagggaaaggc	atctatgtttgc	4380
ttgtatgttgc	ttatcacaca	cttcagggttgc	tagaaagtttgc	ttaccaataat	ttttaaacaaat	4440
cactccaaga	aaatttgcataat	tatthaatttgc	tcatcactac	agagagagtttgc	gattttcccaat	4500
tagagagcac	agcctccatttgc	agtaagggttgc	gtgactatttgc	gtaagaggttgc	gacttcatttgc	4560
acaccaagtgc	ggaggttaggg	aaagcccaat	aatggcaggat	tgatatggtgc	gttctgtcgttgc	4620
tgggaaaggttgc	attgggttttgc	gtgttttgc	tttataactgttgc	ataatagata	ccacgcatttgc	4680
tcttattatgc	tgtatatgttgc	ttgcttttgc	tggttgcatttgc	tttcccatgc	caagattttgc	4740
ttatataatgc	tttcaatgttgc	aaattaaatttgc	gatttgggttgc	actttcttcc	ccaagaaaatgc	4800
attttcccccc	ttaagtataat	atctgacttgc				4829

<210> 13
 <211> 358
 <212> PRT
 <213> Homo sapiens
 <400> 13

Met	Ala	Ala	Ala	Met	Glu	Thr	Glu	Gln	Ieu	Gly	Val	Glu	Ile	Phe	Glu
1				5				10					15		
Thr	Ala	Asp	Cys	Glu	Glu	Asn	Ile	Glu	Ser	Gln	Asp	Arg	Pro	Lys	Ieu
							20		25			30			
Glu	Pro	Phe	Tyr	Val	Glu	Arg	Tyr	Ser	Trp	Ser	Gln	Ieu	Lys	Lys	Ieu
							35		40			45			

Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
 50 55 60
 His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
 65 70 75 80
 Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
 85 90 95
 Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu
 100 105 110
 Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp
 115 120 125
 Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg
 130 135 140
 Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly
 145 150 155 160
 Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly
 165 170 175
 Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu
 180 185 190
 Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp
 195 200 205
 Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn
 210 215 220
 Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu
 225 230 235 240
 Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val
 245 250 255
 Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys
 260 265 270
 Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu
 275 280 285
 Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met
 290 295 300
 Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr
 305 310 315 320
 Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala
 325 330 335
 Glu Gly Arg Ser Lys Leu Met Lys Ser Glu Gly Trp Tyr Ile Leu Lys
 340 345 350
 Ala Pro Lys Thr Pro Leu
 355

<210> 14

<211> 4309

<212> DNA

<213> Homo sapiens

<400> 14

aagtgtaaa	gcctccgagg	ccaaggccgc	tgctactgcc	gcccgtgcctt	cttagtgccg	60
cgttcgcgc	ctgggttgtc	accggcgccg	ccgcccagga	agccactgca	accaggaccg	120
gagtgaggc	ggcgcagcat	gaagcggcgc	aggccgcctc	catagcgcac	gtcgggacgg	180
tccgggcggg	gccgggggga	agaaaaatgc	aacatggcag	cagcaatgga	aacagaacag	240
ctgggtgtt	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acagatcg	300
cctaaattgg	agcctttta	tgttgagcgg	tattcctgga	gtcagcttaa	aaagctgttt	360
gccgatacca	aaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tgcacatcat	tcagacagaa	tctattacct	tgccatgtct	480
ggtgagaaca	gagaaaatac	actgtttat	tctgaaattc	ccaaaactat	caatagagca	540
gcagtcttaa	tgctctttt	gaagcctctt	ttggatcttt	ttcaggcaac	actggactat	600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaaagaa	aacgcattgg	aacagtcgga	660
attgcttctt	acgattatca	ccaaggaagt	ggaacatttc	tgtttcaagc	cggttagtgg	720
atttatcacg	taaaagatgg	agggccacaa	ggatttacgc	aacaacctt	aaggcccaat	780

ctagtggaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgcc	tgctgatcca	840
gactggattg	cttttataca	tagcaacgt	atttggatat	ctaacatcg	aaccagagaa	900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggaagaaga	tgccagatca	960
gctggagtcg	ctaccttgt	tctccaagaa	gaatttgata	gatattctgg	ctattggtgg	1020
tgtccaaaag	ctgaaacaac	tcccagtgg	ggtaaaattc	ttagaattct	atatgaagaa	1080
aatgatgaat	ctgaggtgga	aattattcat	gttacatccc	ctatgttgg	aacaaggagg	1140
gcagattcat	tccgttatcc	taaaacagg	acagcaaata	ctaaagtca	tttaagatg	1200
tcagaaataa	tgattgtatgc	tgaaggaaga	tccaagttga	tgaagtca	aggctggat	1260
atttgaagg	caccaaagac	tcccctttag	agcatcacct	gtacgtatgc	agttacgtaa	1320
atcctggaga	ggtgacaagg	ctgactgacc	gtggctactc	acattcttc	tgcatcagtc	1380
agcaactgtg	cttcttata	agtaagtata	gtaaccagaa	gaatccacac	tgtgtgtccc	1440
tttacaagct	atcaagtcc	gaagatgacc	caacttgc	aacaaaggaa	ttttgggcca	1500
ccattttgga	ttcagcaggt	cctcttcctg	actataactcc	tccagaaatt	ttctctttg	1560
aaagtactac	tggatttaca	ttgtatggg	tgctctacaa	gcctcatgat	ctacagcctg	1620
gaaagaaata	tcctactgtg	ctgttcatat	atgggtgtct	cctcagggtc	agttggtgaa	1680
taatcggtt	aaaggagtca	agatattccg	cttgaatacc	ctagcctctc	tagttatgt	1740
ggttgtatgt	atagacaaca	ggggatcctg	tcaccgaggg	cttaaattttg	aaggcgcctt	1800
taaatataaa	atgggtcaaa	tagaaattga	cgatcagg	gaaggactcc	aatatctagc	1860
ttctcgat	gatttcattt	acttagatcg	tgtggcattc	cacggctgg	cctatggagg	1920
atacctctcc	ctgatgcat	taatgcagag	gtcagatata	ttcagggtt	ctattgtgg	1980
ggccccagtc	actctgtgga	tcttctatga	tacaggatac	acggaacgtt	atatgggtca	2040
ccctgaccag	aatgaacagg	gcttattactt	aggatctgt	gccatgcaag	cagaaaagtt	2100
ccccctctgaa	ccaaatcg	tactgctt	acatggttc	ctggatgaga	atgtccattt	2160
tgcacatacc	agtatattac	ttagttttt	agtggggct	ggaaagccat	atgatttaca	2220
gatctatct	caggagagac	acagcataag	agttcctgaa	tcgggagaac	attatgaact	2280
gcatctttt	cactaccc	aagaaaac	tggatcacgt	attgctgctc	taaaagtat	2340
ataattttg	cctgtgtaga	actctctgt	atacactgg	tatthaacca	aatgaggagg	2400
tttaatcaac	agaaaacaca	gaattgatca	tcacatttt	atacctgca	tgtaacatct	2460
actcctgaaa	ataaaatgtgg	tgccatgcag	gggtctacgg	tttgggttag	taatctaata	2520
ccttaacccc	acatgctcaa	aatcaaata	tacatattcc	tgagagaccc	agcaatacca	2580
taagaattac	taaaaaaaaaa	aaaaaaaaaa	agacattagc	accatgtatt	catactaccc	2640
tattttca	ttaatagta	ttataaactt	catgaactt	attagtgtat	ttttacagta	2700
tac	tttggtag	tttggtaaaa	tatgatgata	tttagtgattt	gttgggttca	2760
ctttgactag	ttacagattt	gatagcattt	aaatgttatt	gaatagctt	tgcttcattt	2820
cttggcata	tccagcatgt	tatgaactaa	taactattaa	acttgactt	accagtcatt	2880
cattaataat	ttttcaagga	taacttagt	gcctccctaa	gacacttgg	ttggcactga	2940
ccagttttt	gccaatttta	tctgtatcta	gtataaataa	ttctcatttt	tcttgatga	3000
tattaacaga	gtgggctttt	ccttttgc	aaaggctgt	aactgtat	gtagcatgga	3060
tttaattttagt	catgatattt	ataatttacag	gcagaaaatt	tttaatcaaa	tgattagagc	3120
ttaaatattt	gcaggcaagt	ttttttttt	cctttaagaa	aaggaaaaaa	tacacattca	3180
ctagaattct	tcagaaaattt	tagtggtgcc	agtttccatt	tgttatttcc	ttattaaaat	3240
attctagaat	tttaaggaga	ttgaagggaa	tcacagtgg	gtggggagac	ctggggttgg	3300
ggaatgacag	agagaagagg	tggtgagggc	ctgattaaaa	actaagcaga	agtagtttta	3360
acaaaaatac	tcatgaaaat	gttggaaaac	tgaaatttta	acaactgtaa	tattaaggaa	3420
accagaatca	ataaaatact	gtcttgc	cacagctaca	gagtaacatg	attcagggg	3480
ggaaaagttc	cttagagtt	cttttataat	tctttttt	tttcctctt	gttttagaaa	3540
tcttacaaat	ttaaacttta	tcctttttaa	attatttga	cataattttag	atatttgaag	3600
cttaaaaatac	aaatgtttat	agataaccc	tttaccataa	actaattccct	ggcaagccat	3660
ggctctctt	tttttttgg	tgtttaaagg	ctgtaacag	tttttctgaa	tgatcatgaa	3720
cttttcttgg	tttagacta	ggatttagct	atgaagagag	ctcataggct	ttcagggtct	3780
aatttagatc	tgcctgtt	gagtcttgg	gtgcttagatt	ggtcacattt	acaccagtgg	3840
cagggaaaggc	atctatgat	ttgatgctt	ttatcacaca	cttcagggtt	tagaaagtta	3900
ttaccaatac	tttaaaacaa	cactccaaga	aaatttgct	tatttctt	tcatcactac	3960
agagagagta	gatttcccc	tagagagcac	agcctccatt	agtaagggtt	tgactattt	4020
gtaagaggtg	gacttcattt	acaccaagt	ggaggttaggg	aaagcccaga	aatggcagga	4080
tgtatgtt	gttctgtct	tggaaaggt	attgggtttt	gtgtttgt	tttataactgt	4140
ataatagata	ccacgcttt	tcttattatc	tgtatatgt	ttgctttca	tggtttagat	4200
tttccatgc	caagattt	ttatataat	tttcaatgtt	aaattaaatt	gatttgggt	4260
actttcttcc	ccaagaaagt	atttcccc	ttaagtataa	atctgact		4309

<210> 15
 <211> 108
 <212> PRT
 <213> Homo sapiens
 <400> 15

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
 1 5 10 15
 Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
 20 25 30
 Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
 35 40 45
 Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
 50 55 60
 His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
 65 70 75 80
 Asp Arg Ile Tyr Tyr Leu Gly Asn Lys Ser Leu Ile Asp His Asp Arg
 85 90 95
 Phe Ser Lys Ser Lys Met Pro Glu Ile Ala Ser Ser
 100 105

<210> 16
 <211> 620
 <212> DNA
 <213> Homo sapiens
 <400> 16

aagtgtaaa	gcctccgagg	ccaaggccgc	tgctactgcc	gccgctgctt	cttagtgccg	60
cgttcgccgc	ctgggttgtc	accggcgccg	ccgcccagga	agccactgca	accaggaccg	120
gagtggaggc	ggcgcagcat	gaagcggcgc	aggcccgc	catagcgcac	gtcgggacgg	180
tccggggggg	gcccggggga	aggaaaatgc	aacatggcag	cagcaatgg	aacagaacag	240
ctgggtgtt	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcgg	300
cctaaaatttgg	ageccttttta	tgttggcgg	tattcctgga	gtcagcttaa	aaagctgctt	360
gccgatacca	gaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tctattacct	tggtaacaag	480
tcattaattt	atcatgatcg	ttttcaaaa	tcgaagatgc	cagaaattgc	ttcttcctaa	540
agctagctt	aaatgcctt	ctttagatgg	tctgattagg	aaaacaaaaca	ataaaaaccat	600
tagtttgttc	ccactcaaca					620

<210> 17
 <211> 194
 <212> PRT
 <213> Homo sapiens
 <400> 17

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
 1 5 10 15
 Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
 20 25 30
 Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
 35 40 45
 Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
 50 55 60
 His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
 65 70 75 80
 Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
 85 90 95
 Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu
 100 105 110
 Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp
 115 120 125
 Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg
 130 135 140
 Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly
 145 150 155 160
 Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly
 165 170 175
 Gly Pro Gln Gly Phe Thr Gln Pro Leu Arg Pro Asn Leu Val Glu Thr
 180 185 190
 Cys Ala

<210> 18
 <211> 832
 <212> DNA
 <213> Homo sapiens
 <400> 18

aagtgtaaa gcctccgagg ccaaggccgc tgctactgcc gcccgtgctt ctttagtgccg 60
 cgttcgcccgc ctgggttgtc accggcgccg cccgcccggagga agccactgca accaggaccg 120
 gagtggaggc ggcgcagcat gaagcggcgc aggcccgtc catagcgcac gtcgggacgg 180
 tccggggcggg gccggggggga agaaaaatgc aacatggcag cagcaatggaa aacagaacag 240
 ctgggtgttg agatatttga aactgcggac tgtgaggaga atattgaatc acaggatcgg 300
 cctaaatttgg agcctttta tggtagcgg tattccttgg gtcagcttaa aaagctgctt 360
 gccgatacca gaaaatatca tggctacatg atggctaagg caccacatga tttcatgttt 420
 gtgaagagga atgatccaga tggacctcat tcagacagaa tctattacct tgccatgtct 480
 ggtgagaaca gagaaaaatac actgttttat tctgaaattc cccaaaactat caatagagca 540
 gcagtcttaa tgctcttgc ggacgcctt ttggatctt ttcaggcaac actggactat 600
 ggaatgtatt ctcgagaaga agaactatta agagaaaagaa aacgcattgg aacagtggaa 660
 attgcttctt acgattatca ccaaggaagt ggaacatttc tgttcaagc cggttagtgga 720
 atttatcacg taaaagatgg agggccacaa ggatttacgc wacaaccctt aaggccaaat 780
 cttagtgaaa ctasttgtsccaracytgca tgacccaaatc agatccctgta ga 832

<210> 19
 <211> 658
 <212> PRT
 <213> Homo sapiens
 <400> 19

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
 1 5 10 15
 Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
 20 25 30
 Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
 35 40 45
 Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro

50	55	60													
His	Phe	Met	Phe	Val	Lys	Arg	Asn	Asp	Pro	Asp	Gly	Pro	His	Ser	
65	70	75	80												
Asp	Arg	Ile	Tyr	Tyr	Leu	Ala	Met	Ser	Gly	Glu	Asn	Arg	Glu	Asn	Thr
85	90	95													
Leu	Phe	Tyr	Ser	Glu	Ile	Pro	Lys	Thr	Ile	Asn	Arg	Ala	Ala	Val	Leu
100	105	110													
Met	Leu	Ser	Trp	Lys	Pro	Leu	Leu	Asp	Leu	Phe	Gln	Ala	Thr	Leu	Asp
115	120	125													
Tyr	Gly	Met	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg	Lys	Arg
130	135	140													
Ile	Gly	Thr	Val	Gly	Ile	Ala	Ser	Tyr	Asp	Tyr	His	Gln	Gly	Ser	Gly
145	150	155	160												
Thr	Phe	Leu	Phe	Gln	Ala	Gly	Ser	Gly	Ile	Tyr	His	Val	Lys	Asp	Gly
165	170	175													
Gly	Pro	Gln	Gly	Phe	Thr	Gln	Gln	Pro	Leu	Arg	Pro	Asn	Leu	Val	Glu
180	185	190													
Thr	Ser	Cys	Pro	Asn	Ile	Arg	Met	Asp	Pro	Lys	Leu	Cys	Pro	Ala	Asp
195	200	205													
Pro	Asp	Trp	Ile	Ala	Phe	Ile	His	Ser	Asn	Asp	Ile	Trp	Ile	Ser	Asn
210	215	220													
Ile	Val	Thr	Arg	Glu	Glu	Arg	Arg	Leu	Thr	Tyr	Val	His	Asn	Glu	Leu
225	230	235	240												
Ala	Asn	Met	Glu	Glu	Asp	Ala	Arg	Ser	Ala	Gly	Val	Ala	Thr	Phe	Val
245	250	255													
Leu	Gln	Glu	Glu	Phe	Asp	Arg	Tyr	Ser	Gly	Tyr	Trp	Trp	Cys	Pro	Lys
260	265	270													
Ala	Glu	Thr	Thr	Pro	Ser	Gly	Gly	Lys	Ile	Leu	Arg	Ile	Leu	Tyr	Glu
275	280	285													
Glu	Asn	Asp	Glu	Ser	Glu	Val	Glu	Ile	Ile	His	Val	Thr	Ser	Pro	Met
290	295	300													
Leu	Glu	Thr	Arg	Arg	Ala	Asp	Ser	Phe	Arg	Tyr	Pro	Lys	Thr	Gly	Thr
305	310	315	320												
Ala	Asn	Pro	Lys	Val	Thr	Phe	Lys	Met	Ser	Glu	Ile	Met	Ile	Asp	Ala
325	330	335													
Glu	Gly	Arg	Ile	Ile	Asp	Val	Ile	Asp	Lys	Glu	Leu	Ile	Gln	Pro	Phe
340	345	350													
Glu	Ile	Leu	Phe	Glu	Gly	Val	Glu	Tyr	Ile	Ala	Arg	Ala	Gly	Trp	Thr
355	360	365													
Pro	Glu	Gly	Lys	Tyr	Ala	Trp	Ser	Ile	Leu	Leu	Asp	Arg	Ser	Gln	Thr
370	375	380													
Arg	Leu	Gln	Ile	Val	Leu	Ile	Ser	Pro	Glu	Leu	Phe	Ile	Pro	Val	Glu
385	390	395	400												
Asp	Asp	Val	Met	Glu	Arg	Gln	Arg	Leu	Ile	Glu	Ser	Val	Pro	Asp	Ser
405	410	415													
Val	Thr	Pro	Leu	Ile	Ile	Tyr	Glu	Glu	Thr	Thr	Asp	Ile	Trp	Ile	Asn
420	425	430													
Ile	His	Asp	Ile	Phe	His	Val	Phe	Pro	Gln	Ser	His	Glu	Glu	Glu	Ile
435	440	445													
Glu	Phe	Ile	Phe	Ala	Ser	Glu	Cys	Lys	Thr	Gly	Phe	Arg	His	Leu	Tyr
450	455	460													
Lys	Ile	Thr	Ser	Ile	Leu	Lys	Glu	Ser	Lys	Tyr	Lys	Arg	Ser	Ser	Gly
465	470	475	480												
Gly	Leu	Pro	Ala	Pro	Ser	Asp	Phe	Lys	Cys	Pro	Ile	Lys	Glu	Glu	Ile
485	490	495													
Ala	Ile	Thr	Ser	Gly	Glu	Trp	Glu	Val	Leu	Gly	Arg	His	Gly	Ser	Asn
500	505	510													
Ile	Gln	Val	Asp	Glu	Val	Arg	Arg	Leu	Val	Tyr	Phe	Glu	Gly	Thr	Lys
515	520	525													
Asp	Ser	Pro	Leu	Glu	His	His	Leu	Tyr	Val	Val	Ser	Tyr	Val	Asn	Pro

530	535	540													
Gly	Glu	Val	Thr	Arg	Leu	Thr	Asp	Arg	Gly	Tyr	Ser	His	Ser	Cys	Cys
545															560
Ile	Ser	Gln	His	Cys	Asp	Phe	Phe	Ile	Ser	Lys	Tyr	Ser	Asn	Gln	Lys
															575
Asn	Pro	His	Cys	Val	Ser	Leu	Tyr	Lys	Leu	Ser	Ser	Pro	Glu	Asp	Asp
															580
Pro	Thr	Cys	Lys	Thr	Lys	Glu	Phe	Trp	Ala	Thr	Ile	Leu	Asp	Ser	Ala
															590
595															605
Gly	Pro	Leu	Pro	Asp	Tyr	Thr	Pro	Pro	Glu	Ile	Phe	Ser	Phe	Glu	Ser
															610
610															620
Thr	Thr	Gly	Phe	Thr	Leu	Tyr	Gly	Met	Leu	Tyr	Lys	Pro	His	Asp	Leu
															625
625															640
Gln	Pro	Gly	Lys	Lys	Tyr	Pro	Thr	Val	Leu	Phe	Ile	Tyr	Gly	Gly	Arg
															645
645															655
Val	Lys														

<210> 20
 <211> 4676
 <212> DNA
 <213> Homo sapiens
 <400> 20

aagtgcataa	gcctccgagg	ccaaggccgc	tgctactgcc	gccgctgctt	cttagtgccg		60
cgttcgcgc	ctgggtgtc	accggcgcgc	ccgcccggagga	agccactgca	accaggaccg		120
gagtggaggc	ggcgcaagcat	gaagcggcgc	aggccccctc	catagcgcac	gtcgggacgg		180
tccggcggg	gccgggggga	agaaaaatgc	aacatggcag	cagcaatgg	aacagaacag		240
ctgggtgtt	agatatttga	aactgcggac	tgtgaggaga	attattgaatc	acaggatcgg		300
cctaaattgg	agcctttta	tgttggcgg	tattcttgg	gtcagcttaa	aaagctgctt		360
gcccatacca	gaaaatatca	tggctacatg	atggcttaagg	caccacatga	tttcatgttt		420
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	totattacct	tgccatgtct		480
ggtgagaaca	gagaaaatac	actgtttat	tctgaaattc	ccaaaactat	caatagagca		540
gcagtcttaa	tgctcttgc	gaagcctctt	ttggatctt	ttcaggcaac	actggactat		600
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtcgga		660
attgcttctt	acgattatca	ccaaggaagt	ggaacatttc	tgtttcaagc	cggttagtgg		720
atttacacg	taaaagatgg	agggccacaa	ggatttacgc	aacaaccttt	aaggccaaat		780
ctagtgaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgccc	tgctgatcca		840
gactggattt	ctttatatac	tagcaacatg	atttgatata	ctaacatcg	aaccagagaa		900
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaaca	tggaagaaga	tgccagatca		960
gctggagtcg	ctaccttgc	tctccaagaa	gaatttgata	gatattctgg	ctattggtgg		1020
tgtccaaaag	ctgaaacaac	tcccagtgg	gttaaaattc	tttagattct	atatgaagaa		1080
aatgatgaat	ctgagggtgg	aattattcat	gttacatccc	ctatgttgg	aacaaggagg		1140
gcagattcat	tccgttatcc	taaaacaggt	acagcaatc	ctaaagtcac	tttaagatg		1200
tcagaaataa	tgattgtatc	tgaaggaagg	atcatagatg	tcatagataa	ggaactaatt		1260
caaccttttgc	agattctatt	tgaaggagtt	gaatatattt	ccagagctgg	atggactcct		1320
gaggggaaat	atgcttggc	catcctacta	gatcgctccc	agactcgcc	acagatagt		1380
tttatttttgc	cctctgaatg	caaaacaggt	ttccgttcatt	tataaaaaat	tacatctatt		1440
ttaaaggaaa	gcaaataataa	acgatccagt	ggtgggctgc	ctgctccaag	tgatttcaag		1500
tgtcctatca	aagaggagat	agcaattacc	agtggtaat	ggaagttct	tggccggcat		1560
ggatctaata	tccaagggt	tgaagtcaga	aggctgtat	atttgaagg	caccaaagac		1620
tcccctttag	agcatcacct	gtacgtatc	agttacgtaa	atccctggaga	ggtgacaagg		1680
ctgactgacc	gtggctactc	acattcttgc	tgcatacg	agcaactgtg	cttctttata		1740
agtaagtata	gtaaaccagaa	gaatccacac	tgtgtgtccc	ttacaagct	atcaagtcc		1800
gaagatgacc	caacttgcaa	aacaaaggaa	ttttggcca	ccattttgg	ttcagcaggt		1860
cctcttcctg	actatactcc	tccagaaatt	ttctcttttgc	aaagtactac	tggatttaca		1920
ttgtatggaa	tgctctacaa	gcctcatgt	ctacagcctg	gaaagaaata	tcctactgtg		1980
ctgttcatat	atgggtggc	ggtcaaata	aaattgacga	tcaggtggaa	ggactccaat		2040
							2220

atcttagttc tcgatatatgtat ttcatttgact	tagatcggtt gggcatccac ggctggctt	2280
atggaggata cctctccctg atggcattaa	tgcagaggtc agatatctt agggttgctt	2340
ttgctggggc cccagtcact ctgtggatct	tctatgatac aggatacacg gaacgttata	2400
tgggtcaccct tgaccagaat gaacagggtt	attacttagg atctgtggcc atgcaagcag	2460
aaaaggcccc ctctgaacca aatcgtttac	tgctcttaca tggtttctg gatgagaatg	2520
tccatttgc acataccagt atattactga	gttttttagt gagggctgga aagccatatg	2580
atttacagat ctatcctcag gagagacaca	gcataagagt tcctgaatcg ggagaacatt	2640
atgaactgca tcttttgcac tacottcaag	aaaaccttgg atcacgtt gctgctctaa	2700
aagtgtatata attttgacct gtgtagaact	ctctggtata cactggctat ttaaccaaata	2760
gaggagggtt aatcaacaga aaacacagaa	ttgatcatca cattttgata cctgccatgt	2820
aacatctact cctgaaaata aatgtgggtc	catgcagggg tctacgggtt gtggtagtaa	2880
tctaataccct taacccccaca tgctcaaaat	caaatgatac atattcctga gagaccagc	2940
aataccataa gaattactaa aaaaaaaaaaa	aaaaaaaaaga cattagcacc atgtattcat	3000
actaccctat tttcactttt aatagtatta	taaacttcat gaacttaatt agtgtatttt	3060
tacagtatac ttttgagttt gttaaaatata	gatgatatta gtgattgggtt tggttcagtt	3120
ccagaatctt tgacttagta cagatttgat	agcacttaaa tgaattgaa tagcttatgc	3180
ttcattgctt gggcatatcc agcatgttat	gaactaataa ctattaaact tgacttaacc	3240
agtcattcat taataatttt tcaaggataa	cttagtggcc tcctaaagac acttggttt	3300
gcactgacca gtttttagcc aatttaatct	gtatcttaga taaaataattc tcattttct	3360
ttgatgatata taacagagtg ggcttttctt	tttgcataaa ggctagtaac tttatgtat	3420
gcatggatt aattagtcat gatattgata	attacaggca gaaaattttt aatcaaataatg	3480
tttagagctta aatatttgca ggcaagttt	ttttttctt ttaagaaaag gaaaaagtac	3540
acatttacta gaattcttca gaaaattttt	ttggccagt ttccatttgg tattttctta	3600
ttaaaatattt ctagaattttt aaggagattt	aagggaatca cagtgggtt gggagacctg	3660
ggtttgggaa atgacagagaa gaagagggtt	tgagggcctt attaaaaact aagcagaagt	3720
agtttaaca aaaatactca tgaaaatgtt	tggaaactga aattttaaaca actgtatata	3780
taaggaaacc agaatcaata aatcaactgtc	ttgccagcac agctacagag taacatgatt	3840
caggggagga aaagttccctt agagttactt	ttataattct tttttttttt cctcttaggt	3900
tttagaaatct tacaaattta aactttatcc	ttttaaaattt atttgaacat aatttagata	3960
ttgttaagctt aaaaataaaaaa tgtttataga	taacctctt accataaaact aatccctggc	4020
aagccatggc tctctttttt tttttgggtt	ttaaaggctt taaacagttt ttctgaatga	4080
tcatgaactt ttcttggtt agcacttagga	tttagctatg aagagagctc ataggcttc	4140
agggtctaat ttagagatctgc cctgttttag	tcttgggtt ctagattggt cacattgaca	4200
ccagttggcag ggaaggcatc tatgagttt	atgctttta tcacacactt cagtttttag	4260
aaagtttata ccaatacttt taaaacaaacac	tccaagaaaa tttgcttat ttccttctca	4320
tcactacaga gagagtagat ttccccatag	agagcacagc ctccatttagt aaggttgggt	4380
actatggta agaggtggac ttcattgaca	ccaagtggga ggttagggaaa gcccagaaat	4440
ggcaggatga tatgggtttt ctgtcggtt	gaaaggattt gggttttgtt gtttgtat	4500
atactgtata atagataccca cgcttttctt	tattatctgt atatgtattt cttttcatgt	4560
ttgatattttt cccatgccaa gatttggta	tataatatttt caatgttaaa taaaattgtat	4620
ttgggttaact ttcttccccca agaaagtatt	ttccccctta agtataaaatc tgactg	4676

<210> 21
<211> 613
<212> PRT
<213> *Homo sapiens*
<400> 21

```

Met Ala Ala Ala Met Glu Thr Glu Gln Leu Gly Val Glu Ile Phe Glu
1 5 10 15
Thr Ala Asp Cys Glu Glu Asn Ile Glu Ser Gln Asp Arg Pro Lys Leu
20 25 30
Glu Pro Phe Tyr Val Glu Arg Tyr Ser Trp Ser Gln Leu Lys Lys Leu
35 40 45
Leu Ala Asp Thr Arg Lys Tyr His Gly Tyr Met Met Ala Lys Ala Pro
50 55 60
His Asp Phe Met Phe Val Lys Arg Asn Asp Pro Asp Gly Pro His Ser
65 70 75 80
Asp Arg Ile Tyr Tyr Leu Ala Met Ser Gly Glu Asn Arg Glu Asn Thr
85 90 95

```

Leu Phe Tyr Ser Glu Ile Pro Lys Thr Ile Asn Arg Ala Ala Val Leu
 100 105 110
 Met Leu Ser Trp Lys Pro Leu Leu Asp Leu Phe Gln Ala Thr Leu Asp
 115 120 125
 Tyr Gly Met Tyr Ser Arg Glu Glu Glu Leu Leu Arg Glu Arg Lys Arg
 130 135 140
 Ile Gly Thr Val Gly Ile Ala Ser Tyr Asp Tyr His Gln Gly Ser Gly
 145 150 155 160
 Thr Phe Leu Phe Gln Ala Gly Ser Gly Ile Tyr His Val Lys Asp Gly
 165 170 175
 Gly Pro Gln Gly Phe Thr Gln Gln Pro Leu Arg Pro Asn Leu Val Glu
 180 185 190
 Thr Ser Cys Pro Asn Ile Arg Met Asp Pro Lys Leu Cys Pro Ala Asp
 195 200 205
 Pro Asp Trp Ile Ala Phe Ile His Ser Asn Asp Ile Trp Ile Ser Asn
 210 215 220
 Ile Val Thr Arg Glu Glu Arg Arg Leu Thr Tyr Val His Asn Glu Leu
 225 230 235 240
 Ala Asn Met Glu Glu Asp Ala Arg Ser Ala Gly Val Ala Thr Phe Val
 245 250 255
 Leu Gln Glu Glu Phe Asp Arg Tyr Ser Gly Tyr Trp Trp Cys Pro Lys
 260 265 270
 Ala Glu Thr Thr Pro Ser Gly Gly Lys Ile Leu Arg Ile Leu Tyr Glu
 275 280 285
 Glu Asn Asp Glu Ser Glu Val Glu Ile Ile His Val Thr Ser Pro Met
 290 295 300
 Leu Glu Thr Arg Arg Ala Asp Ser Phe Arg Tyr Pro Lys Thr Gly Thr
 305 310 315 320
 Ala Asn Pro Lys Val Thr Phe Lys Met Ser Glu Ile Met Ile Asp Ala
 325 330 335
 Glu Gly Arg Ile Ile Asp Val Ile Asp Lys Glu Leu Ile Gln Pro Phe
 340 345 350
 Glu Ile Leu Phe Glu Gly Val Glu Tyr Ile Ala Arg Ala Gly Trp Thr
 355 360 365
 Pro Glu Gly Lys Tyr Ala Trp Ser Ile Leu Leu Asp Arg Ser Gln Thr
 370 375 380
 Arg Leu Gln Ile Val Leu Ile Ser Pro Glu Leu Phe Ile Pro Val Glu
 385 390 395 400
 Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro Asp Ser
 405 410 415
 Val Thr Pro Leu Ile Ile Tyr Glu Glu Thr Thr Asp Ile Trp Ile Asn
 420 425 430
 Ile His Asp Ile Phe His Val Phe Pro Gln Ser His Glu Glu Ile
 435 440 445
 Glu Phe Ile Phe Ala Ser Glu Cys Lys Thr Gly Phe Arg His Leu Tyr
 450 455 460
 Lys Ile Thr Ser Ile Leu Lys Glu Ser Lys Tyr Lys Arg Ser Ser Gly
 465 470 475 480
 Gly Leu Pro Ala Pro Ser Asp Phe Lys Cys Pro Ile Lys Glu Glu Ile
 485 490 495
 Ala Ile Thr Ser Gly Glu Trp Glu Val Leu Gly Arg His Gly Ser Asn
 500 505 510
 Ile Gln Val Asp Glu Val Arg Arg Leu Val Tyr Phe Glu Gly Thr Lys
 515 520 525
 Asp Ser Pro Leu Glu His His Leu Tyr Val Val Ser Tyr Val Asn Pro
 530 535 540
 Gly Glu Val Thr Arg Leu Thr Asp Arg Gly Tyr Ser His Ser Cys Cys
 545 550 555 560
 Ile Ser Gln His Cys Asp Phe Phe Ile Ser Lys Tyr Ser Asn Gln Lys
 565 570 575

Asn	Pro	His	Cys	Val	Ser	Leu	Tyr	Lys	Leu	Ser	Ser	Pro	Glu	Asp	Asp
				580				585				590			
Pro	Thr	Cys	Lys	Thr	Lys	Glu	Phe	Trp	Ala	Thr	Ile	Leu	Asp	Ser	Val
				595			600				605				
Leu	Arg	Cys	Ser	Trp											
				610											

<210> 22

<211> 4685

<212> DNA

<213> Homo sapiens

<400> 22

aagtgc	aaa	gcctccgagg	ccaaggccgc	tgctactgcc	gcccgtgctt	cttagtgccg	60
cgttcgccgc	ctgggttgtc	accggcgccg	ccgcccggagga	agccactgca	accaggaccg	120	
gagtggaggc	ggcgcagcat	gaagcggcgc	aggcccgctc	catagcgcac	gtcgggacgg	180	
tccggggcggg	gcccggggga	aggaaaatgc	aacatggcag	cagcaatgg	aacagaacag	240	
ctgggtgttg	agatatttga	aactgcggac	tgtgaggaga	atattgaatc	acaggatcg	300	
cctaaattgg	agcctttta	tgttggcgg	tattcctgga	gtcagcttaa	aaagctgctt	360	
gccgatacc	aaaaatatca	tggctacatg	atggctaagg	caccacatga	tttcatgttt	420	
gtgaagagga	atgatccaga	tggacctcat	tcagacagaa	tctattacct	tgccatgtct	480	
ggtgagaaca	gagaaaatac	actgttttat	tctgaaattc	ccaaaactat	caatagagca	540	
gcagtcttaa	tgctcttgc	gaagcctctt	ttggatctt	ttcaggcaac	actggactat	600	
ggaatgtatt	ctcgagaaga	agaactatta	agagaaagaa	aacgcattgg	aacagtccg	660	
attgtttctt	acgattatca	ccaaggaagt	ggaacatttc	tgtttcaagc	cggttagtgg	720	
atttatacgc	taaaagatgg	agggccacaa	ggatttacgc	aacaacctt	aaggcccaat	780	
ctagtggaaa	ctagttgtcc	caacatacgg	atggatccaa	aattatgcc	tgctgatcca	840	
gactggattg	cttttataca	tagcaacgt	atttggatat	ctaacatcg	aaccagagaa	900	
gaaaggagac	tcacttatgt	gcacaatgag	ctagccaaca	tggaagaaga	tgccagatca	960	
gctggagtgc	ctacctttgt	tctccaagaa	gaatttgata	gatattctgg	ctattggtgg	1020	
tgtccaaaag	ctgaaacaac	tcccagtgg	ggtaaaattc	ttagaattct	atatgaagaa	1080	
aatgatgaat	ctgagggtgg	aattattat	gttacatccc	ctatgttgg	aacaaggagg	1140	
gcagattcat	tccgttatcc	taaaacaggt	acagcaaattc	ctaaagtcc	ttttaagatg	1200	
tcagaaataa	tgattgtatc	tgaaggaagg	atcatagat	tcatagataa	ggaactaatt	1260	
caaccttttgc	agattctatt	tgaaggagtt	gaatatattg	ccagagctgg	atggactcct	1320	
gaggaaaat	atgcttggc	catcctacta	gatcgctccc	agactcgcc	acagatagt	1380	
ttgatctcac	ctgaattatt	tatcccagta	gaagatgatg	ttatggaaag	gcagagactc	1440	
attgagtcag	tgcctgattc	tgtgacgcca	ctaattatct	atgaagaaaac	aacagacatc	1500	
tggataataa	tccatgacat	ctttcatgtt	tttccccaaa	gtcacgaaga	ggaatttgag	1560	
tttatttttg	cctctgaatg	caaaacaggt	ttccgtcatt	tataaaaaat	tacatctatt	1620	
ttaaaggaaa	gcaaatataa	acgatccagt	ggtgggctgc	ctgctccaag	tgatttcaag	1680	
tgtcctatca	aagaggagat	agcaattacc	agtggtgaat	ggtggatctt	tggccggcat	1740	
ggatctaata	tccaaaggta	tgaagtcaga	aggctggat	attttgaagg	caccaaagac	1800	
tcccctttag	agcatcacct	gtacgtatc	agttacgtaa	atccctggaga	ggtgacaagg	1860	
ctgactgacc	gtggctactc	acattctgc	tgcatacgat	agcactgtga	cttcttata	1920	
agtaagtata	gtaaccagaa	gaatccacac	tgtgttccc	tttacaagat	atcaagtcc	1980	
gaagatgacc	caacttgc	aaacaaaggaa	ttttggcca	ccattttgg	ttcagtcc	2040	
aggtgcagtt	ggtgaataat	cggtttaaag	gagtcaagta	tttccgtt	aataccctag	2100	
cctctctagg	ttatgtgg	gtatgtatag	acaacagggg	atccgtc	cgaggccta	2160	
aatttgaagg	cgccctttaaa	tataaaatgg	gtcaaata	aatttgc	cagggtgg	2220	
gactccaata	tctagttct	cgatatgatt	tcatttgc	agatcggt	ggcatccacg	2280	
gctggtccta	tggaggatac	cttccctg	tggcattaa	gcagaggta	gatatttca	2340	
gggttgcata	tgctggggcc	ccagtca	tgtggatctt	ctatgata	ggatacacgg	2400	
aacgttatata	gggtcaccc	gaccagaatg	aacagggtca	ttacttagga	tctgtggcc	2460	
tgcaagcaga	aaagtcccc	tctgaaccaa	atcgat	gcttttacat	ggtttcc	2520	
atgagaatgt	ccattttgc	cataccagta	tattactgag	ttttttat	agggtggaa	2580	
agccatata	tttacagatc	tatcctcagg	agagacacag	cataagagg	cctgaatcgg	2640	
gagaacatta	tgaactgc	cttttgcact	accttcaaga	aaaccttgg	tcacgtatt	2700	
ctgctctaa	agtgtatataa	tttgacctg	tgttagaactc	tctgttata	actggctt	2760	
taaccaaata	aggagttt	atcaacagaa	aacacagaat	tgatcatc	attttata	2820	

ctgccatgt	acatctactc	ctgaaaataa	atgtgggcc	atgcagggt	ctacggtt	2880
tggtagtaat	ctaataccct	aaccccccacat	gctcaaaatc	aatgataca	tattcctgag	2940
agacccagca	ataccataag	aattactaaa	aaaaaaaaaa	aaaaaaagac	attagcacca	3000
tgtattcata	ctaccctatt	ttcactttt	atagtattat	aaacttcatg	aacttaatta	3060
gtgtatTTT	acagtatact	tttgagTTT	ttaaaatatg	atgatattag	tgattggTTT	3120
ggttcagttc	cagaatctt	gactagttac	agatttgata	gcacttaaat	gtaattgaat	3180
agctttagct	tcattgctt	ggcatatcca	gcatgtatg	aactaataac	tattaaactt	3240
gacttaacca	gtcattcatt	aataattttt	caaggataac	ttagtgccct	cctaaagaca	3300
cttgTTTgg	caactgaccag	tttttagcca	atthaatctg	tatctagtat	aaataattct	3360
cattttctt	tgatgatatt	aacagagtgg	gctttcctt	ttgcataaaag	gctagtaact	3420
gtatatgtag	catggattta	attagtcatg	atattgataa	ttacagggcag	aaaatttttta	3480
atcaaatgtat	tagagcttaa	atatttgcag	gcaagttttt	tttttcctt	taagaaaagg	3540
aaaaaagtaca	cattcactag	aattcttcag	aaaatttagt	ggtgccagtt	tccatttggt	3600
atttccttat	taaaatattc	tagaatttttta	aggagattga	aggaaatcac	agtggggTgg	3660
ggagacctgg	gtttggggaa	tgacagagag	aagagggtgt	gagggcctga	ttaaaaacta	3720
agcagaagta	gttttaacaa	aaatactcat	gaaaatgttt	ggaaactgaa	atttaaacaa	3780
ctgtaatatt	aaggaacca	gaatcaataa	atcaactgtct	tgccagcaca	gctacagagt	3840
aacatgattc	aggggaggaa	aagttcctt	gagttacttt	tataatttctt	ttttttttc	3900
ctcttaggtt	tagaaatctt	acaaatttaa	actttatcct	tttaaaatattt	tttgaacata	3960
atttagatat	tgtaagctt	aaatacaaaat	gtttatagat	aacctctttt	ccataaaacta	4020
atccctggca	agccatggct	ctctttttt	tttgggttt	taaaggctgt	aaacagttt	4080
tctgaatgtat	catgaacttt	tcttggttt	gcaactaggat	ttagctatga	agagagctca	4140
taggctttca	ggtgcttaatt	gagatctgcc	ctgttagagt	cttggggTgc	tagattggc	4200
acattgacac	cagtggcagg	gaaggcatct	atgagttga	tgctttttat	cacacacttc	4260
agtgttttaga	aagtattac	caatactttt	aaacaacact	ccaagaaaat	ttgctatatt	4320
tcttctcat	cactacagag	agagtagatt	tccccataga	gagcacagcc	tccatttagta	4380
aggttggta	ctattgttaa	gaggtggact	tcattgacac	caagtggag	gtaggaaag	4440
cccagaaaatg	gcaggatgtat	atgggtggc	tgtcgttggg	aaaggatttg	ggtttgctg	4500
tttgcatttt	tactgtataa	tagataccac	gcttttctt	attatctgt	tatgtattgc	4560
ttttcatgtt	tgatattttc	ccatgccaag	atttggTTT	atataattttc	aatgttaaat	4620
taaattgatt	tggtaactt	tctccccaa	gaaagtattt	tcccccttaa	gtataaaatct	4680
gactg						4685

<210> 23
 <211> 892
 <212> PRT
 <213> Homo sapiens
 <400> 23

Met	Arg	Lys	Val	Lys	Lys	Leu	Arg	Leu	Asp	Lys	Glu	Asn	Thr	Gly	Ser	
1					5					10				15		
Trp	Arg	Ser	Phe	Ser	Leu	Asn	Ser	Glu	Gly	Ala	Glu	Arg	Met	Ala	Thr	
								20			25			30		
Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala	Thr	Asp	Asp	
								35			40			45		
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg	
								50			55			60		
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys	
								65			70			75		80
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro	
								85			90			95		
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu	
								100			105			110		
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala	
								115			120			125		
Leu	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr	
								130			135			140		
Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg	
								145			150			155		160
Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe	His	Ser	Glu	

165	170	175
Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg		
180	185	190
Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu		
195	200	205
Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro		
210	215	220
Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val		
225	230	235
Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln		
245	250	255
Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr		
260	265	270
Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys		
275	280	285
Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile		
290	295	300
Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro		
305	310	315
Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg		
325	330	335
Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln		
340	345	350
Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val		
355	360	365
Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala		
370	375	380
Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg		
385	390	395
Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile		
405	410	415
Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val		
420	425	430
Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val		
435	440	445
Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly		
450	455	460
Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe		
465	470	475
Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp		
485	490	495
Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile		
500	505	510
Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg		
515	520	525
His Gly Ser Lys Ile Trp Val Asn Glu Glu Thr Lys Leu Val Tyr Phe		
530	535	540
Gln Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr Val Val Ser		
545	550	555
Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro Gly Phe Ser		
565	570	575
His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val Ser His Tyr		
580	585	590
Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys Leu Ser Gly		
595	600	605
Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp Ala Ser Met		
610	615	620
Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro Glu Ile Phe		
625	630	635
His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met Ile Tyr Lys		

	645	650	655
Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val Leu Phe Val			
660	665	670	
Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe Lys Gly Ile			
675	680	685	
Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr Ala Val Val			
690	695	700	
Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg Phe Glu Gly			
705	710	715	720
Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp Gln Val Glu			
725	730	735	
Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp Leu Ser Arg			
740	745	750	
Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser Leu Met Gly			
755	760	765	
Leu Ile His Lys Pro Gln Val Phe Lys Val Ala Ile Ala Gly Ala Pro			
770	775	780	
Val Thr Val Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu Arg Tyr Met			
785	790	795	800
Asp Val Pro Glu Asn Asn Gln His Gly Tyr Glu Ala Gly Ser Val Ala			
805	810	815	
Leu His Val Glu Lys Leu Pro Asn Glu Pro Asn Arg Leu Leu Ile Leu			
820	825	830	
His Gly Phe Leu Asp Glu Asn Val His Phe Phe His Thr Asn Phe Leu			
835	840	845	
Val Ser Gln Leu Ile Arg Ala Gly Lys Pro Tyr Gln Leu Gln Ile Tyr			
850	855	860	
Pro Asn Glu Arg His Ser Ile Arg Cys Pro Glu Ser Gly Glu His Tyr			
865	870	875	880
Glu Val Thr Leu Leu His Phe Leu Gln Glu Tyr Leu			
885	890		

<210> 24
 <211> 4302
 <212> DNA
 <213> Homo sapiens
 <400> 24

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaagg	gcctgagccg	gcgggtcccc	60
tgtgtccgccc	gcccgtgtcg	tcccccgctc	ccgcccacttc	cggggtcgca	gtccccggca	120
tggagccgccc	accgtgaggc	gcccgtggac	ccgggacgac	ctgcccagtc	cgcccccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaaatg	gaggctctct	ggacccttta	240
gaaggccaccc	ctgcccctct	gaggtcagct	gagcggtaa	tgcggaaagg	taagaaaactg	300
cgcctggaca	aggagaacac	cgaaagg	agaagttct	cgctgaattc	cgaggggct	360
gagaggatgg	ccaccacccgg	gaccccaacg	gcccggccgg	gcccacagat	cgccacagat	420
gacccggccg	cccgcttcca	ggtgcagaag	cactcg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagtt	540
gtcagaaga	cgatgagtc	tggcccccac	tcccaccgcc	tctactacct	ggaaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaagg	ccggaaagag	660
gtctgtgtgc	tcctgtctcg	gaagcagatg	ctggatcatt	tcaggccac	gccccaccat	720
ggggctact	ctcgggagga	ggagctgtcg	agggagcgg	aacgcctgg	ggtcttcggc	780
atcacctcct	acgacttcca	cagcggagat	ggcctcttcc	tcttccaggc	cagcaacagc	840
ctcttccact	ggcgccgacgg	cgcaagaac	ggcttcatgg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	aggccccgg	atggacccca	aatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcg	gacaggcgag	1020
gagcggccggc	tgaccttctg	ccaccaagg	ttatccaatg	tcctggatga	ccccaaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttcactgg	gtactgg	1140
tgccccacag	cctcctggga	agttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtcccct	ctcctgcgc	agaagaaagg	1260
aagacggact	cgtatcggt	ccccaggaca	ggcagcaaga	atcccaagat	tgccttgaaa	1320

ctggctgagt	tccagactga	cagccagggo	aagatcgct	cgacccagga	gaaggagctg	1380
gtcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgcccaggc	cgggtggacc	1440
cgggatggca	aatacgccctg	ggccatgttc	ctggaccggc	cccagcagtg	gctccagctc	1500
gtccctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gcccgttagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgcttc	tcccgcccaa	tgaatgcaag	accggcttct	gccatttgt	caaagtacc	1740
gccgtttaa	aatcccagg	ctacgattgg	agtgagccct	tcagccccgg	ggaagatgaa	1800
ttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggga	gttttggcg	1860
aggcacggct	ccaagatctg	ggtcaatgag	gagaccaagc	tggtgtactt	ccagggcacc	1920
aaggacacgc	cgctggagca	ccacctctac	gtggtcagct	atgaggcggc	cggcagatc	1980
gtacccctca	ccacgccccg	cttctccat	agctgctcca	tgagccagaa	cttcgacatg	2040
ttcgtcagcc	actacagcag	cgtgagcacg	ccgcctcg	tgcacgtcta	caagctgagc	2100
ggcccccacg	acgacccct	gcacaaggcag	ccccgcttct	gggctagcat	gatggaggca	2160
gccagctgcc	ccccggattt	tgttcctcca	gagatcttcc	atttccacac	gcgctcgat	2220
gtgcggctct	acggcatgtat	ctacaagccc	cacgccttgc	agccagggaa	gaagcacc	2280
accgtcctct	ttgtatatgg	aggcccccag	gtgcagctgg	tgaataactc	cttcaaaggc	2340
atcaagtact	tgcggctcaa	cacactggcc	tccctggct	acgcccgtgt	tgtgattgac	2400
ggcaggggct	cctgtcagcg	agggttcgg	ttcgaagggg	ccctgaaaaaa	ccaaatggc	2460
caggtggaga	tgcaggacca	ggtggagggc	ctgcagttcg	tggccgagaa	gtatggctc	2520
atcgacactga	gcccggattgc	catccatggc	tggtcctacg	ggggcttct	ctcgctcatg	2580
gggctaattcc	acaagcccca	ggtgttcaag	gtggccatcg	cgggtgcccc	ggtcaccgtc	2640
tggatggcct	acgacacagg	gtacactgag	cgctacatgg	acgtccctga	gaacaaccag	2700
cacggctatg	aggcgggttc	cgtggccctg	cacgtggaga	agctgccc	tgagccaa	2760
cgcttgc	tcctccacgg	cttcctggac	gaaaacgtgc	acttttcca	cacaaacttc	2820
ctcgctccc	aactgatccg	acgaggaaa	ccttaccagc	tccagatcta	ccccaaacgag	2880
agacacagta	tgcgtgccc	cgagtccggc	gagcaactatg	aagtca	gctgacttt	2940
ctacaggaat	acctctgagc	ctgcccaccc	ggagccgca	catcacagca	caagtggctg	3000
cagcctccgc	ggggaaaccag	gccccgggg	ctgagtgcc	cgccggcccc	agtgaggc	3060
tttgcgtccgc	ccagcgtcg	ccagccccga	ggagccgctg	ccttcaccc	ccgcacgc	3120
tttatactttt	tttaaacgc	cttgggtttt	atgtccgctg	cttcttggtt	ggccgagacag	3180
agagatggtg	gtctcggcc	agccctct	ctccccc	tctgggagga	ggaggtcaca	3240
cgcttgc	acttggagag	gcccagaagag	actcagagga	gcccgtg	ttccgcctgg	3300
ggctccctgt	gacctctcag	tcccctggcc	cgccagcca	ccgtcccc	caccaagca	3360
tgcaattgcc	tgtccccccc	ggccagc	cccaacttga	tgttgcgtt	ttgttgggg	3420
ggatattttt	cataattatt	taaaagacag	gcccggc	gtggctc	tctgtatcc	3480
cagcactttg	ggaggctgag	gccccggat	cacctgaggt	tgggagttca	agaccagc	3540
ggccaacatg	ggggaaacccc	gtctctacta	aaaataaaaa	aaattagcc	ggtgtgg	3600
cgcgtgc	taatccc	actcggag	gctgaggcag	gagaatcg	tgaaccc	3660
agg	gggt	gagc	caagatcg	ccattgc	caacaagagc	3720
gaaactctgt	ctcaaaataa	ataaaaaata	aaagacagaa	agcaagg	gcctaaatct	3780
agacttgggg	tccacaccgg	gcagcggg	tgcaaccc	cac	ctgcatttc	3840
ttcccaagcc	cgagcagagg	gtcatgc	cccc	ccag	gggccc	3900
ggggcaccac	ctgtggacag	ccctctgtc	cccaag	ccag	ctgaaac	3960
ccgaacttcc	acgctctgct	ggtca	ggctgt	cccc	agccccc	4020
ccacatgtgt	ctgcctgacc	cgta	ccac	agg	ctgaacc	4080
cccaccc	ggttatattt	ccctctccc	ttcc	ccaa	gggttgg	4140
cgggcaaaaa	aaaaagtaaa	aagaaaagaa	aaaaaaa	aagaaaca	ccac	4200
atattatgg	aagaaaat	tttgcgt	tcttattt	ttataattat	gctgt	4260
agt	acaca	ttaaacgatt	ccagttgg	acatgtc	aa	4302

<210> 25
 <211> 518
 <212> PRT
 <213> Homo sapiens
 <400> 25

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
 1 5 10 15
 Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr

20	25	30													
Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala	Thr	Asp	Asp
35								40					45		
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg
50								55					60		
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys
65								70					75		80
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro
									85				90		95
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu
									100				105		110
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala
									115				120		125
Leu	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr
									130				135		140
Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg
									145				150		160
Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe	His	Ser	Glu
									165				170		175
Ser	Gly	Leu	Phe	Leu	Phe	Gln	Ala	Ser	Asn	Ser	Leu	Phe	His	Cys	Arg
									180				185		190
Asp	Gly	Gly	Lys	Asn	Gly	Phe	Met	Val	Ser	Pro	Met	Lys	Pro	Leu	Glu
									195				200		205
Ile	Lys	Thr	Gln	Cys	Ser	Gly	Pro	Arg	Met	Asp	Pro	Lys	Ile	Cys	Pro
									210				215		220
Ala	Asp	Pro	Ala	Phe	Phe	Ser	Phe	Ile	Asn	Asn	Ser	Asp	Leu	Trp	Val
									225				230		240
Ala	Asn	Ile	Glu	Thr	Gly	Glu	Glu	Arg	Arg	Leu	Thr	Phe	Cys	His	Gln
									245				250		255
Gly	Leu	Ser	Asn	Val	Leu	Asp	Asp	Pro	Lys	Ser	Ala	Gly	Val	Ala	Thr
									260				265		270
Phe	Val	Ile	Gln	Glu	Glu	Phe	Asp	Arg	Phe	Thr	Gly	Tyr	Trp	Trp	Cys
									275				280		285
Pro	Thr	Ala	Ser	Trp	Glu	Gly	Ser	Glu	Gly	Leu	Lys	Thr	Leu	Arg	Ile
									290				295		300
Leu	Tyr	Glu	Glu	Val	Asp	Glu	Ser	Glu	Val	Glu	Val	Ile	His	Val	Pro
									305				310		320
Ser	Pro	Ala	Leu	Glu	Glu	Arg	Lys	Thr	Asp	Ser	Tyr	Arg	Tyr	Pro	Arg
									325				330		335
Thr	Gly	Ser	Lys	Asn	Pro	Lys	Ile	Ala	Leu	Lys	Leu	Ala	Glu	Phe	Gln
									340				345		350
Thr	Asp	Ser	Gln	Gly	Lys	Ile	Val	Ser	Thr	Gln	Glu	Lys	Glu	Leu	Val
									355				360		365
Gln	Pro	Phe	Ser	Ser	Leu	Phe	Pro	Lys	Val	Glu	Tyr	Ile	Ala	Arg	Ala
									370				375		380
Gly	Trp	Thr	Arg	Asp	Gly	Lys	Tyr	Ala	Trp	Ala	Met	Phe	Leu	Asp	Arg
									385				390		400
Pro	Gln	Gln	Trp	Leu	Gln	Leu	Val	Leu	Leu	Pro	Pro	Ala	Leu	Phe	Ile
									405				410		415
Pro	Ser	Thr	Glu	Asn	Glu	Glu	Gln	Arg	Leu	Ala	Ser	Ala	Arg	Ala	Val
									420				425		430
Pro	Arg	Asn	Val	Gln	Pro	Tyr	Val	Val	Tyr	Glu	Glu	Val	Thr	Asn	Val
									435				440		445
Trp	Ile	Asn	Val	His	Asp	Ile	Phe	Tyr	Pro	Phe	Pro	Gln	Ser	Gly	
									450				455		460
Glu	Asp	Glu	Leu	Cys	Phe	Leu	Arg	Ala	Asn	Glu	Cys	Lys	Thr	Gly	Phe
									465				470		480
Cys	His	Leu	Tyr	Lys	Val	Thr	Ala	Val	Leu	Lys	Ser	Gln	Gly	Tyr	Asp
									485				490		495
Trp	Ser	Glu	Pro	Phe	Ser	Pro	Gly	Glu	Gly	Glu	Gln	Ser	Leu	Thr	Asn

500
 Ala Val Asp Ser Ser Arg
 515

505

510

<210> 26
 <211> 2411
 <212> DNA
 <213> Homo sapiens
 <400> 26

caggccgccc cctgggtcgc tcaacttccg ggtcaaagggt gcctgagccg gcgggtcccc 60
 tgtgtccgccc gcggtcgctg tcccccgctc cccgcacttc cggggtcgcgtc gtcccgcc 120
 tggagccgccc accgtgaggc gccgctggac cggggacgac ctgcccagtc cggccgccc 180
 cccacgtccc ggtctgtgtc ccaacgcctgc agctggaaatg gaggctctct ggacccttta 240
 gaaggcaccct ctgccttcct gaggtcagct gagcggtaa tgccggaaagggt taagaaaactg 300
 cgcctggaca aggagaacac cggaaagggttgg agaagcttct cgctgaattt cggggggct 360
 gagaggatgg ccaccaccgg gaccccaacg gccgaccggag gcgacgcagc cgccacagat 420
 gaccggccg cccgcttcca ggtgcagaag cactcggtgg acgggctccg gagcatcatc 480
 cacggcagcc gcaagtactc gggcctcatt gtcaacaagg cgccccacgca cttccagttt 540
 gtgcagaaga cggatgagtc tggggccac tcccaccgc tctactaccc gggatgcca 600
 tatggcagcc gagagaactc cctcctctac tctgagattt ccaagaagggt cggaaaagag 660
 gctctgtgc tcctgtctcg gaagcagatg ctggatcatt tccaggccac gcccaccat 720
 ggggtctact ctcgggagga ggagctgtgg agggagcggaa aacgcctggg ggtcttcggc 780
 atcaccttcc acgacttcca cagcggagatg ggccttcc tcttcaggc cagcaacagc 840
 ctcttccact gccgcgacgg cggcaagaac ggcttcatgg tgcctccat gaaaccgctg 900
 gaaatcaaga cccagtgtc agggcccccgg atggacccca aatctgccc tgccgaccct 960
 gccttcttct cttcatcaa taacagcgac ctgtgggtgg ccaacatcga gacaggcgag 1020
 gagggcgcc tgaccttctg ccaccaagggt ttatccaatg tcctggatga ccccaagtct 1080
 gcggtgtgg ccaccttcgt catacaggaa gagttcgacc gcttcactgg gtactgggtgg 1140
 tgccccacag cctcttggaa aggttcagag ggcctcaaga cgctgcgaat cctgtatgag 1200
 gaagtcgtg agtccggaggt ggaggtcatt cacgtccccct ctccctgcgt agaagaaaagg 1260
 aagaacggact cgtatcggtt ccccaggaca ggcagcaaga atcccaagat tgccttggaaa 1320
 ctgggtgtggatgttccagactgtt cagccggc aagatcgtct cgacccaggaa gaggagctg 1380
 gtgcagccct tcagctcgct gtcccgaaag gtggagtaca tcgcccaggc cgggtggacc 1440
 cgggatggca aatacgcctg gcccattttc ctggaccggc cccagcagtg gctccagctc 1500
 gtccttcctcc ccccgccctt gtcatcccg agcacaaggaa atgaggagca gcggttagcc 1560
 tctgccagag ctgtccccag gaatgtccag ccgtatgtgg tgcctccat ggtcaccaac 1620
 gtctggatca atgttcatga catttctat ccctttttttt aatcagaggg agaggacgg 1680
 ctctgttttc tccgcggccaa tgaatgcaag accgggttctt gccattttgtt caaagtccacc 1740
 gccgttttaa aatcccagggtt ctacgattgg agtggccct tcagcccccgg ggaaggtgag 1800
 cagacgcctga cgaatgtgtt cgaactcatcg cgttagtcac gtgtgggttca atatgtgtt 1860
 tgttcattgg tcggcccccc cactcagcca gcacaccctg cggggagaagg aacagggatc 1920
 ggcaggaagc cagccttcctt cagtgactgc atgatctggc agggctttaga gcacccaaact 1980
 gttggcttat tcaggcagca gatttactga gcacccccc tgcggccaggc ctttagcaca 2040
 accagggggtt ggcacccctac gcccacacgg tcaaatccgg cccaccacccgtgttcataa 2100
 ataaaatgtttt atggcactg agccacacggc acttgggttac agagactgtc tgcgtgtcgct 2160
 tttgtgtgc agcagcagaa ctgggttagtc ccagcagaaa ctgttgcgtca aggcaagat 2220
 ttactgtcta gcccatttttta gaaacatggcc ccagcttcgt ctgttaggtt tgcgtgtgg 2280
 attgttcaact gtaaataaaag aaaaaggaaa atccctgttc ttgggacccctt tgcgtggagg 2340
 aggcaatggc ccagaaacag ttagaggtgc tgccttcgtt gtgtgtggg tggcagatgc 2400
 agatcctagt c 2411

<210> 27
 <211> 892
 <212> PRT
 <213> Homo sapiens
 <400> 27

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
 1 5 10 15

Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
 20 25 30
 Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Ala Thr Asp Asp
 35 40 45
 Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
 50 55 60
 Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
 65 70 75 80
 Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
 85 90 95
 His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
 100 105 110
 Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
 115 120 125
 Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr
 130 135 140
 Pro His His Gly Val Tyr Ser Arg Glu Glu Leu Leu Arg Glu Arg
 145 150 155 160
 Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu
 165 170 175
 Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg
 180 185 190
 Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu
 195 200 205
 Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro
 210 215 220
 Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val
 225 230 235 240
 Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln
 245 250 255
 Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr
 260 265 270
 Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys
 275 280 285
 Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile
 290 295 300
 Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro
 305 310 315 320
 Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg
 325 330 335
 Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln
 340 345 350
 Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val
 355 360 365
 Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala
 370 375 380
 Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg
 385 390 395 400
 Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile
 405 410 415
 Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val
 420 425 430
 Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val
 435 440 445
 Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly
 450 455 460
 Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe
 465 470 475 480
 Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp
 485 490 495

Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile
 500 505 510
 Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg
 515 520 525
 His Gly Ser Lys Ile Trp Val Asn Glu Glu Thr Lys Leu Val Tyr Phe
 530 535 540
 Gln Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr Val Val Ser
 545 550 555 560
 Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro Gly Phe Ser
 565 570 575
 His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val Ser His Tyr
 580 585 590
 Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys Leu Ser Gly
 595 600 605
 Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp Ala Ser Met
 610 615 620
 Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro Glu Ile Phe
 625 630 635 640
 His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met Ile Tyr Lys
 645 650 655
 Pro His Ala Leu Gln Pro Gly Lys His Pro Thr Val Leu Phe Val
 660 665 670
 Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe Lys Gly Ile
 675 680 685
 Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr Ala Val Val
 690 695 700
 Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg Phe Glu Gly
 705 710 715 720
 Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp Gln Val Glu
 725 730 735
 Gly-Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp Leu Ser Arg
 740 745 750
 Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser Leu Met Gly
 755 760 765
 Leu Ile His Lys Pro Gln Val Phe Lys Val Ala Ile Ala Gly Ala Pro
 770 775 780
 Val Thr Val Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu Arg Tyr Met
 785 790 795 800
 Asp Val Pro Glu Asn Asn Gln His Gly Tyr Glu Ala Gly Ser Val Ala
 805 810 815
 Leu His Val Glu Lys Leu Pro Asn Glu Pro Asn Arg Leu Leu Ile Leu
 820 825 830
 His Gly Phe Leu Asp Glu Asn Val His Phe Phe His Thr Asn Phe Leu
 835 840 845
 Val Ser Gln Leu Ile Arg Ala Gly Lys Pro Tyr Gln Leu Gln Ile Tyr
 850 855 860

Pro	Asn	Glu	Arg	His	Ser	Ile	Arg	Cys	Pro	Glu	Ser	Gly	Glu	His	Tyr
865															880
Glu	Val	Thr	Leu	Leu	His	Phe	Leu	Gln	Glu	Tyr	Leu				
												885		890	

<210> 28
<211> 4219
<212> DNA
<213> Homo sapiens
<400> 28

caggccgcg	cctgggtcgc	tcaacttccg	ggtcaaagg	gcctgagccg	gcgggtcccc	60
tgttccgcc	gcggctgtcg	tccccgcgc	ccgcccacttc	cggggtcgc	gtcccgggca	120
tggagccgcg	accgtgaggc	gccgctggac	ccgggacgc	ctgcccagtc	cgccgcgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctgaaatg	gaggctctc	ggacccttta	240
gaaggcaccc	ctgcccctct	gaggtcagct	gagcggtaa	tgcgaaagg	taagaaaactg	300
cgccctggaca	aggagaacac	cggaagttgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gaccccaacg	gccgaccgg	gcgacgcagc	cgccacagat	420
gacccggccg	cccgcttcca	ggtgcagaag	cactcgtggg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttcagttt	540
gtgcagaaga	cggatgagtc	tggcccccac	tcccacggcc	tctactacct	gggaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaagg	ccggaaagag	660
gctctgtgc	tcctgttctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
gggtctact	ctcgggagga	ggagctgctg	agggagcgg	aacgccttggg	ggttttccgc	780
atcacctct	acgacttcca	cagcgagat	ggccttctcc	tcttccagggc	cagcaacagc	840
ctcttccact	gcccgcacgg	cgcaagaac	ggtttcatgg	tgtcccttat	gaaaccgctg	900
gaaatcaaga	cccagtctc	aggccccgg	atggacccca	aatctgccc	tgccgaccct	960
gccttcttct	ctttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcggc	tgaccttctg	ccaccaagg	ttatccaatg	tcctggatga	ccccaaagtct	1080
gcccgtgtgg	ccacccctgt	catacaggaa	gagttcgacc	gttcaactgg	gtactgggtgg	1140
tgccccacag	ctcttcttgg	agtttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtccct	ctcctgcgt	agaagaaagg	1260
aagacggact	cgtatcggt	ccccaggaca	ggcagaaga	atcccaagat	tgccttggaaa	1320
ctggctgagt	tccagactga	cagccagggg	aagatcgtt	cgacccagg	gaaggagctg	1380
gtcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tgccttggggc	cggttggacc	1440
cggatggca	aatacgctg	ggccatgttc	ctggaccggc	cccaggatgt	gtccagctc	1500
gtctctctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gcccgttagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	ccctttccccc	aatcagagg	agaggacgag	1680
ctctgctttc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgt	caaagtccacc	1740
gccgttttaa	aatcccagg	ctacgattgg	agtggccct	ttagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggg	ggttttggcg	1860
aggcacggct	ccaagatctg	ggtaaatgag	gagaccaagc	ttgtgtactt	ccagggcacc	1920
aaggacacgc	cgctggagca	ccacctctac	gtggtcagct	atgaggcggc	cgccgagatc	1980
gtacgcctca	ccacgcgg	cttctccat	agctgctcca	tgagccagaa	cttcgacatg	2040
ttcgtcagcc	actacagcag	cgtgagcagc	ccgcctcg	tgcacgtcta	caagctgagc	2100
ggccccgacg	acgccccct	gcacaagg	ccccgttct	gggctagcat	gatggaggca	2160
gccagctgcc	ccccggatta	tgttccctcc	gagatctcc	atttccacac	gcccgtggat	2220
gtgcggctct	acggcatgat	ctacaagccc	cacgccttgc	agccagggg	gaaggaccc	2280
accgtctct	ttgtatatgg	aggccccccag	gtgcagctgg	tgaataactc	cttcaaaggc	2340
atcaagact	tgccgctcaa	cacactggcc	tccctgggt	acgcccgtgt	tgtgattgac	2400
ggcaggggct	cctgtcagcg	agggttcgg	ttcgaagggg	ccctgaaaaa	ccaaatgggc	2460
caggtggaga	tcgaggacca	ggtggagggg	ctgcagttcg	tggcegagaa	gtatggctc	2520
atcgacctga	gccgagg	catccatggc	tggcctacg	ggggcttcct	ctcgctcatg	2580
ggcataatcc	acaagccca	ggtgttcaag	gtggccatcg	cggggtcccc	ggtcacccgtc	2640
tggatggcct	acgacacagg	gtacactgag	cgctacatgg	acgtccctga	gaacaaccag	2700
cacggctatg	aggcggttc	cgtggccctg	cacgtggaga	agctgccccaa	tgagcccaac	2760
cgcttgcctt	tcctccacgg	cttcctggac	aaaaacgtgc	acttttccca	cacaaacttc	2820
ctcgctctcc	aactgatccg	agcaggggaaa	ccttaccagc	tccagatcta	ccccaaacgag	2880
agacacagta	ttcgctcccc	cgagtcgggg	gagcaactatg	aagtcaacgtt	gctgcacttt	2940

ctacaggaat	acctctgagc	ctgcccacccg	ggagccgcca	catcacagca	caagtggctg	3000
cagcctccgc	ggggAACCCAG	gccccggggga	ctgagtgcc	cgccgggcccc	agtgaggcac	3060
tttgcctccgc	ccagcgctgg	ccagccccga	ggagccgctg	ccttcaccgc	cccgacgcct	3120
tttatccttt	tttaaacgct	cttgggtttt	atgtccgctg	cttcttggtt	gcccggagacag	3180
agagatggtg	gtctcgggcc	agccccctct	ctccccccct	tctgggagga	ggagggtcaca	3240
cgctgtggg	cactggagag	gccagaagag	actcagagga	gcgggctgcc	ttccgcctgg	3300
ggctccctgt	gacctctcag	tcccctggcc	cggccagcca	ccgtccccag	cacccaagca	3360
tgcaattgcc	tgtccccccc	ggccagcctc	cccaacttga	tgtttgggtt	ttgtttgggg	3420
ggatatttt	cataattatt	taaaaagacag	gccgggcccgc	gtggctcacg	tctgtatcc	3480
cagcacttg	ggaggctgag	gccccggat	cacctgaggt	tgggagttca	agaccagcct	3540
ggccaacatg	ggggaaacccc	gtctctacta	aaaatacaaa	aaattagccg	ggtgtgggtgg	3600
cgcgtgccta	taatcccagc	tactcgggag	gctgaggcag	gagaatcgct	tgaacccggg	3660
aggtggaggt	tgcggtgagc	caagatcgca	ccattgcact	ccagcctggg	caacaagagc	3720
gaaactctgt	ctcaaaataa	ataaaaaata	aaagacagaa	agcaaggggt	gcctaaatct	3780
agacttgggg	tccacaccgg	gcagcggggt	tgcaacccag	cacctggtag	gctccatttc	3840
tcccaagcc	cgactttcag	gcaggcactg	aaacgcaccg	aacttccacg	ctctgctgg	3900
cagtggcgc	tgtccccctcc	ccagccccgc	cggccagcca	catgtgtctg	cctgaccgcgt	3960
acacaccagg	ggttccgggg	ttgggagctg	aaccatcccc	acctcagggt	tatatttccc	4020
tctcccttc	cctcccccc	aagagctctg	ccagggcggg	gcaaaaaaaaaa	aagtaaaaaag	4080
aaaagaaaaa	aaaaaaaaaaag	aaacaaacca	cctctacata	ttatggaaag	aaaatatttt	4140
tgtcgattct	tattcttta	taattatgct	tggaagaagt	agacacat	aacgattcca	4200
gttggaaaca	tgtcacctg					4219

<210> 29
 <211> 832
 <212> PRT
 <213> Homo sapiens
 <400> 29

Met	Arg	Lys	Val	Lys	Lys	Lys	Leu	Arg	Leu	Asp	Lys	Glu	Asn	Thr	Gly	Ser	
1							5				10						15
Trp	Arg	Ser	Phe	Ser	Leu	Asn	Ser	Glu	Gly	Ala	Glu	Arg	Met	Ala	Thr		
							20				25						30
Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala	Thr	Asp	Asp		
							35				40						45
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg		
							50				55						60
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys		
							65				70						80
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro		
							85				90						95
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu		
							100				105						110
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala		
							115				120						125
Leu	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr		
							130				135						140
Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg		
							145				150						160
Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe	His	Ser	Glu		
							165				170						175
Ser	Gly	Leu	Phe	Leu	Phe	Gln	Ala	Ser	Asn	Ser	Leu	Phe	His	Cys	Arg		
							180				185						190
Asp	Gly	Gly	Lys	Asn	Gly	Phe	Met	Val	Ser	Pro	Met	Lys	Pro	Leu	Glu		
							195				200						205
Ile	Lys	Thr	Gln	Cys	Ser	Gly	Pro	Arg	Met	Asp	Pro	Lys	Ile	Cys	Pro		
							210				215						220
Ala	Asp	Pro	Ala	Phe	Phe	Ser	Phe	Ile	Asn	Asn	Ser	Asp	Leu	Trp	Val		
							225				230						240
Ala	Asn	Ile	Glu	Thr	Gly	Glu	Arg	Arg	Ile	Thr	Phe	Cys	His	Gln			

245	250	255
Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr		
260	265	270
Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys		
275	280	285
290	295	300
Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile		
305	310	315
Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro		
320	325	330
Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg		
335	340	345
Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln		
350	355	360
Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val		
365	370	375
Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala		
380	385	390
Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg		
400	405	410
Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile		
415	420	425
Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val		
430	435	440
Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val		
445	450	455
Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly		
460	465	470
Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe		
480	485	490
Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp		
495	500	505
Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile		
510	515	520
Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg		
525	530	535
His Gly Ser Lys Ile Trp Val Asn Glu Glu Thr Lys Leu Val Tyr Phe		
540	545	550
Gln Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr Val Val Ser		
560	565	570
Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro Gly Phe Ser		
575	580	585
His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val Ser His Tyr		
590	595	600
Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys Leu Ser Gly		
605	610	615
Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp Ala Ser Met		
620	625	630
Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro Glu Ile Phe		
640	645	650
His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met Ile Tyr Lys		
655	660	665
Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val Leu Phe Val		
670	675	680
Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe Lys Gly Ile		
685	690	695
Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr Ala Val Val		
700	705	710
Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg Phe Glu Gly		
720	725	730
Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp Gln Val Glu		

	725	730	735
Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp Leu Ser Arg			
740	745	750	
Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser Leu Met Gly			
755	760	765	
Leu Ile His Lys Pro Gln Val Phe Lys Ala Gln Pro Leu Ala Tyr Pro			
770	775	780	
Pro Arg Leu Pro Gly Arg Lys Arg Ala Leu Phe Pro His Lys Leu Pro			
785	790	795	800
Arg Leu Pro Thr Asp Pro Ser Arg Glu Thr Leu Pro Ala Pro Asp Leu			
805	810		815
Pro Gln Arg Glu Thr Gln Tyr Ser Leu Pro Arg Val Gly Arg Ala Leu			
820	825		830

<210> 30
 <211> 4159
 <212> DNA
 <213> Homo sapiens
 <400> 30

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaagggt	gcctgagccg	gcgggtcccc	60
tgtgtccgccc	gcggctgtcg	tcccccgctc	ccgcccacttc	cggggtcgc	gtcccccggca	120
tggagccgccc	accgtgaggc	gccgctggac	ccgggacgcac	ctgcccagtc	cgcccgccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctgaaatg	gaggctctct	ggacccttta	240
gaaggcacc	ctgcccctcct	gagggtcagct	gagcggtaa	tgcgaaagggt	taagaaaactg	300
cgcctggaca	aggagaacac	cggaagttgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccacccgg	gaccccaacg	gccgacccgg	gcgacgcagc	cgccacagat	420
gaccggcccg	cccgccttcca	ggtgcagaag	cactcggtgg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgeagaaga	cggtatgatc	tgggccccac	tcccacccgc	tctactaccc	gggaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaagggt	ccggaaagag	660
gctctgtgc	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gcccaccat	720
gggggtetact	ctegggagggag	ggagctgctg	agggagcgg	aacgcctggg	ggtttcggc	780
atcacctcct	acgacttcca	cagcagagat	ggcctcttcc	tcttccaggc	cagcaacagc	840
ctcttccact	gcccgcacgg	cgccaagaac	ggcttcatgg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggcccccgg	atggacccca	aatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgc	ctgtgggtgg	ccaacatcga	gacaggcag	1020
gagccggccgc	tgaccttctg	ccaccaagggt	ttatccaatg	tcctggatga	ccccaaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gatgtcgacc	gcttacttgg	gtactgggtgg	1140
tgcaccacag	cctcttggga	agttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtgcatg	agtccgaggt	ggaggtcatt	cacgtcccct	ctcctgcgc	agaagaaaagg	1260
aagacggact	cgtatcggt	ccccaggaca	ggcagcaaga	atcccaagat	tgccttggaa	1320
ctggctgagt	tccagactga	cagccaggc	aagatcgtct	cgacccagg	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaag	gtggagttaca	tgcaggggc	cggttggacc	1440
cgggatggca	aatacgcctg	ggccatgttc	ctggaccggc	cccaggcagtg	gctccagctc	1500
gtccctctcc	ccccggccct	gttcatccc	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgttttc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgc	caaagtacc	1740
gccgttttaa	aatcccaagg	ctacgattgg	agtggccct	ttagccccgg	ggaagatgaa	1800
tttaagtgc	ccattaagga	agagattgt	ctgaccagg	gtaaatggg	ggttttggcg	1860
aggcacggct	ccaagatctg	ggtaatgag	gagaccaagc	ttgtgtactt	ccagggcacc	1920
aaggacacgc	cgctggagca	ccacctctac	gtggtcagct	atgaggcggc	cgccgagatc	1980
gtacgcctca	ccacgccccgg	cttctccat	agctgtc	tgcaggcagaa	cttcgcacat	2040
ttcgtcagcc	actacagcag	cgtgagcag	ccggccctgc	tgcacgtcta	caagctgagc	2100
ggcccccacg	acgacccct	gcacaagg	ccccgcttct	gggctagcat	gatggaggca	2160
gccagctgcc	ccccggatta	tgttcccca	gagatcttcc	atttccacac	gctgcggat	2220
gtgcggctct	acggcatgtat	ctacaagccc	cacgccttgc	agccaggaa	gaagcacccc	2280
accgtcttct	ttgttatatgg	aggcccccag	gtgcagctgg	tgaataactc	cttcaaaggc	2340
atcaagtact	tgccgctcaa	cacactggc	tccctgggct	acggcgttgt	tgtgattgac	2400

ggcaggggct	cctgtcagcg	agggcttcgg	ttcgaagggg	ccctgaaaaa	ccaaatgggc	2460
caggtggaga	tcgaggacca	ggtggagggc	ctgcagttcg	tggccgagaa	gtatggcttc	2520
atcgacctga	gcccagttgc	catccatggc	tggccctacg	ggggcttcct	ctcgctcatg	2580
gggctaattcc	acaagccccca	ggtgttcaag	gcccaaccgc	ttgcttatcc	tccacggctt	2640
cctggacgaa	aacgtgcaact	tttccacac	aaacttcctc	gtctcccaac	tgatccgagc	2700
agggaaacct	taccagctcc	agatctaccc	caacgagaga	cacagtattc	gctgccccga	2760
gtcgggagag	cactatgaag	tcacggttgc	gcactttcta	caggaatacc	tctgagccctg	2820
cccacccggg	gcccgcacat	cacagcacaa	gtggctgcag	cctccgcggg	gaaccaggcg	2880
ggagggactg	agtggcccg	gggccccagt	gaggcactt	gtcccgccca	gctggccca	2940
gccccgagga	gcccgtgcct	tcaccgcccc	gacgcctttt	atcccttttt	aaacgctttt	3000
gggtttatg	tccgctgttt	cttgggttgc	gagacagaga	gatgggtggtc	tcgggcccagc	3060
ccctcccttc	cccgccctct	gggaggagga	ggtcacacgc	tgatgggcac	tggagaggcc	3120
agaagagact	cagaggagcg	ggctgccttc	cgccctgggc	tccctgtgac	ctctcagtcc	3180
cctggcccg	ccagccaccc	tccccagcac	ccaagcatgc	aattgcctgt	cccccccgcc	3240
cagcctcccc	aacttgcgt	ttgtgtttt	tttgggggga	tattttcat	aattatttaa	3300
aagacaggcc	gggcgcgggt	gctcacgtct	gtaatcccag	cactttggga	ggctgaggcg	3360
ggcggatcac	ctgaggttgg	gagttcaaga	ccagcctggc	caacatgggg	aaaccccgtc	3420
tctactaaaa	atacaaaaaa	ttagccgggt	gtgggtggcg	gtgcctataa	tcccaagctac	3480
tcgggaggct	gaggcaggag	aatcgcttga	acccgggagg	tggaggttgc	ggtgagccaa	3540
gatcgacca	ttgcacttca	gcctggcaa	caagagcga	actctgtctc	aaaataaaata	3600
aaaaataaaa	gacagaaagc	aaggggtgcc	taaatctaga	cttgggttcc	acaccggca	3660
gcgggggtgc	aaccaggcac	ctggtaggct	ccattttttc	ccaagcccg	gcagagggtc	3720
atcgggggcc	cacaggagaa	gcccgcagg	cccgcggggg	gcaccacctg	tggacagccc	3780
tcctgtcccc	aagctttcag	gcaggcactg	aaacgcaccg	aacttccacg	ctctgctggt	3840
cagtggccgc	tgtccctcc	ccagcccagc	cgcccgagca	catgtgtctg	cctgaccctgt	3900
acacaccagg	ggttccgggg	ttgggagctg	aaccatcccc	acctcagggt	tatattttcc	3960
tctcccttc	cctccccc	aagagctctg	ccagggcg	gcaaaaaaaaaa	aagtaaaaaaag	4020
aaaagaaaaa	aaaaaaaaag	aaacaaacca	cctctacata	ttatggaaag	aaaatatttt	4080
tgtcgattct	tattttta	taattatgcg	tggaagaagt	agacacatta	aacgattcca	4140
gttggaaaca	tgtcacctg					4159

<210> 31
 <211> 832
 <212> PRT
 <213> Homo sapiens
 <400> 31

Met	Arg	Lys	Val	Lys	Leu	Arg	Leu	Asp	Lys	Glu	Asn	Thr	Gly	Ser	
1				5					10			15			
Trp	Arg	Ser	Phe	Ser	Leu	Asn	Ser	Glu	Gly	Ala	Glu	Arg	Met	Ala	Thr
					20				25			30			
Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala	Thr	Asp	Asp
					35			40			45				
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg
					50			55			60				
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys
					65			70			75			80	
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro
					85			90			95				
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu
					100			105			110				
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala
					115			120			125				
Leu	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr
					130			135			140				
Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg
					145			150			155			160	
Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe	His	Ser	Glu
					165			170			175				
Ser	Gly	Leu	Phe	Leu	Phe	Gln	Ala	Ser	Asn	Ser	Leu	Phe	His	Cys	Arg

180	185	190
Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu		
195	200	205
Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro		
210	215	220
Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val		
225	230	235
Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln		
245	250	255
Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr		
260	265	270
Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys		
275	280	285
Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile		
290	295	300
Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro		
305	310	315
Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg		
325	330	335
Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln		
340	345	350
Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val		
355	360	365
Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala		
370	375	380
Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg		
385	390	395
Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile		
405	410	415
Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val		
420	425	430
Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val		
435	440	445
Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly		
450	455	460
Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe		
465	470	475
Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp		
485	490	495
Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile		
500	505	510
Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg		
515	520	525
His Gly Ser Lys Ile Trp Val Asn Glu Glu Thr Lys Leu Val Tyr Phe		
530	535	540
Gln Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr Val Val Ser		
545	550	555
Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro Gly Phe Ser		
565	570	575
His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val Ser His Tyr		
580	585	590
Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys Leu Ser Gly		
595	600	605
Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp Ala Ser Met		
610	615	620
Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro Glu Ile Phe		
625	630	635
His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met Ile Tyr Lys		
645	650	655
Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val Leu Phe Val		

660	665	670	
Tyr Gly Gly Pro Gln Val Gln	Leu Val Asn Asn Ser	Phe Lys Gly Ile	
675	680	685	
Lys Tyr Leu Arg Leu Asn Thr	Leu Ala Ser Leu Gly	Tyr Ala Val Val	
690	695	700	
Val Ile Asp Gly Arg Gly	Ser Cys Gln Arg Gly	Leu Arg Phe Glu Gly	
705	710	715	720
Ala Leu Lys Asn Gln Met	Gly Gln Val Glu Ile	Glu Asp Gln Val Glu	
725	730	735	
Gly Leu Gln Phe Val Ala Glu	Lys Tyr Gly Phe Ile	Asp Leu Ser Arg	
740	745	750	
Val Ala Ile His Gly Trp Ser	Tyr Gly Gly Phe	Leu Ser Leu Met Gly	
755	760	765	
Leu Ile His Lys Pro Gln Val	Phe Lys Ala Gln	Pro Leu Ala Tyr Pro	
770	775	780	
Pro Arg Leu Pro Gly Arg Lys	Arg Ala Leu Phe	Pro His Lys Leu Pro	
785	790	795	800
Arg Leu Pro Thr Asp Pro Ser	Arg Glu Thr Leu	Pro Ala Pro Asp Leu	
805	810	815	
Pro Gln Arg Glu Thr Gln Tyr	Ser Leu Pro Arg Val	Gly Arg Ala Leu	
820	825	830	

<210> 32
 <211> 4076
 <212> DNA
 <213> Homo sapiens
 <400> 32

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaagggt	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggctgtcg	tcccccgctc	ccgcccacttc	cggggtcgc	gtcccccggca	120
tggagccg	accgtgaggc	gccgctggac	ccgggacgcac	ctgcccagtc	cgcccccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaaatg	gaggctctct	ggacccttta	240
gaaggcaccc	ctgcccctcct	gaggtcagct	gagcggtaa	tgcgaaagggt	taagaaaactg	300
cgcctggaca	aggagaacac	cggaagttgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gaccccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gacccggccg	cccgcttcca	ggtgcagaag	caactcggtgg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	ggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	cggatgagtc	tggcccccac	tcccaccgccc	tctactacct	ggaaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaagggt	ccggaaaagag	660
gctctgctgc	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
ggggtctact	ctcgggagga	ggagctgctg	agggagcgg	aacgcctggg	ggtcttcggc	780
atcacctcct	acgacttcca	cagcgagagt	ggcctcttcc	tcttccaggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cgcaagaac	ggttcatgg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggcccccgg	atggacccca	aatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggcggc	tgaccttctg	ccaccaagggt	ttatccaatg	tcctggatga	ccccaaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gattcgacc	gtttcaactgg	gtactgggtgg	1140
tgccccacag	cctcctggga	agttcagag	ggcctaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtcccct	ctctcgcgct	agaagaaaagg	1260
aagacggact	cgtatcggt	ccccaggaca	ggcagcaaga	atcccaagat	tgccttgaaa	1320
ctggctgagt	tccagactga	cagccaggcc	aagatcgtct	cgacccaggaa	gaaggagctg	1380
gtcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tgcaggggc	cggggtggacc	1440
cgggatggca	aatacgctg	ggccatgttc	ctggaccggc	cccaggcgtg	gtccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	cgggctagcc	1560
tctgcccag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgcttcc	tccgcggcaa	tgaatgcaag	accggcttct	gccatitgt	caaagtccacc	1740
gccgttttaa	aatcccagg	ctacgattgg	agtggccct	ttagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgt	ctgaccagcg	gtgaatggg	ggttttggcg	1860
aggcacggct	ccaagatctg	ggtaatgag	gagaccaagc	tggtgtactt	ccagggcacc	1920

aaggacacgc	cgctggagca	ccacctctac	gtggtcagct	atgaggcg	cg	cgagatc	1980
gtacgcctca	ccacgcccgg	cttctccat	agctgctcca	tgagcc	agaa	cttcgacatg	2040
ttcgtcagcc	actacagcag	cgtgagc	ccgccc	tgcacgtct	caag	ctgaggc	2100
ggccccgacg	acgacccc	gcacaagcag	ccccgctt	gggctagcat	gat	ggaggca	2160
gccagctgcc	ccccggatta	tgttcctcca	gagatctcc	atttcc	acac	gcgctcg	2220
gtgcggctct	acggcatgat	ctacaagccc	cacgccttgc	agccagg	gaa	gacacccc	2280
accgtcctct	ttgttatatgg	aggccccag	gtgcagctgg	tgaataactc	cttcaa	aggc	2340
atcaagtact	tgccgctcaa	cacactggcc	tccctgg	acgccc	gtgt	tgatgac	2400
ggcagggct	cctgtcagcg	agggcttcgg	ttcgaagg	ccctgaaa	ccaa	atgggc	2460
cagg	tcgaggacca	gttggagg	ctgcagttcg	ttggcc	gagaa	gtatggctc	2520
atcgac	gccc	gagg	catccatggc	ttgtcctacg	ggggctt	ctcgctcatg	2580
ggg	acaagcccc	gttgg	caag	gcccaaccgc	ttgctt	atacc	2640
cctgg	aacgtgcact	tttcc	aaact	gtctcc	tgat	ccgag	2700
agg	taccagctcc	agatctaccc	caac	gagaga	cacat	tgc	2760
gtc	gtcggc	gag	actat	gaga	atacc	tc	2820
ccc	ccaccgg	gac	tg	ggctgc	cc	accagg	2880
gg	ggagggact	gttgg	ccc	gg	cc	gctgg	2940
g	ccccc	gag	cc	gttgc	cc	gttgc	3000
gg	gggtttat	tc	acc	gg	ttt	ttt	aaacgctt
cc	cc	cc	cc	ttt	ttt	ttt	3060
cc	cc	cc	cc	ttt	ttt	ttt	3120
cc	cc	cc	cc	ttt	ttt	ttt	3180
cc	cc	cc	cc	ttt	ttt	ttt	3240
cc	cc	cc	cc	ttt	ttt	ttt	3300
cc	cc	cc	cc	ttt	ttt	ttt	3360
cc	cc	cc	cc	ttt	ttt	ttt	3420
cc	cc	cc	cc	ttt	ttt	ttt	3480
cc	cc	cc	cc	ttt	ttt	ttt	3540
cc	cc	cc	cc	ttt	ttt	ttt	3600
cc	cc	cc	cc	ttt	ttt	ttt	3660
cc	cc	cc	cc	ttt	ttt	ttt	3720
cc	cc	cc	cc	ttt	ttt	ttt	3780
cc	cc	cc	cc	ttt	ttt	ttt	3840
cc	cc	cc	cc	ttt	ttt	ttt	3900
cc	cc	cc	cc	ttt	ttt	ttt	3960
cc	cc	cc	cc	ttt	ttt	ttt	4020
cc	cc	cc	cc	ttt	ttt	ttt	4076

<210> 33
 <211> 879
 <212> PRT
 <213> Homo sapiens
 <400> 33

Met	Arg	Lys	Val	Lys	Leu	Arg	Leu	Asp	Lys	Glu	Asn	Thr	Gly	Ser	
1			5			10						15			
Trp	Arg	Ser	Phe	Ser	Leu	Asn	Ser	Glu	Gly	Ala	Glu	Arg	Met	Ala	Thr
			20				25					30			
Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala	Thr	Asp	Asp
			35			40						45			
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg
			50			55						60			
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys
			65			70						75			80
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro
			85			90						95			
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu
			100			105						110			
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala
			115			120						125			
Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr	

130	135	140
Pro	His	His
Gly	Val	Tyr
145	150	155
Lys	Arg	Leu
Gly	Val	Phe
165	170	175
Ser	Gly	Gly
Leu	Phe	Ile
Phe	Gln	Thr
180	185	190
Ser	Gly	Asn
Leu	Phe	Asn
Phe	Ala	Gly
195	200	205
Ile	Lys	Thr
Gln	Cys	Ser
210	215	220
Ala	Asp	Pro
Pro	Ala	Phe
Phe	Ser	Phe
Ile	Asn	Asn
Asn	Ser	Asp
Leu	Trp	Leu
225	230	235
Ala	Asn	Ile
Glu	Thr	Gly
Glu	Glu	Arg
245	250	255
Gly	Leu	Ser
Ser	Asn	Val
Asn	Leu	Asp
Leu	Asp	Asp
260	265	270
Phe	Val	Ile
Gln	Glu	Glu
Glu	Phe	Asp
275	280	285
Pro	Thr	Ala
Ala	Ser	Trp
Glu	Gly	Ser
Glu	Gly	Leu
290	295	300
Leu	Tyr	Glu
Glu	Glu	Val
305	310	315
Ser	Pro	Ala
Ala	Glu	Glu
Glu	Arg	Lys
325	330	335
Thr	Gly	Ser
Lys	Asn	Pro
340	345	350
Thr	Asp	Ser
Gln	Gly	Lys
Ile	Val	Ser
355	360	365
Gln	Pro	Phe
Pro	Ser	Ser
Leu	Phe	Pro
Phe	Pro	Lys
370	375	380
Gly	Trp	Thr
Arg	Asp	Gly
Gly	Lys	Tyr
Tyr	Ala	Trp
385	390	395
Pro	Gln	Gln
Trp	Leu	Gln
Leu	Leu	Leu
405	410	415
Pro	Ser	Thr
Glu	Asn	Glu
Glu	Gln	Arg
420	425	430
Pro	Arg	Asn
Asn	Val	Gln
435	440	445
Trp	Ile	Asn
Asn	Val	His
450	455	460
Glu	Asp	Glu
Glu	Leu	Cys
Phe	Leu	Arg
465	470	475
Cys	His	Leu
Tyr	Lys	Val
Lys	Val	Thr
485	490	495
Trp	Ser	Glu
Glu	Pro	Phe
Phe	Ser	Pro
Gly	Glu	Asp
Glu	Phe	Glu
500	505	510
Lys	Glu	Glu
Ile	Ala	Leu
Leu	Thr	Ser
515	520	525
His	Gly	Ser
Lys	Gly	Thr
530	535	540
Val	Val	Ser
Tyr	Glu	Ala
Ala	Gly	Glu
545	550	555
560		

Gly Phe Ser His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val
 565 570 575
 Ser His Tyr Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys
 580 585 590
 Leu Ser Gly Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp
 595 600 605
 Ala Ser Met Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro
 610 615 620
 Glu Ile Phe His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met
 625 630 635 640
 Ile Tyr Lys Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val
 645 650 655
 Leu Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe
 660 665 670
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr
 675 680 685
 Ala Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg
 690 695 700
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp
 705 710 715 720
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp
 725 730 735
 Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser
 740 745 750
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Val Ala Ile Ala
 755 760 765
 Gly Ala Pro Val Thr Val Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu
 770 775 780
 Arg Tyr Met Asp Val Pro Glu Asn Asn Gln His Gly Tyr Glu Ala Gly
 785 790 795 800
 Ser Val Ala Leu His Val Glu Lys Leu Pro Asn Glu Pro Asn Arg Leu
 805 810 815
 Leu Ile Leu His Gly Phe Leu Asp Glu Asn Val His Phe Phe His Thr
 820 825 830
 Asn Phe Leu Val Ser Gln Leu Ile Arg Ala Gly Lys Pro Tyr Gln Leu
 835 840 845
 Gln Ile Tyr Pro Asn Glu Arg His Ser Ile Arg Cys Pro Glu Ser Gly
 850 855 860
 Glu His Tyr Glu Val Thr Leu Leu His Phe Leu Gln Glu Tyr Leu
 865 870 875

<210> 34

<211> 4263

<212> DNA

<213> Homo sapiens

<400> 34

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaaggt	gcctgagccg	gcgggtcccc	60
tgttccgccc	gccccgtcg	tcccccgctc	ccggccacttc	ccgggtcgca	gtcccccggca	120
tggagccgccc	accgtgaggc	gccgctggac	ccgggacgac	ctgcccagtc	cgcccgccgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctgaaatg	gaggctctct	ggacccttta	240
gaaggcacc	ctgcccctcct	gaggtcagct	gagcggtaa	tgcggaaagg	taagaaaactg	300
cgcctggaca	aggagaacac	cggaagttgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccacccg	gaccccaacg	gccgaccgag	gcgacgcagc	cgccacagat	420
gacccggccg	cccgcttcca	ggtgcagaag	cactcggtgg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	cggatgagtc	tggcccccac	tcccaccgccc	tctactacct	ggaaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaagg	ccggaaaagag	660
gctctgctgc	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
ggggtctact	ctcgggagga	ggagctgctg	agggagcgg	aacgcctggg	ggtcttcggc	780

atcacccct	acgacttcca	cagcgagagt	ggcctttcc	tcttccaggc	cagcaacagc	840
ctcttccact	gcccgcacgg	cgccaagaac	ggcttcatgg	tgtccccat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggccccgg	atggacccc	aaatctgcc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcg	gacaggcgag	1020
gagcggcggc	tgaccttctg	ccaccaaggt	ttatccaat	tcctggatga	cccccaagtct	1080
gcgggtgtgg	ccaccttctg	catacaggaa	gagttcgacc	gcttcactgg	gtactgggtgg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctcaaga	cgtctgcgaat	cctgtatgag	1200
gaagtctgatg	agtccgaggt	ggaggtcatt	cacgtccc	ctcctgcgc	agaagaaaagg	1260
aagacggact	cgtatcggt	ccccaggaca	ggcagcaaga	atcccaagat	tgccttgaaa	1320
ctggctgagt	tccagactga	cagccagggc	aagatctgt	cgacccagg	gaaggagctg	1380
gtgcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgcccagg	cgggtggacc	1440
cgggatggca	aatacgctg	ggccatgttc	ctggacccgc	cccagcagt	gctccagctc	1500
gtccctctcc	ccccggccct	gttcatccc	agcacagaga	atgaggagca	gcggctagcc	1560
tctgccagag	ctgtccccag	gaatgtccag	ccgtatgtgg	tgtacgagga	ggtcaccaac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagaggg	agaggacgag	1680
ctctgttttc	tccgcgcca	tgaatgcaag	accggcttct	gccatttgt	caaagtccacc	1740
gccgttttaa	aatcccagg	ctacgattgg	agtgagccct	tcagccccgg	ggaagatgaa	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggga	gttttggcg	1860
aggcacggct	ccaagggcac	caaggacacg	ccgctggagc	accacctcta	cgtggtcagc	1920
tatgagggcg	ccggcgagat	cgtacgcctc	accacgccc	gttctccca	tagtgcctcc	1980
atgagccaga	acttcgacat	gttcgtcagc	cactacagca	gcgtgagcac	gccgcctgc	2040
gtgcacgtct	acaagctgag	cggccccgac	gacgacccccc	tgcacaagca	gcccccttc	2100
tggcttagca	tgtggaggc	agccagctgc	ccccggatt	atgttctcc	agagatcttc	2160
catttccaca	cgcgctcgga	tgtcggtc	tacggcatga	tctacaagcc	ccacgcctt	2220
cagccaggga	agaagcaccc	caccgtc	tttgtatatg	gaggccccca	gtgcagctg	2280
gtgaataact	ccttcaaagg	catcaagtac	ttcggtctca	acacactggc	ctccctggc	2340
tacccgtgg	ttgtgattga	cgccaggggc	tcctgtcagc	gagggttctg	gttcgaaggg	2400
gccctgaaaa	accaaattgg	ccaggtggag	atcgaggacc	aggtggaggg	cctgcagttc	2460
gtggccgaga	agtatggctt	catcgacctg	agccgagttg	ccatccatgg	ctggctctac	2520
gggggcttcc	tctcgctcat	ggggcta	cacaagcccc	aggtgttcaa	gttggccatc	2580
gcgggtgccc	cggtcaccgt	ctggatggcc	tacgacacag	gttacactga	gctacatg	2640
gacgtccctg	agaacaacca	gcacggctat	gaggcggtt	ccgtggccct	gcacgtggag	2700
aagctgccc	atgagccaa	ccgcttgc	atcctccac	gttccctgg	cgaaaacgt	2760
cacttttcc	acacaactt	cctcgctc	caactgatcc	gagcagg	accttaccag	2820
ctccagatct	accccaacga	gagacacagt	attcgctgc	ccgagtcggg	cgagcactat	2880
gaagtcacgt	tgctgcactt	tctacaggaa	tacctctgag	cctgcccacc	gggagccg	2940
acatcacagc	acaagtggct	gcagcctcc	cggggaa	ggcgggaggg	actgagtggc	3000
ccgcgggccc	cagtgggca	cttgc	cccagcg	gccagcccc	aggagccg	3060
gccttcacccg	ccccgacg	tttac	tttac	tcttgggtt	tatgtccg	3120
gcttcttgg	tgccgagaca	gagagatgg	ggtctcgg	cagccctcc	tctcccc	3180
ttctgggagg	aggaggtcac	acgctgatgg	gcactggaga	ggccaga	gactcagagg	3240
agccggctgc	cttgc	gggctcc	tgac	gtccc	ccggccag	3300
accgtcccca	gcacccaa	atgcaatt	ctgtcccc	cgcc	c	3360
atgtttgtt	ttt	ggatattt	tcataatt	ttaaa	agaca	ggccggg
ggggctcac	gtctgtat	ccagcactt	gggagg	ggcggg	tcac	3480
ttgggagttc	aagaccagcc	tgccaacat	ggggaa	cgtct	tact	aaaaataca
aaaattagcc	gggtgtgg	gcccgtgc	ataat	ccag	ctact	ggc
ggagaatcgc	ttgaacccgg	gagg	ttgcgtg	gag	ccaagat	gc
tccagcctgg	gcaacaagag	cggaa	tctca	aaaata	aataaaaa	aaaagacaga
aagaagg	tgcctaaatc	tagactt	ggc	ccacacc	ggc	gggg
gcacctggta	ggtcc	ttt	ccac	cccg	gg	gggg
agaagcggcc	agggcc	cc	cgt	ccat	cc	ccacagg
tcagggcaggc	actgaa	acc	actt	cac	cc	ccaa
ctccccagcc	cagcc	cc	cat	gt	cc	ctcc
ggggttggga	gctgaaccat	ccc	acc	tc	cc	ctcc
cgc	tc	cc	at	tt	cc	cccc
aaagaaacaa	accac	cc	at	tt	cc	tttt
tttataat	tgcgt	gg	at	tt	cc	tatt
ctg	tg	gg	ag	tt	cc	tct

<210> 35
 <211> 879
 <212> PRT
 <213> Homo sapiens
 <400> 35

Met Arg Lys Val Lys Lys Leu Arg Leu Asp Lys Glu Asn Thr Gly Ser
 1 5 10 15
 Trp Arg Ser Phe Ser Leu Asn Ser Glu Gly Ala Glu Arg Met Ala Thr
 20 25 30
 Thr Gly Thr Pro Thr Ala Asp Arg Gly Asp Ala Ala Thr Asp Asp
 35 40 45
 Pro Ala Ala Arg Phe Gln Val Gln Lys His Ser Trp Asp Gly Leu Arg
 50 55 60
 Ser Ile Ile His Gly Ser Arg Lys Tyr Ser Gly Leu Ile Val Asn Lys
 65 70 75 80
 Ala Pro His Asp Phe Gln Phe Val Gln Lys Thr Asp Glu Ser Gly Pro
 85 90 95
 His Ser His Arg Leu Tyr Tyr Leu Gly Met Pro Tyr Gly Ser Arg Glu
 100 105 110
 Asn Ser Leu Leu Tyr Ser Glu Ile Pro Lys Lys Val Arg Lys Glu Ala
 115 120 125
 Leu Leu Leu Ser Trp Lys Gln Met Leu Asp His Phe Gln Ala Thr
 130 135 140
 Pro His His Gly Val Tyr Ser Arg Glu Glu Leu Leu Arg Glu Arg
 145 150 155 160
 Lys Arg Leu Gly Val Phe Gly Ile Thr Ser Tyr Asp Phe His Ser Glu
 165 170 175
 Ser Gly Leu Phe Leu Phe Gln Ala Ser Asn Ser Leu Phe His Cys Arg
 180 185 190
 Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu
 195 200 205
 Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro
 210 215 220
 Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val
 225 230 235 240
 Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln
 245 250 255
 Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr
 260 265 270
 Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys
 275 280 285
 Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile
 290 295 300
 Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro
 305 310 315 320
 Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg
 325 330 335
 Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln
 340 345 350
 Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val
 355 360 365
 Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala
 370 375 380
 Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg
 385 390 395 400
 Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile
 405 410 415

Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val
 420 425 430
 Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val
 435 440 445
 Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly
 450 455 460
 Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe
 465 470 475 480
 Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp
 485 490 495
 Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile
 500 505 510
 Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg
 515 520 525
 His Gly Ser Lys Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr
 530 535 540
 Val Val Ser Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro
 545 550 555 560
 Gly Phe Ser His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val
 565 570 575
 Ser His Tyr Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys
 580 585 590
 Leu Ser Gly Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp
 595 600 605
 Ala Ser Met Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro
 610 615 620
 Glu Ile Phe His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met
 625 630 635 640
 Ile Tyr Lys Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val
 645 650 655
 Leu Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe
 660 665 670
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr
 675 680 685
 Ala Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg
 690 695 700
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp
 705 710 715 720
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp
 725 730 735
 Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser
 740 745 750
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Val Ala Ile Ala
 755 760 765
 Gly Ala Pro Val Thr Val Trp Met Ala Tyr Asp Thr Gly Tyr Thr Glu
 770 775 780
 Arg Tyr Met Asp Val Pro Glu Asn Asn Gln His Gly Tyr Glu Ala Gly
 785 790 795 800
 Ser Val Ala Leu His Val Glu Lys Leu Pro Asn Glu Pro Asn Arg Leu
 805 810 815
 Leu Ile Leu His Gly Phe Leu Asp Glu Asn Val His Phe Phe His Thr
 820 825 830
 Asn Phe Leu Val Ser Gln Leu Ile Arg Ala Gly Lys Pro Tyr Gln Leu
 835 840 845
 Gln Ile Tyr Pro Asn Glu Arg His Ser Ile Arg Cys Pro Glu Ser Gly
 850 855 860
 Glu His Tyr Glu Val Thr Leu Leu His Phe Leu Gin Glu Tyr Leu
 865 870 875

<210> 36
 <211> 4180
 <212> DNA
 <213> Homo sapiens
 <400> 36

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaagg	gtctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggctgtcg	tcccccgc	ccgccacttc	cggggtcgc	gtcccccggca	120
tggagccg	accgtgaggc	gcgcgtggac	ccgggacgc	ctgcccagtc	cgccgcgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctggaaatg	gaggctctc	ggaccctta	240
gaaggcaccc	ctgcccctc	gaggtcagct	gagcggtaa	tgcgaaagg	taagaaactg	300
cgcctggaca	aggagaacac	cggaaagtgg	agaagctt	cgtgaattc	cgagggggct	360
gagaggatgg	ccaccacccg	gaccccaacg	gccgaccgag	gcgcgcage	cgccacagat	420
gacccggccg	cccgcttcca	ggtcagaag	caactcg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtcagaaga	cggatgagtc	tggcccccac	tcccacccgc	tctactac	ggaaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaagg	ccggaaagag	660
gctctgctgc	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
gggtctact	ctcgggagga	ggagctgctg	agggagcgg	aacgcctggg	ggtcttcggc	780
atcacctc	acgacttcca	cagcagagt	ggcctcttcc	tcttccaggc	cagcaacagc	840
ctcttccact	gcccgcacgg	cgccaaac	ggcttcatgg	tgtccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggcccccgg	atggacccca	aaatctgccc	tgccgaccct	960
gccttcttct	cttcatcaa	taacagcgc	ctgtgggtgg	ccaacatcga	gacaggcgg	1020
gagccggcgc	tgaccttctg	ccaccaagg	ttatccaatg	tcctggatg	ccccaaagtct	1080
gcgggtgtgg	ccaccttcgt	catacaggaa	gagttcgacc	gcttcaactgg	gtactgggtgg	1140
tgccccacag	cctcctggga	aggttcagag	ggcctaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtccc	ctcctgcgc	agaagaaagg	1260
aagacggact	cgtatcggt	ccccaggaca	ggcagcaaga	atcccaagat	tgccttggaa	1320
ctggctgagt	tccagactga	cagccaggc	aagatcgtct	cgaccagg	gaaggagctg	1380
gtcagccct	tcagctcgct	gttcccgaag	gtggagtaca	tcgcaggggc	cgggtggacc	1440
cgggatggca	aatacgctg	ggccatgttc	ctggaccggc	cccagcgtg	gctccagctc	1500
gtcctcctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gcccgtagcc	1560
tctgccagag	ctgtccccag	aatgtccag	ccgtatgtgg	tgtacgagg	ggtcaccac	1620
gtctggatca	atgttcatga	catcttctat	cccttcccc	aatcagagg	agaggacgag	1680
ctctgtttc	tccgcctcaa	tgaatgc	accggctt	gccatttgt	caaagtacc	1740
gccgtttaa	aatcccagg	ctacgattgg	agtggccct	tca	ccccccgg	1800
tttaagtgcc	ccattaagga	agagattgct	ctgaccagcg	gtgaatggg	gttttggcg	1860
aggcaeggct	ccaaggggcac	caaggacacg	ccgctggagc	accac	ctcgtcagc	1920
tatgaggccg	ccggcgcagat	cgtacgcctc	accacgccc	gcttctcc	tagctgctc	1980
atgagccaga	acttcgcacat	gttcgtc	ca	gctgagc	gcccctgc	2040
gtgcacgtct	acaagctgag	cggccccgac	gacgacccc	tgcacaag	gcccccttc	2100
tggctagca	tgatggaggc	agccagctgc	ccccggatt	atgttctcc	agagatctc	2160
catttccaca	cgcgctcg	tgtcggtc	tacggcatg	tctacaagg	ccacgcctt	2220
cagccaggga	agaagcacc	caccgtc	tttgtatatg	gaggcccc	ggtcagctg	2280
gtgaataact	ccttcaaagg	catcaag	ttgcggctca	acacactgg	ctccctggc	2340
tacgcccgt	ttgtgattga	cggcaggggc	tcctgtc	gagggttc	gttgcagg	2400
gcctgaaaa	accaaattgg	ccaggtggag	atcgaggacc	aggtggagg	cctgcagtt	2460
gtggccgaga	agtatggctt	catcgac	agccgagtt	ccatccatgg	ctggcctac	2520
gggggcttcc	tctcgctcat	gggcta	cacaagcccc	aggtgtt	ggtggccatc	2580
gcgggtgccc	cggtcaccgt	ctggatggc	tacgacacag	gttacactg	gctacatg	2640
gacgtccctg	agaacaacca	gcacggctat	gaggcgggtt	ccgtggcc	gcacgtggag	2700
aagctgccc	atgagccaa	ccgcttgctt	atcctccacg	gcttcc	tgg	2760
cacttttcc	acacaaactt	cctcgctcc	caactgatcc	gagcagg	acccatc	2820
ctccagatct	accccaacga	gagacac	attcg	ccgagtcgg	cgagcactat	2880
gaagtacgt	tgctgcactt	tctacaggaa	tacctctg	cctgccc	gggagccg	2940
acatcacagc	acaagtggct	gcagcctcc	cgggaa	gcccggag	actgagtgg	3000
ccgcgggccc	cagtgaggca	cttgcctcc	cccagcg	gccagcccc	aggagccg	3060
gccttcaccg	ccccgacg	tttatc	ttttaaacgc	tcttgggtt	tatgtccg	3120
gcttcttgg	tgccgagaca	gagagatgg	ggtctcg	ggc	cagccccctt	3180

ttctgggagg	aggaggtcac	acgctgatgg	gcactggaga	ggccagaaga	gactcagagg	3240
agcgggctgc	tttccgcctg	ggctccctg	tgacctctca	gtccctggc	ccggccagcc	3300
accgtccccca	gcacccaagc	atcaattgc	ctgtcccccc	cgccagcc	ccccaaacttg	3360
atgtttgtgt	tttgggggg	ggatatttt	tcataattat	ttaaaagaca	ggccgggcgc	3420
ggtggtcac	gtctgtatc	ccagcactt	gggaggctga	ggcgggcccga	tcacctgagg	3480
ttgggagttc	aagaccagcc	tggccaacat	ggggaaaccc	cgtctctact	aaaaatacaa	3540
aaaattagcc	gggtgtggtg	gcgcgtgcct	ataatcccag	ctactcggga	ggctgaggca	3600
ggagaatcgc	ttgaaccgg	gaggtggagg	ttgcggtag	ccaagatcgc	accattgcac	3660
tccagcctgg	gcaacaagag	cgaactctg	tctcaaaata	aataaaaaat	aaaagacaga	3720
aagcaagggg	tgcctaaatc	tagacttggg	gtccacaccg	ggcagcgggg	ttgcaaccca	3780
gcacctggta	ggctccattt	cttcccaagc	ccgacttca	ggcaggcact	gaaacgcacc	3840
gaacttccac	gctctgtgg	tcagtgccgg	ctgtccctc	cccagccca	ccgcccagcc	3900
acatgtgtct	gcctgaccgg	tacacaccag	gggtccggg	gttgggagct	gaaccatccc	3960
cacccatggg	ttatatttcc	ctctccctt	ccctcccccgc	caagagctct	gccagggcg	4020
ggcaaaaaaaa	aaagtaaaaaa	gaaaagaaaa	aaaaaaaaaa	gaaacaaacc	acctctacat	4080
attatggaaa	gaaaatattt	ttgtcgattc	ttattcttt	ataattatgc	gtggaagaag	4140
tagacacatt	aaacgattcc	agttggaaac	atgtcacctg			4180

<210> 37
 <211> 819
 <212> PRT
 <213> Homo sapiens
 <400> 37

Met	Arg	Lys	Val	Lys	Lys	Leu	Arg	Leu	Asp	Lys	Glu	Asn	Thr	Gly	Ser
1						5				10			15		
Trp	Arg	Ser	Phe	Ser	Leu	Asn	Ser	Glu	Gly	Ala	Glu	Arg	Met	Ala	Thr
								20			25			30	
Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala	Thr	Asp	Asp
								35			40			45	
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg
								50			55			60	
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys
								65			70			75	
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro
								85			90			95	
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu
								100			105			110	
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala
								115			120			125	
Leu	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr
								130			135			140	
Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg
								145			150			155	
Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe	His	Ser	Glu
								165			170			175	
Ser	Gly	Leu	Phe	Leu	Phe	Gln	Ala	Ser	Asn	Ser	Leu	Phe	His	Cys	Arg
								180			185			190	
Asp	Gly	Gly	Lys	Asn	Gly	Phe	Met	Val	Ser	Pro	Met	Lys	Pro	Leu	Glu
								195			200			205	
Ile	Lys	Thr	Gln	Cys	Ser	Gly	Pro	Arg	Met	Asp	Pro	Lys	Ile	Cys	Pro
								210			215			220	
Ala	Asp	Pro	Ala	Phe	Phe	Ser	Phe	Ile	Asn	Asn	Ser	Asp	Leu	Trp	Val
								225			230			235	
Ala	Asn	Ile	Glu	Thr	Gly	Glu	Arg	Arg	Leu	Thr	Phe	Cys	His	Gln	
								245			250			255	
Gly	Leu	Ser	Asn	Val	Leu	Asp	Asp	Pro	Lys	Ser	Ala	Gly	Val	Ala	Thr
								260			265			270	

Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys
 275 280 285
 Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile
 290 295 300
 Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro
 305 310 315 320
 Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg
 325 330 335
 Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln
 340 345 350
 Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val
 355 360 365
 Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala
 370 375 380
 Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg
 385 390 395 400
 Pro Gln Gln Trp Leu Gln Leu Val Leu Pro Pro Ala Leu Phe Ile
 405 410 415
 Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val
 420 425 430
 Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val
 435 440 445
 Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly
 450 455 460
 Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe
 465 470 475 480
 Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp
 485 490 495
 Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile
 500 505 510
 Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg
 515 520 525
 His Gly Ser Lys Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr
 530 535 540
 Val Val Ser Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro
 545 550 555 560
 Gly Phe Ser His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val
 565 570 575
 Ser His Tyr Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys
 580 585 590
 Leu Ser Gly Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp
 595 600 605
 Ala Ser Met Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro
 610 615 620
 Glu Ile Phe His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met
 625 630 635 640
 Ile Tyr Lys Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val
 645 650 655
 Leu Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe
 660 665 670
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr
 675 680 685
 Ala Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg
 690 695 700
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp
 705 710 715 720
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp
 725 730 735

Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser
 740 745 750
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Ala Gln Pro Leu
 755 760 765
 Ala Tyr Pro Pro Arg Leu Pro Gly Arg Lys Arg Ala Leu Phe Pro His
 770 775 780
 Lys Leu Pro Arg Leu Pro Thr Asp Pro Ser Arg Glu Thr Leu Pro Ala
 785 790 795 800
 Pro Asp Leu Pro Gln Arg Glu Thr Gln Tyr Ser Leu Pro Arg Val Gly
 805 810 815
 Arg Ala Leu

<210> 38
 <211> 4120
 <212> DNA
 <213> Homo sapiens
 <400> 38

caggccgccc	cctgggtcgc	tcaacttccg	ggtcaaagg	gcctgagccg	gcgggtcccc	60
tgtgtccgcc	gcggctgtcg	tccccgcgc	ccgccaactc	cggggtcgca	gtcccgggca	120
tggagccgcg	accgtgaggc	gccgctggac	ccgggacgc	ctgcccagtc	cgccgcgc	180
cccacgtccc	ggtctgtgtc	ccacgcctgc	agctgaaatg	gaggctctc	ggacccttta	240
gaaggcacc	ctgcccctct	gaggtcagct	gagcggtaa	tgcggaaggt	taagaaactg	300
cgcctggaca	aggagaacac	cggaagtgg	agaagcttct	cgctgaattc	cgagggggct	360
gagaggatgg	ccaccaccgg	gaccccaacg	gccgaccgag	gcaacgcgc	cgccacagat	420
gaccggccg	cccgcttcca	ggtgcagaag	cactcggtgg	acgggctccg	gagcatcatc	480
cacggcagcc	gcaagtactc	gggcctcatt	gtcaacaagg	cgccccacga	cttccagttt	540
gtgcagaaga	cggatgagtc	tggcccccac	tcccacccgc	tctactacct	ggaaatgcca	600
tatggcagcc	gagagaactc	cctcctctac	tctgagattc	ccaagaagg	ccggaaagag	660
gctctgtgc	tcctgtcctg	gaagcagatg	ctggatcatt	tccaggccac	gccccaccat	720
ggggtctact	ctcgggagga	ggagctgtg	agggagcgg	aacgcctggg	gttcttcggc	780
atcacctct	acgacttcca	cagcagagt	ggcctcttc	tcttccaggc	cagcaacagc	840
ctcttccact	gccgcgacgg	cgcaagaac	ggcttcatgg	tgtcccctat	gaaaccgctg	900
gaaatcaaga	cccagtgtc	agggcccccgg	atggacccca	aatctgccc	tgccgaccct	960
gccttcttct	ccttcatcaa	taacagcgac	ctgtgggtgg	ccaacatcga	gacaggcgag	1020
gagcggccgc	tgaccttctg	ccaccaagg	ttatccaatg	tcttggatga	ccccaaagtct	1080
gccccgtgtgg	ccaccttcgt	catacaggaa	gattcgacc	gcttcaactgg	gtactgggtgg	1140
tgccccacag	cctcctggga	agttcagag	ggcctcaaga	cgctgcgaat	cctgtatgag	1200
gaagtcgatg	agtccgaggt	ggaggtcatt	cacgtcccct	ctcctgcgc	agaagaaagg	1260
aagacggact	cgtatecgta	ccccaggaca	ggcagcaaga	atcccaagat	tgccttggaaa	1320
ctggctgagt	tccagactga	cagccagggg	aagatcgtct	cgacccagg	gaaggagctg	1380
gtgcagccct	tcaagtcgt	gttcccgaag	gtggagtaca	tgcccagg	cggggtggacc	1440
cggatggca	aatacgctg	ggccatgttc	ctggaccggc	cccagcagt	gctccagctc	1500
gtctctctcc	ccccggccct	gttcatcccg	agcacagaga	atgaggagca	gcccgtagcc	1560
tctgcccag	ctgtccccag	aatgtccag	cgtatgtgg	tgtacgagg	ggtcacaac	1620
gtctggatca	atgttcatga	catcttctat	ccctttcccc	aatcagagg	agaggacgag	1680
ctctgttttc	tccgcgccaa	tgaatgcaag	accggcttct	gccatttgt	caaagtccacc	1740
gccgttttaa	aatcccagg	ctacgattgg	agtggccct	tcaagcccccgg	ggaagatgaa	1800
ttaaagtggcc	ccattaagga	agagattgt	ctgaccagcg	gtgaatggg	ggtttggcg	1860
aggcacggct	ccaagggcac	caaggacacg	ccgctggagc	accacctcta	cgtggcagc	1920
tatgaggccgg	ccggcgcagat	cgtacgcctc	accaccccg	gcttctccca	tagctgctc	1980
atgagccaga	acttcgacat	gttcgtcagc	cactacagca	gcgtgagcac	gcccccctgc	2040
gtgcacgtct	acaagctgag	cgccccggac	gacgacccccc	tgcacaagca	gcccccttc	2100
tgggctagca	tgtggaggc	agccagctgc	ccccggatt	atgttcttc	agagatctc	2160
catttccaca	cgcgctcga	tgtcggtctc	tacggcatga	tctacaagcc	ccacgccttgc	2220
cagccaggaa	agaagcaccc	caccgtctc	tttgtatatg	gaggccccca	ggtgcagctg	2280
gtgaataact	ccttcaaagg	catcaagtac	ttgcgctca	acacactggc	ctccctgggc	2340
tacgcccgtgg	ttgtgattga	cggcaggggc	tcctgtcagc	gagggttcg	gttcaaggg	2400
gccctgaaaa	accaaatggg	ccaggtggag	atcgaggacc	aggtggaggg	cctgcagttc	2460

gtggccgaga	agtatggctt	catcgacctg	agccgagttg	ccatccatgg	ctggctcac	2520
gggggcttc	tctcgctcat	ggggctaatac	cacaagcccc	aggtgttcaa	ggcccaaccg	2580
cttgcttatac	ctccacggct	tcctggacga	aaacgtgcac	tttttccaca	caaacttcct	2640
cgtctcccaa	ctgatccgag	cagggaaaco	ttaccagctc	cagatctacc	ccaaacgagag	2700
acacagtatt	cgctgccccg	agtcgggcga	gcactatgaa	gtcacgttgc	tgcactttct	2760
acagaatac	ctctgagccct	gcccacccggg	agccgcacaca	tcacagcaca	agtggctgca	2820
gcctccgggg	ggaaccaggc	gggaggggact	gagtggcccg	cgggccccag	tgaggcactt	2880
tgtcccgccc	agcgctggcc	agccccgagg	agccgctgcc	ttcaccgccc	cgacgccttt	2940
tatcctttt	taaacgctct	tgggtttat	gtccgctgct	tcttgggtgc	cgagacagag	3000
agatgggtgt	ctcggccag	ccccctcctct	ccccgccttc	tgggaggagg	aggtcacacg	3060
ctgatggca	ctggagaggc	cagaagagac	tcagaggagc	gggctgcctt	ccgcctgggg	3120
ctccctgtga	cctctcagtc	ccctggcccg	gccagccacc	gtccccagca	cccaagcatg	3180
caattgcctg	tcccccccg	ccagcctccc	caacttgatg	tttgtgtttt	gtttgggggg	3240
atattttca	taattattha	aaagacaggc	cgggcgcggt	ggctcacgtc	tgtaatccca	3300
gcactttggg	aggctgagggc	gggcggatca	cctgaggttg	ggagttcaag	accagcctgg	3360
ccaaacatggg	gaaaacccgt	ctctactaaa	aataaaaaaa	attagccggg	tgtggtggcg	3420
cgtgcctata	atcccagcta	ctcgggaggc	tgaggcagga	gaatcgctt	aacccgggag	3480
gtggaggttg	cggtgagcca	agatcgcacc	attgcactcc	agcctggca	acaagagcga	3540
aactctgtct	caaaaataat	aaaaaataaa	agacagaaag	caaggggtgc	ctaaatctag	3600
acttgggttc	cacaccgggc	agcggggttg	caacccagca	cctggtaggc	tccatttctt	3660
cccaagcccg	agcagagggt	catgcgggccc	ccacaggaga	agcggccagg	gccccgggg	3720
ggcaccaccc	gtggacagcc	ctccctgtccc	caagcttca	ggcaggcact	gaaacgcacc	3780
gaacttccac	gctctgtcg	tcagttggcg	ctgtccccctc	cccagccag	ccgccccagcc	3840
acatgtgtct	gcctgacccg	tacacaccag	gggttccggg	gttgggagct	gaaccatccc	3900
cacccatcagg	ttatatttcc	ctctcccccctt	ccctccccgc	caagagctct	gccagggcg	3960
ggcaaaaaaa	aaagtaaaaaa	gaaaagaaaaa	aaaaaaaaaa	gaaacaaacc	acctctatcat	4020
attatggaaa	gaaaatattt	ttgtcgattc	ttattctttt	ataattatgc	gtggaagaag	4080
tagacacatt	aaacgattcc	agttggaaac	atgtcacctg			4120

<210> 39
 <211> 819
 <212> PRT
 <213> Homo sapiens
 <400> 39

Met	Arg	Lys	Val	Lys	Lys	Leu	Arg	Leu	Asp	Lys	Glu	Asn	Thr	Gly	Ser
1					5					10				15	
Trp	Arg	Ser	Phe	Ser	Leu	Asn	Ser	Glu	Gly	Ala	Glu	Arg	Met	Ala	Thr
								20			25			30	
Thr	Gly	Thr	Pro	Thr	Ala	Asp	Arg	Gly	Asp	Ala	Ala	Ala	Thr	Asp	Asp
								35			40			45	
Pro	Ala	Ala	Arg	Phe	Gln	Val	Gln	Lys	His	Ser	Trp	Asp	Gly	Leu	Arg
								50			55			60	
Ser	Ile	Ile	His	Gly	Ser	Arg	Lys	Tyr	Ser	Gly	Leu	Ile	Val	Asn	Lys
								65			70			75	
Ala	Pro	His	Asp	Phe	Gln	Phe	Val	Gln	Lys	Thr	Asp	Glu	Ser	Gly	Pro
								85			90			95	
His	Ser	His	Arg	Leu	Tyr	Tyr	Leu	Gly	Met	Pro	Tyr	Gly	Ser	Arg	Glu
								100			105			110	
Asn	Ser	Leu	Leu	Tyr	Ser	Glu	Ile	Pro	Lys	Lys	Val	Arg	Lys	Glu	Ala
								115			120			125	
Leu	Leu	Leu	Leu	Ser	Trp	Lys	Gln	Met	Leu	Asp	His	Phe	Gln	Ala	Thr
								130			135			140	
Pro	His	His	Gly	Val	Tyr	Ser	Arg	Glu	Glu	Glu	Leu	Leu	Arg	Glu	Arg
								145			150			155	
Lys	Arg	Leu	Gly	Val	Phe	Gly	Ile	Thr	Ser	Tyr	Asp	Phe	His	Ser	Glu
								165			170			175	
Ser	Gly	Leu	Phe	Leu	Phe	Gln	Ala	Ser	Asn	Ser	Leu	Phe	His	Cys	Arg
								180			185			190	

Asp Gly Gly Lys Asn Gly Phe Met Val Ser Pro Met Lys Pro Leu Glu
 195 200 205
 Ile Lys Thr Gln Cys Ser Gly Pro Arg Met Asp Pro Lys Ile Cys Pro
 210 215 220
 Ala Asp Pro Ala Phe Phe Ser Phe Ile Asn Asn Ser Asp Leu Trp Val
 225 230 235 240
 Ala Asn Ile Glu Thr Gly Glu Glu Arg Arg Leu Thr Phe Cys His Gln
 245 250 255
 Gly Leu Ser Asn Val Leu Asp Asp Pro Lys Ser Ala Gly Val Ala Thr
 260 265 270
 Phe Val Ile Gln Glu Glu Phe Asp Arg Phe Thr Gly Tyr Trp Trp Cys
 275 280 285
 Pro Thr Ala Ser Trp Glu Gly Ser Glu Gly Leu Lys Thr Leu Arg Ile
 290 295 300
 Leu Tyr Glu Glu Val Asp Glu Ser Glu Val Glu Val Ile His Val Pro
 305 310 315 320
 Ser Pro Ala Leu Glu Glu Arg Lys Thr Asp Ser Tyr Arg Tyr Pro Arg
 325 330 335
 Thr Gly Ser Lys Asn Pro Lys Ile Ala Leu Lys Leu Ala Glu Phe Gln
 340 345 350
 Thr Asp Ser Gln Gly Lys Ile Val Ser Thr Gln Glu Lys Glu Leu Val
 355 360 365
 Gln Pro Phe Ser Ser Leu Phe Pro Lys Val Glu Tyr Ile Ala Arg Ala
 370 375 380
 Gly Trp Thr Arg Asp Gly Lys Tyr Ala Trp Ala Met Phe Leu Asp Arg
 385 390 395 400
 Pro Gln Gln Trp Leu Gln Leu Val Leu Leu Pro Pro Ala Leu Phe Ile
 405 410 415
 Pro Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val
 420 425 430
 Pro Arg Asn Val Gln Pro Tyr Val Val Tyr Glu Glu Val Thr Asn Val
 435 440 445
 Trp Ile Asn Val His Asp Ile Phe Tyr Pro Phe Pro Gln Ser Glu Gly
 450 455 460
 Glu Asp Glu Leu Cys Phe Leu Arg Ala Asn Glu Cys Lys Thr Gly Phe
 465 470 475 480
 Cys His Leu Tyr Lys Val Thr Ala Val Leu Lys Ser Gln Gly Tyr Asp
 485 490 495
 Trp Ser Glu Pro Phe Ser Pro Gly Glu Asp Glu Phe Lys Cys Pro Ile
 500 505 510
 Lys Glu Glu Ile Ala Leu Thr Ser Gly Glu Trp Glu Val Leu Ala Arg
 515 520 525
 His Gly Ser Lys Gly Thr Lys Asp Thr Pro Leu Glu His His Leu Tyr
 530 535 540
 Val Val Ser Tyr Glu Ala Ala Gly Glu Ile Val Arg Leu Thr Thr Pro
 545 550 555 560
 Gly Phe Ser His Ser Cys Ser Met Ser Gln Asn Phe Asp Met Phe Val
 565 570 575
 Ser His Tyr Ser Ser Val Ser Thr Pro Pro Cys Val His Val Tyr Lys
 580 585 590
 Leu Ser Gly Pro Asp Asp Asp Pro Leu His Lys Gln Pro Arg Phe Trp
 595 600 605
 Ala Ser Met Met Glu Ala Ala Ser Cys Pro Pro Asp Tyr Val Pro Pro
 610 615 620
 Glu Ile Phe His Phe His Thr Arg Ser Asp Val Arg Leu Tyr Gly Met
 625 630 635 640
 Ile Tyr Lys Pro His Ala Leu Gln Pro Gly Lys Lys His Pro Thr Val
 645 650 655

Leu Phe Val Tyr Gly Gly Pro Gln Val Gln Leu Val Asn Asn Ser Phe
 660 665 670
 Lys Gly Ile Lys Tyr Leu Arg Leu Asn Thr Leu Ala Ser Leu Gly Tyr
 675 680 685
 Ala Val Val Val Ile Asp Gly Arg Gly Ser Cys Gln Arg Gly Leu Arg
 690 695 700
 Phe Glu Gly Ala Leu Lys Asn Gln Met Gly Gln Val Glu Ile Glu Asp
 705 710 715 720
 Gln Val Glu Gly Leu Gln Phe Val Ala Glu Lys Tyr Gly Phe Ile Asp
 725 730 735
 Leu Ser Arg Val Ala Ile His Gly Trp Ser Tyr Gly Gly Phe Leu Ser
 740 745 750
 Leu Met Gly Leu Ile His Lys Pro Gln Val Phe Lys Ala Gln Pro Leu
 755 760 765
 Ala Tyr Pro Pro Arg Leu Pro Gly Arg Lys Arg Ala Leu Phe Pro His
 770 775 780
 Lys Leu Pro Arg Leu Pro Thr Asp Pro Ser Arg Glu Thr Leu Pro Ala
 785 790 795 800
 Pro Asp Leu Pro Gln Arg Glu Thr Gln Tyr Ser Leu Pro Arg Val Gly
 805 810 815
 Arg Ala Leu

```
<210> 40
<211> 4037
<212> DNA
<213> Homo sapiens
<400> 40
```

caggccgcgc cctgggtcgc tcaacttccg ggtcaaagggt gcctgagccg gcgggtcccc
tgtgtccgcc cgggctgtcg tcccccgctc ccgcccacttc cggggctcga gtcccgggca 120
tggagccgcg accgtgaggg gccgctggac cggggacgac ctgcccagtc cggccgccc 180
cccacgtccc ggtctgtgtc ccacgctgc agctggaatg gaggetctct ggaccctta 240
gaaggcaccc ctgccttcct gaggtcagct gagcgggtaa tgcggaaggt taagaaaactg 300
cgccctggaca aggagaacac cggaagttgg agaagcttct cgctgaattc cgagggggct 360
gagaggatgg ccaccacccg gaccccaacg gccgaccgag gcgacgcagc cgccacagat 420
gaccggccg cccgcttcca ggtcagaag cactcgtggg acgggctccg gagcatcatc 480
cacggcagcc gcaagtactc gggcctcatt gtcaacaagg cggccacga cttccagtt 540
gtcagaaga cggatgagtc tgggccccac tcccaccgcc tctactacct gggaaatgcca 600
tatggcagcc gagagaactc ctcctctac tctgagattc ccaagaagggt cggaaagag 660
gctctgtgc tcctgtcctg gaagcagatg otggatcatt tccaggccac gccccaccat 720
ggggctact ctggggagga ggagctgctg agggagcggg aacgcctggg ggtttccggc 780
atcaccttc acgacttcca cagcagagt ggcctttcc tcttccaggc cagcaacagc 840
ctttccact gccgcacgg cggcaagaac ggttcatgg tgccccat gaaaccgctg 900
gaaatcaaga cccagtgtc agggccccgg atggacccca aaatctgccc tgccgaccct 960
gccttcttct cttcatcaa taacagcgc ac tctgggtgg ccaacatcga gacaggcgg 1020
gagcggccgc tgaccttctg ccaccaagggt ttatccaatg tcctggatga ccccaagtct 1080
gcgggtgtgg ccacccctcg tatacaggaa gagttcgacc gcttcaactgg gtactgg 1140
tgccccacag ctcctggga agttcagag ggcctcaaga cgctcgaat cctgtatgag 1200
gaagtcgtat agtccgaggt ggaggtcatt cacgtccct ctcctcgcgt agaagaaaagg 1260
aagacggact cgtatcggtt ccccaggaca ggcagcaaga atcccaagat tgccttgaaa 1320
ctggctgagt tccagactga cagccaggcc aagatcgctc cgaccaggaa gaaggagctg 1380
gtcagccct tcagctcgct gttcccgaa agtggagtaca tcgcccaggcc cgggtggacc 1440
cgggatggca aatacgcctg ggcctatgttc ctggaccggc cccagcagtg gctccagctc 1500
gtcttcctcc cccccggccct gttcatcccg agcacagaga atgaggagca gcccgttagcc 1560
tctgcacagag ctgtccccag gaatgtccag ccgtatgtgg tgtacgagga ggtcaccac 1620
gtctggatca atgttcatga catcttctat cccttcccccc aatcagaggg agaggacgag 1680
ctctgttcc tccgcgccaa tgaatgcaag accggcttct gccatttgc caaagtccacc 1740
gccgttttaa aatcccaggg ctacgattgg agtgagccct tcagccccgg ggaagatgaa 1800
tttaagtgc ccattaagga agagattgct ctgaccaggc gtgaatggga ggtttggcg 1860

aggcacggct	ccaagggcac	caaggacacg	ccgctggagc	accacctcta	cgtggtcagc	1920
tatgaggcgg	ccggcgagat	cgtacgcctc	accacgccc	gcttctccca	tagtgcgtcc	1980
atgagccaga	acttcgacat	gttcgtcagc	cactacagca	gcgtgagcac	gccgcctgc	2040
gtgcacgtct	acaagctgag	cgccccgac	gacgaccccc	tgcacaagca	gccccgccttc	2100
tgggctagca	tgtggaggc	agccagctgc	ccccccgatt	atgttcctcc	agagatctc	2160
catttccaca	cgcgctcgg	tgtcggtc	tacggcatga	tctacaagcc	ccacgccttg	2220
cagccaggga	agaagcaccc	caccgtcctc	tttgtatatg	gaggccccca	ggtgcagctg	2280
gtgaataact	ccttcaaagg	catcaagtac	ttgcggctca	acacactggc	ctccctgggc	2340
tacgcccgtgg	ttgtgattga	cggcaggggc	tcctgtcagc	gagggcttcg	tttgcgaaagg	2400
gccctgaaaa	accaaattggg	ccaggtggag	atcgaggacc	aggtggaggg	cctgcagttc	2460
gtggccgaga	agtatggctt	catcgacctg	agccgagatg	ccatccatgg	ctggctctac	2520
gggggcttc	tctcgctcat	ggggctaattc	cacaagcccc	aggtgttcaa	ggcccaaccg	2580
cttgcttata	ctccacggct	tcctggacga	aaacgtgcac	tttttccaca	caaacttcct	2640
cgtctccaa	ctgatccgag	cagggaaacc	ttaccagctc	cagatctacc	ccaacgagag	2700
acacagtatt	cgctgccccg	agtcgggcga	gcactatgaa	gtcacgttgc	tgcactttct	2760
acaggaatac	ctctgagcct	gcccacccgg	agccgcacaca	tcacagcaca	agtggctgca	2820
gcctccgcgg	ggaaccaggc	gggaggact	gagtggcccg	cgggccccag	tgaggcactt	2880
tgtcccgccc	agcgctggcc	agccccgagg	agccgctgcc	ttcaccgccc	cgacgcctt	2940
tatcctttt	taaacgtct	tgggtttat	gtccgtct	tettggttgc	cgagacagag	3000
agatgggtgt	ctcgggccag	cccttcctc	ccccgccttc	tgggaggagg	aggtcacacg	3060
ctgatggcga	ctggagaggc	cagaagagac	tcagaggagc	gggctgcctt	ccgcctgggg	3120
ctccctgtga	cctctcagtc	ccctggcccg	gccagccacc	gtccccagca	cccaagcatg	3180
caattgcctg	cccccccccgg	ccagcctccc	caacttgcgt	tttgcgtttt	gtttgggggg	3240
atattttca	taattattta	aaagacaggc	cgggcgcggt	ggctcacgtc	tgtaatccca	3300
gcactttggg	aggctgaggc	gggctgatca	cctgagggtt	ggagttcaag	accagcctgg	3360
ccaaacatggg	gaaaccccg	ctctactaaa	aataaaaaaa	attagccggg	tgtggggcg	3420
cgtgcctata	atcccagcta	ctcgggaggc	tgaggcagga	gaatcgcttgc	aacccgggag	3480
gtggaggttg	cggtgagcca	agatcgacc	attgcactcc	agcctgggca	acaagagcga	3540
aactctgtct	caaaaataat	aaaaaataaa	agacagaaag	caaggggtgc	ctaaatctag	3600
acttggggtc	cacaccggc	agcggggtttgc	caacccagca	cctggtaggc	tccatttctt	3660
cccaagcccg	actttcaggc	aggcactgaa	acgcacccgaa	cttccacgc	ctgctggtca	3720
gtggcgctg	tccctccccc	agcccagccg	cccagccaca	tgtgtctgcc	tgaccctgtac	3780
acaccagggg	ttccggggtt	gggagctgaa	ccatccccac	ctcagggtta	tatcccttc	3840
tcccttccc	tcccgccaa	gagctctgcc	agggggggc	aaaaaaaaaa	gtaaaaagaa	3900
aagaaaaaaaaa	aaaaaaaaaa	acaaaccacc	tctacatatt	atggaaagaa	aatatttttg	3960
tcgattctta	ttctttata	attatgcgtg	gaagaagtag	acacattaaa	cgattccagt	4020
tggaaacatg	tcacactg					4037

<210> 41
 <211> 706
 <212> PRT
 <213> Homo sapiens
 <400> 41

Asp	Thr	Asp	Val	Val	Tyr	Lys	Ser	Glu	Asn	Gly	His	Val	Ile	Lys	Leu
1						5			10				15		
Asn	Ile	Glu	Thr	Asn	Ala	Thr	Thr	Leu	Leu	Leu	Glu	Asn	Thr	Thr	Phe
							20			25			30		
Val	Thr	Phe	Lys	Ala	Ser	Arg	His	Ser	Val	Ser	Pro	Asp	Leu	Lys	Tyr
							35		40			45			
Val	Leu	Leu	Ala	Tyr	Asp	Val	Lys	Gln	Ile	Phe	His	Tyr	Ser	Tyr	Thr
									50	55		60			
Ala	Ser	Tyr	Val	Ile	Tyr	Asn	Ile	His	Thr	Arg	Glu	Val	Trp	Glu	Leu
									65	70	75		80		
Asn	Pro	Pro	Glu	Val	Glu	Asp	Ser	Val	Leu	Gln	Tyr	Ala	Ala	Trp	Gly
									85	90		95			
Val	Gln	Gly	Gln	Gln	Leu	Ile	Tyr	Ile	Phe	Glu	Asn	Asn	Ile	Tyr	Tyr
									100	105		110			

Gln Pro Asp Ile Lys Ser Ser Ser Leu Arg Leu Thr Ser Ser Gly Lys
 115 120 125
 Glu Glu Ile Ile Phe Asn Gly Ile Ala Asp Trp Leu Tyr Glu Glu Glu
 130 135 140
 Leu Leu His Ser His Ile Ala His Trp Trp Ser Pro Asp Gly Glu Arg
 145 150 155 160
 Leu Ala Phe Leu Met Ile Asn Asp Ser Leu Val Pro Thr Met Val Ile
 165 170 175
 Pro Arg Phe Thr Gly Ala Leu Tyr Pro Lys Gly Lys Gln Tyr Pro Tyr
 180 185 190
 Pro Lys Ala Gly Gln Val Asn Pro Thr Ile Lys Leu Tyr Val Val Asn
 195 200 205
 Leu Tyr Gly Pro Thr His Thr Leu Glu Leu Met Pro Pro Asp Ser Phe
 210 215 220
 Lys Ser Arg Glu Tyr Tyr Ile Thr Met Val Lys Trp Val Ser Asn Thr
 225 230 235 240
 Lys Thr Val Val Arg Trp Leu Asn Arg Pro Gln Asn Ile Ser Ile Leu
 245 250 255
 Thr Val Cys Glu Thr Thr Gly Ala Cys Ser Lys Lys Tyr Glu Met
 260 265 270
 Thr Ser Asp Thr Trp Leu Ser Gln Gln Asn Glu Glu Pro Val Phe Ser
 275 280 285
 Arg Asp Gly Ser Lys Phe Phe Met Thr Val Pro Val Lys Gln Gly Gly
 290 295 300
 Arg Gly Glu Phe His His Ile Ala Met Phe Leu Ile Gln Ser Lys Ser
 305 310 315 320
 Glu Gln Ile Thr Val Arg His Leu Thr Ser Gly Asn Trp Glu Val Ile
 325 330 335
 Lys Ile Leu Ala Tyr Asp Glu Thr Thr Gln Lys Ile Tyr Phe Leu Ser
 340 345 350
 Thr Glu Ser Ser Pro Arg Gly Arg Gln Leu Tyr Ser Ala Ser Thr Glu
 355 360 365
 Gly Leu Leu Asn Arg Gln Cys Ile Ser Cys Asn Phe Met Lys Glu Gln
 370 375 380
 Cys Thr Tyr Phe Asp Ala Ser Phe Ser Pro Met Asn Gln His Phe Leu
 385 390 395 400
 Leu Phe Cys Glu Gly Pro Arg Val Pro Val Val Ser Leu His Ser Thr
 405 410 415
 Asp Asn Pro Ala Lys Tyr Phe Ile Leu Glu Ser Asn Ser Met Leu Lys
 420 425 430
 Glu Ala Ile Leu Lys Lys Ile Gly Lys Pro Glu Ile Lys Ile Leu
 435 440 445
 His Ile Asp Asp Tyr Glu Leu Pro Leu Gln Leu Ser Leu Pro Lys Asp
 450 455 460
 Phe Met Asp Arg Asn Gln Tyr Ala Leu Leu Ile Met Asp Glu Glu
 465 470 475 480
 Pro Gly Gly Gln Leu Val Thr Asp Lys Phe His Ile Asp Trp Asp Ser
 485 490 495
 Val Leu Ile Asp Met Asp Asn Val Ile Val Ala Arg Phe Asp Gly Arg
 500 505 510
 Gly Ser Gly Phe Gln Gly Leu Lys Ile Leu Gln Glu Ile His Arg Arg
 515 520 525
 Leu Gly Ser Val Glu Val Lys Asp Gln Ile Thr Ala Val Lys Phe Leu
 530 535 540
 Leu Lys Leu Pro Tyr Ile Asp Ser Lys Arg Leu Ser Ile Phe Gly Lys
 545 550 555 560
 Gly Tyr Gly Gly Tyr Ile Ala Ser Met Ile Leu Lys Ser Asp Glu Lys
 565 570 575

<210> 42
<211> 4541
<212> DNA
<213> *Homo sapiens*
<400> 42

gkctykgtkwtsmagatac agatgtggtg tataaaaagcg agaatggaca tgcattaaa
ctgaatataaaacaaatgc taccacatta ttattggaaa acacaacttt tgtaaccttc 120
aaagcatcaa gacattcagt ttccaccatg taaaatatg tccttctggc atatgatgtc 180
aaacagattt ttcatatttc gtatactgct tcataatgtga ttacaacat acacactagg 240
gaagtttggg agttaaatcc tccagaagta gaggactccg tcttgcagta cgcggcctgg 300
ggtgtccaag ggcagcagct gatttatatt ttgaaaata atatctacta tcaacctgtat 360
ataaaagagca gtcatttgcg actgacatct tctggaaaag aagaaataat tttatggg 420
attgtctgact gtttatatga agaggaactc ctgcatttcc acatcgccca ctgggtgtca 480
ccagatggag aaagacttgc ctccctgtatg ataaaatgact ctttggtacc caccatggtt 540
atccctcggt ttactggagc gttgtatccc aaaggaaagc agtatccgtt tcctaaggca 600
ggtcaagtga acccaacaat aaaattatat gttgtaaacc tttatggacc aactcacact 660
ttggagctca tgccacactga cagctttaaa tcaagagaat actatatcac tatggtaaaa 720
tgggtaaagca ataccaagac tttgtttaaga tggttaaacc gacccatcgaa catctccatc 780
ctcacagtct gttaggaccac tacagggtct ttgtataaa aatatgagat gacatcgat 840
acgtggctct cttagcagaa tgaggagccc gtgttttca gagacggcag caaattctt 900
atgacagtgc ctgttaagca agggggacgt ggagaatttc accacatagc tatgttctc 960
atccagatgaa aagtggcata aattaccgtt cggcatctga catcaggaaa ctgggaagtg 1020
ataaaagatct tggcatacga tggaaactact caaaaaattt actttcttagt cactgaatct 1080
tctccagag gaaggcagct gtacagtgtc tctactgaag gattattgaa tgccaaatgc 1140
atttcatgtat atttcatgaa agaacaatgt acatatttt atggccagtt tagtcccatt 1200
aatcaacatt ttttatttctgttgaaggt ccaagggtcc cagtggtagt cctacatagt 1260
acggacaacc cagcaaaaata ttttatattt gaaagcaatt ctatgctgaa ggaagctatc 1320
ctgaagaaga agataggaaa gccagaaattt aaaatccctc atattgacga ctatgaactt 1380
cctttacagt tttcccttcc caaagatttt atggaccgaa accagtatgc tcttctgtta 1440
ataatggatg aagaaccagg aggccagctg ttacagata agttccatata tgactggat 1500
tccgtactca ttgacatggta taatgtcatt ttagcaagat ttgatggcag aggaagtgga 1560
ttccagggtc tggaaaattttt gcaggagattt catcgaagat taggttcaagt agaagtaaag 1620
gaccaaaataa cagctgtgaa atttttgtt gttacagata agttccatata tgactggat 1680
agcattttt gaaagggttta tgggttcaattt gttacagata tgatcttaaa atcagatgaa 1740
aagctttta aatgtggatc cgtggttgca cttatcacag acttggaaattt gtatgcctca 1800
gctttctctg aaagatacct tggatgcca tctaaaggaaag aagcactt ccaggcagcc 1860
agtgtgttac ataatgttca tggcttggaaa gaagaaaata tattaataat tcatggaaact 1920
gctgacacaa aagtgcattt ccaacactca gcagaattaa tcaagcacct aataaaagct 1980
ggagtgaattt atactatgtca ggtctacccca gatgaaggcataacgtatc tgagaagagc 2040

aagtatcatc	tctacagcac	aatccctcaaa	ttcttcagtg	attgtttgaa	ggaagaaaata	2100
tctgtctac	cacaggaacc	agaagaagat	gaataatgga	ccgtatttat	acagaactga	2160
aggaaatatt	gaggctcaat	gaaacctgac	aaagagactg	taatattgtt	gttgcgtccag	2220
aatgtcaagg	gcagcttacg	gagatgtcac	tggagcagca	cgctcagaga	cagtgaacta	2280
gcatttgaat	acacaagtcc	aagtctactg	tgttgcgttgg	ggtcagaac	ccgtttcttt	2340
gtatgagaga	ggtcaaaggg	ttggtttccct	gggagaaaatt	agttttgcatt	taaagtagga	2400
gtatgtcatg	ttttcttctg	ttatccccct	gtttgttctg	taactagttt	ctctcatttt	2460
aatttcaactg	gccaccatca	tcttgcata	taatgcacaa	tctatcatct	gtcctacagt	2520
ccctgatctt	tcatggctga	gctgcaatct	aacactttac	tgacccctta	taataagtgc	2580
aattcttca	ttgtcttatt	ttatgcttaa	gaaaatattc	agttataaaa	aaacagagta	2640
tttatgtaa	tttctgtttt	taaaaagaca	ttattaaatg	ggtcaaaggaa	catatagaaa	2700
tgtgatttc	agcaccttcc	aaagttcago	cagttatcag	tagatacaat	atctttaaat	2760
gaacacacga	gtgtatgtct	cacaatataat	atacacaagt	gtgcatacatac	agttatgaa	2820
actatcttta	aatgttattt	atgtatataaa	gagtaaacgt	ttgtatgaatt	agaagagatg	2880
ctctttcca	agctataatg	gatgtttgt	ttaatgagcc	aaatatgtat	aaacattttt	2940
tccaattcaa	attctagcta	ttgtttccct	ataaaatgttt	gggttgttgg	ttgtattgtt	3000
tttagtggtt	aatagttttc	cagttgcatt	taattttttg	aatatgatac	cttgcacat	3060
gtaaattaga	tacttaaata	ttaaattata	gttctgata	aagaaaatttt	gttaacaatg	3120
caatgccact	gagtgctatt	ttgtctttt	ggtggagaag	gttttttca	aaactcttgg	3180
tcctttact	tcttctctc	agtgcagaat	caattctcat	tttcatcgta	aaagcaataa	3240
gctggattat	ttcatttgcc	agtttctatt	tagtattcca	tgccctgccc	attcatctgt	3300
tactgtttaa	tttcaatttct	tctggtgaga	attagaaaatg	aaatattttt	tattcattgg	3360
ccaaaaagtt	cacagacagc	agtgtttgt	atttacttt	aattgaaggc	acaaaatgca	3420
tcaattcttg	tgctgtgtt	acttgcagta	gtaagtaact	gagagcataa	aataaacctg	3480
actgtatgaa	gtcaatttaa	gtgatgagaa	catttaactt	tgtgactaa	agtcagaata	3540
tcttctact	tcacttaagg	gatcttccag	aagataatcta	aaagtctgt	ataagcttag	3600
aagttcagat	aaatcttaggc	aggatactgc	atttttgtgg	ttttaaaaaa	gtccttagga	3660
·cagactgaat	tatcataact	tatggcatca	ggagggaaact	ttaaaatatac	aaggaatcac	3720
tcagtcaccc	tcctgtttt	ttgaaggatc	aaccccaat	tctgggtatt	tgagtacatg	3780
tgaatcatgg	atttggatt	caacttttc	cctggatgt	ttggaatcgt	gtcttccatg	3840
ctccactggg	ttcaatttaa	aataggagag	gtttctctt	ctgaaagatc	cattttaggt	3900
cttttcaag	aatagtgaac	acattttta	acaaaataag	ttgtatttt	aaaagggaaag	3960
ttttgcctat	tttattaaga	tggaaattt	tttttaggt	aatttgaat	ccactgtaa	4020
cttttaacc	aatattttaa	atttgaacca	ctagagttt	ttatgatgca	aatgattatg	4080
ttgtctgaaa	ggtgtggttt	tattgaatgt	ctatttgagt	atcattttaa	aagtatttgc	4140
cttttactgt	catcatttct	cttgcattt	tattattatc	aatgtttatc	tattttcaa	4200
ttaatttaat	acagtttcta	atgtgaaaga	cattttctg	gaaccgggtt	tccccttaaa	4260
cactaaagag	acctcaagt	aaagcatatt	gtttagtagg	aaggtagaaa	atgttaatcc	4320
ctgctgatct	ttgagtttta	atgacaggg	cattttcagt	aaagggaaatg	ctcaccacaa	4380
catagtccacc	aactattaaa	ggaatcatgt	gattggattt	tcccctgtat	acatgtaccc	4440
ttggtcataa	tcccactatt	tcatacatat	ttatgcattt	ctagattttc	ctaggactcc	4500
aatagcatgc	tttccaagtg	ttattattcc	cttaatgtta	a		4541

<210> 43
 <211> 691
 <212> PRT
 <213> Homo sapiens
 <400> 43

Asp	Thr	Asp	Val	Val	Tyr	Lys	Ser	Glu	Asn	Gly	His	Val	Ile	Lys	Leu
1					5				10					15	
Asn	Ile	Glu	Thr	Asn	Ala	Thr	Thr	Leu	Leu	Leu	Glu	Asn	Thr	Thr	Phe
								20				25		30	
Val	Thr	Phe	Lys	Ala	Ser	Arg	His	Ser	Val	Ser	Pro	Asp	Leu	Lys	Tyr
									35			40		45	
Val	Leu	Leu	Ala	Tyr	Asp	Val	Lys	Gln	Ile	Phe	His	Tyr	Ser	Tyr	Thr
								50			55		60		
Ala	Ser	Tyr	Val	Ile	Tyr	Asn	Ile	His	Thr	Arg	Glu	Val	Trp	Glu	Leu
								65			70		75		80

Asn Pro Pro Glu Val Glu Asp Ser Val Leu Gln Tyr Ala Ala Trp Gly
 85 90 95
 Val Gln Gly Gln Gln Leu Ile Tyr Ile Phe Glu Asn Asn Ile Tyr Tyr
 100 105 110
 Gln Pro Asp Ile Lys Ser Ser Ser Leu Arg Leu Thr Ser Ser Gly Lys
 115 120 125
 Glu Glu Ile Ile Phe Asn Gly Ile Ala Asp Trp Leu Tyr Glu Glu Glu
 130 135 140
 Leu Leu His Ser His Ile Ala His Trp Trp Ser Pro Asp Gly Glu Arg
 145 150 155 160
 Leu Ala Phe Leu Met Ile Asn Asp Ser Leu Val Pro Thr Met Val Ile
 165 170 175
 Pro Arg Phe Thr Gly Ala Leu Tyr Pro Lys Gly Lys Gln Tyr Pro Tyr
 180 185 190
 Pro Lys Ala Gly Gln Val Asn Pro Thr Ile Lys Leu Tyr Val Val Asn
 195 200 205
 Leu Tyr Gly Pro Thr His Thr Leu Glu Leu Met Pro Pro Asp Ser Phe
 210 215 220
 Lys Ser Arg Glu Tyr Tyr Ile Thr Met Val Lys Trp Val Ser Asn Thr
 225 230 235 240
 Lys Thr Val Val Arg Trp Leu Asn Arg Pro Gln Asn Ile Ser Ile Leu
 245 250 255
 Thr Val Cys Glu Thr Thr Gly Ala Cys Ser Lys Lys Tyr Glu Met
 260 265 270
 Thr Ser Asp Thr Trp Leu Ser Gln Gln Asn Glu Glu Pro Val Phe Ser
 275 280 285
 Arg Asp Gly Ser Lys Phe Phe Met Thr Val Pro Val Lys Gln Gly Gly
 290 295 300
 Arg Gly Glu Phe His His Ile Ala Met Phe Leu Ile Gln Ser Lys Ser
 305 310 315 320
 Glu Gln Ile Thr Val Arg His Leu Thr Ser Gly Asn Trp Glu Val Ile
 325 330 335
 Lys Ile Leu Ala Tyr Asp Glu Thr Thr Gln Lys Ile Ser Ala Ser Thr
 340 345 350
 Glu Gly Leu Leu Asn Arg Gln Cys Ile Ser Cys Asn Phe Met Lys Glu
 355 360 365
 Gln Cys Thr Tyr Phe Asp Ala Ser Phe Ser Pro Met Asn Gln His Phe
 370 375 380
 Leu Leu Phe Cys Glu Gly Pro Arg Val Pro Val Val Ser Leu His Ser
 385 390 395 400
 Thr Asp Asn Pro Ala Lys Tyr Phe Ile Leu Glu Ser Asn Ser Met Leu
 405 410 415
 Lys Glu Ala Ile Leu Lys Lys Lys Ile Gly Lys Pro Glu Ile Lys Ile
 420 425 430
 Leu His Ile Asp Asp Tyr Glu Leu Pro Leu Gln Leu Ser Leu Pro Lys
 435 440 445
 Asp Phe Met Asp Arg Asn Gln Tyr Ala Leu Leu Ile Met Asp Glu
 450 455 460
 Glu Pro Gly Gly Gln Leu Val Thr Asp Lys Phe His Ile Asp Trp Asp
 465 470 475 480
 Ser Val Leu Ile Asp Met Asp Asn Val Ile Val Ala Arg Phe Asp Gly
 485 490 495
 Arg Gly Ser Gly Phe Gln Gly Leu Lys Ile Leu Gln Glu Ile His Arg
 500 505 510
 Arg Leu Gly Ser Val Glu Val Lys Asp Gln Ile Thr Ala Val Lys Phe
 515 520 525
 Leu Leu Lys Leu Pro Tyr Ile Asp Ser Lys Arg Leu Ser Ile Phe Gly
 530 535 540

Lys Gly Tyr Gly Gly Tyr Ile Ala Ser Met Ile Leu Lys Ser Asp Glu
 545 550 555 560
 Lys Leu Phe Lys Cys Gly Ser Val Val Ala Pro Ile Thr Asp Leu Lys
 565 570 575
 Leu Tyr Ala Ser Ala Phe Ser Glu Arg Tyr Leu Gly Met Pro Ser Lys
 580 585 590
 Glu Glu Ser Thr Tyr Gln Ala Ala Ser Val Leu His Asn Val His Gly
 595 600 605
 Leu Lys Glu Glu Asn Ile Leu Ile Ile His Gly Thr Ala Asp Thr Lys
 610 615 620
 Val His Phe Gln His Ser Ala Glu Leu Ile Lys His Leu Ile Lys Ala
 625 630 635 640
 Gly Val Asn Tyr Thr Met Gln Val Tyr Pro Asp Glu Gly His Asn Val
 645 650 655
 Ser Glu Lys Ser Lys Tyr His Leu Tyr Ser Thr Ile Leu Lys Phe Phe
 660 665 670
 Ser Asp Cys Leu Lys Glu Glu Ile Ser Val Leu Pro Gln Glu Pro Glu
 675 680 685
 Glu Asp Glu
 690

<210> 44
<211> 4496
<212> DNA
<213> *Homo sapiens*
<400> 44

gkctykgtkwtsmagatac	agatgtggtg	tataaaaagcg	agaatggaca	tgtcattaaa	60
ctgaatatacg	aaacaatgc	taccacatta	ttattggaaa	acacaactt	120
aaagcatcaa	gacattcagt	ttcaccagat	ttaaaaatatg	tcctctggc	180
aaacagattt	ttcattattt	gtatactgct	tcataatgt	tttacaacat	240
gaagtttggg	agttaaatcc	tccagaagta	gaggactccg	tcttgcagta	300
ggtgtccaag	ggcagcagct	gatttatatt	tttggaaaata	atatctacta	360
ataaaagagca	gttcattgcg	actgacatct	tctggaaaag	aagaaaataat	420
attgctgact	ggttatatga	agaggaactc	ctgcattctc	acatcgccc	480
ccagatggag	aaagacttgc	cttcctgatg	ataaatgact	ctttggtacc	540
atccctcggt	ttactggagc	gttgtatccc	aaaggaaaagc	agtatccgta	600
ggtcaagtga	acccaacaat	aaaattatata	gttgtaaacc	tgtatggacc	660
ttggagctca	tgccacactga	cagcttaaa	tcaagagaat	actatatcac	720
tgggtaagca	ataccaagac	tgtggtaaga	tggtttaaacc	gacctcagaa	780
ctcacagtct	gtgagaccac	tacaggtgct	tgttagaaaa	aatatgagat	840
acgtggctct	ctcagcagaa	tgaggagccc	gtgtttctc	gagacggcag	900
atgacagtgc	ctgttaagca	agggggacgt	ggagaatttc	accacatagc	960
atccagagta	aaagtgagca	aattaccgtg	cgccatctga	catcaggaaa	1020
ataaaagatct	tggcatacga	tgaaactact	aaaaaaaatca	gtgottctac	1080
ttgaatcgcc	aatgcatttc	atgttaatttc	atgaaaagaac	aatgtacata	1140
agtttttagtc	ccatgaatca	acatttctta	ttattctgt	aaggtccaag	1200
gtcagctac	atagtacgga	caaccaggca	aatatatttta	tattggaaaag	1260
ctgaaggaaag	ctatcctgaa	gaagaagata	ggaaaagccag	aaattaaaat	1320
gacgactatg	aacttcctt	acagttgtcc	cttcccaaag	attttatgg	1380
tatgctcttc	tgttaataat	ggatgaagaa	ccaggaggcc	agctggttac	1440
catatttgact	gggattccgt	actcattgac	atggataatg	tcattgtac	1500
ggcagaggaa	gtggattcctt	gggtctgaaa	attttgcagg	agatccatcg	1560
tcagtagaaag	taaaggacca	aataacagct	gtgaaatttt	tgctgaaact	1620
gactccaaaa	gattaagcat	ttttggaaaag	gtttaggt	gccttacatt	1680
ttaaaaatcag	atgaaaagct	ttttaaatgt	ggatccgtgg	ttgcacctat	1740
aaattgtatg	cctcagctt	ctctgaaaga	taccttggga	ggaagaaaagc	1800
acttaccagg	cagccagtgt	gctacataat	gttcatggct	tgaaaagaaga	1860
ataattcatg	gaactgctga	cacaaaagtt	catttccaaac	actcagcaga	1920

cacctaataa	aagctggagt	gaattatact	atgcaggct	accagatga	aggtcataac	1980
gtatctgaga	agagcaagta	tcatctctac	agcacaatcc	tcaaattctt	cagtgattgt	2040
ttgaaggaag	aaatatctgt	gctaccacag	gaaccagaag	aagatgaata	atggaccgta	2100
tttatacaga	actgaaggga	atattgaggc	tcaatgaaac	ctgacaaaga	gactgtataa	2160
ttgttagttgc	tccagaatgt	caagggcago	ttacggagat	gtcactggag	cagcacgctc	2220
agagacagtg	aactagcatt	tgaatacaca	agtccaagtc	tactgtttg	ctaggggtgc	2280
agaacccgtt	tctttgtatg	agagaggta	aagggttgg	ttcctggag	aaatttagtt	2340
tgcattaaag	taggagtagt	gcatgtttc	ttctgttac	cccctgttt	ttctgttaact	2400
agttgctctc	attttaattt	cactggccac	catcatctt	gcatataatg	cacaatctat	2460
catctgtcct	acagtcctg	atcttcatg	gctgagctgc	aatctaacac	tttactgtac	2520
ctttataata	agtcaattc	tttcattgtc	tattattatg	cttaagaaaa	tattcagtt	2580
ataaaaaaaca	gagtatttt	tgttaattct	gtttttaaaa	agacattatt	aatgggtca	2640
aaggacatata	agaaatgtgg	atttcagcac	cttccaaagt	tcagccagtt	atcagtagat	2700
acaatatactt	taaatgaaca	cacgagtgt	tgtctcacaa	tatataataca	caagtgtgc	2760
tatacagtta	atgaaactat	ctttaatgt	tattcatgt	ataaaagagta	aacgtttgat	2820
gaattagaag	agatgcttt	ttccaagcta	taatggatgc	tttgcatttt	gagccaaata	2880
tgtgaaaca	tttttccaa	ttcaattct	agctattgt	ttcctataaa	tgtttgggtt	2940
gtgtttggta	ttgttttag	ttgttaatag	tttccagtt	gcatttaatt	tttgaatat	3000
gataccttgt	cacatgtaaa	ttagatactt	aaatataaa	ttatagttt	tgataaagaa	3060
attttgttaa	caatgcaatg	ccactgagtg	ctattttgct	ctttgggtgg	agaaggcttt	3120
tttcaaaact	tttggcctt	ttacttctt	ctctcaagtgc	agaatcaatt	ctcattttca	3180
tcgtaaaagc	aaatagctgg	attatttcat	ttgcccattt	ctattttagta	ttccatgcct	3240
gcccaattca	tctgttactg	tttaatttca	attcttctgg	tgagaattag	aaatgaaata	3300
ttttttattt	attggccaaa	aagttcacag	acagcagtt	ttgtctattt	ctttgaattt	3360
aaggcacaaa	atgcataat	tctgtgtct	ttgttgcattt	cagtagtaag	taacttgagag	3420
cataaaaataa	acctgactgt	atgaaagtca	tttaagtgtat	gagaacattt	aactttgggt	3480
actaaagtca	gaatatcttc	tcacttcact	taagggatct	tccagaagat	atctaaaagt	3540
ctgtataataag	cttagaagtt	cagataatc	taggcaggat	actgcatttt	tgtggttta	3600
aaaaagtcct	taggacagac	tgaattatca	taacttatgg	catcaggagg	aaactttaaa	3660
atatcaagga	atcactcagt	caccctcctg	ttttgttga	ggatcaacccc	caaattctgg	3720
gtatgttgc	acatgtgaat	catggatttgc	gtattcaact	ttttccctgg	atgctttgg	3780
atcggtctt	ccatgttcca	ctgggttcaa	tttaaaatag	gagaggcttt	ctcttctgaa	3840
agatccattt	taggtcttt	tcaagaatag	tgaacacattt	tttaacaaa	ataagttgt	3900
atttaaaag	gaaagttttgc	ccatattttat	taagatggaa	atttcttttt	aggcttattt	3960
gaaatccaaac	tgaagctttt	taaccaatat	tttaaatttg	aaccactaga	gtttttatgt	4020
atgcaaatga	ttatgttgc	tggaaagggtgt	ggttttatttgc	aatgtctatt	tgagtatcat	4080
ttaaaaagta	tttgcctttt	actgtcatca	tttctcttgc	tttatttattt	ttatcaatgt	4140
ttatctattt	ttcaatttat	ttaatacagt	ttctaatgttgc	aaagacattt	ttctggacc	4200
cgtttccccc	ttaaacacta	aagagacctc	aagtggaaagc	atattgctta	gtaggaagggt	4260
agaaaatgtt	aatccctgcg	attctttgag	tttaatgtac	agggtcattt	tcaagaaagg	4320
aaatgctcac	caacacatag	tcaccaacta	ttaaaggaat	catgtgattt	gattttcccc	4380
tgtatacatg	taccctgg	cataatccca	ctatttcata	catattttagt	cattgttaga	4440
tttccttagg	actccaatag	catgctttcc	aagtgttattt	attcccttaa	tgttaa	4496

<210> 45
 <211> 29
 <212> DNA
 <213> Homo sapiens
 <400> 45

cggttaccatg gcagcagcaa tggaaacag

29

<210> 46
 <211> 39
 <212> DNA
 <213> Homo sapiens
 <400> 46

ggagctcgcg gcccgtcata tcacttttag agcagcaat

39

<210> 47
 <211> 27
 <212> DNA
 <213> Homo sapiens
 <400> 47

caagctttat cactttaga gcagcaa

27

<210> 48
 <211> 22
 <212> DNA
 <213> Homo sapiens
 <400> 48

cacattcttg ctgcatcagt ca

22

<210> 49
 <211> 22
 <212> DNA
 <213> Homo sapiens
 <400> 49

ttgggtcatc ttcaggactt ga

22

<210> 50
 <211> 27
 <212> DNA
 <213> Homo sapiens
 <400> 50

caagcttacc atggccacca ccgggac

27

<210> 51
 <211> 37
 <212> DNA
 <213> Homo sapiens
 <400> 51

cgatatccgcg gccgctcaga ggtattcctg tagaaag

37

<210> 52
 <211> 27
 <212> DNA
 <213> Homo sapiens
 <400> 52

cggatccagg tattcctgtt gaaaatgt

27

<210> 53
 <211> 20
 <212> DNA
 <213> Homo sapiens
 <400> 53

tacgccgtgg ttgtgattga

20

<210> 54
 <211> 20
 <212> DNA

<213> Homo sapiens
<400> 54

ccatacttct cggccacgaa

20

<210> 55
<211> 19
<212> DNA
<213> Homo sapiens
<400> 55

gcctgggatt gtgcactgt

19

<210> 56
<211> 29
<212> DNA
<213> Homo sapiens
<400> 56

gtgtattcaa atgctagttc actgtctct

29

<210> 57
<211> 22
<212> DNA
<213> Homo sapiens
<400> 57

agctagcact gtccagggtc ct

22

<210> 58
<211> 25
<212> DNA
<213> Homo sapiens
<400> 58

agggcccttc atcttcttct ggttc

25

<210> 59
<211> 19
<212> PRT
<213> Homo sapiens
<400> 59

Val Glu Asp Asp Val Met Glu Arg Gln Arg Leu Ile Glu Ser Val Pro
1 5 10 15
Asp Ser Val

<210> 60
<211> 19
<212> PRT
<213> Homo sapiens
<400> 60

Ser Thr Glu Asn Glu Glu Gln Arg Leu Ala Ser Ala Arg Ala Val Pro
1 5 10 15
Arg Asn Val

<210> 61
<211> 15

<212> PRT
<213> Homo sapiens
<400> 61

Lys Glu Ala Ile Leu Lys Lys Lys Ile Gly Lys Pro Glu Ile Lys
1 5 10 15

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)